Original Article
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
N Engl J Med 1999; 341:410-418August 5, 1999
- Abstract
Background
Although it is generally accepted that lowering elevated serum levels of low-density lipoprotein (LDL) cholesterol in patients with coronary heart disease is beneficial, there are few data to guide decisions about therapy for patients whose primary lipid abnormality is a low level of high-density lipoprotein (HDL) cholesterol.
Methods
We conducted a double-blind trial comparing gemfibrozil (1200 mg per day) with placebo in 2531 men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, and an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less. The primary study outcome was nonfatal myocardial infarction or death from coronary causes.
Results
The median follow-up was 5.1 years. At one year, the mean HDL cholesterol level was 6 percent higher, the mean triglyceride level was 31 percent lower, and the mean total cholesterol level was 4 percent lower in the gemfibrozil group than in the placebo group. LDL cholesterol levels did not differ significantly between the groups. A primary event occurred in 275 of the 1267 patients assigned to placebo (21.7 percent) and in 219 of the 1264 patients assigned to gemfibrozil (17.3 percent). The overall reduction in the risk of an event was 4.4 percentage points, and the reduction in relative risk was 22 percent (95 percent confidence interval, 7 to 35 percent; P=0.006). We observed a 24 percent reduction in the combined outcome of death from coronary heart disease, nonfatal myocardial infarction, and stroke (P< 0.001). There were no significant differences in the rates of coronary revascularization, hospitalization for unstable angina, death from any cause, and cancer.
Conclusions
Gemfibrozil therapy resulted in a significant reduction in the risk of major cardiovascular events in patients with coronary disease whose primary lipid abnormality was a low HDL cholesterol level. The findings suggest that the rate of coronary events is reduced by raising HDL cholesterol levels and lowering levels of triglycerides without lowering LDL cholesterol levels.
Media in This Article
Figure 2
Kaplan–Meier Estimates of the Incidence of Death from Coronary Heart Disease and Nonfatal Myocardial Infarction in the Gemfibrozil and Placebo Groups.Figure 1
Lipid Concentrations According to Year of Study and Treatment Group.Article Activity
- Article
Clinical trials have demonstrated that cholesterol-lowering therapy reduces the incidence of major cardiac events in patients with coronary heart disease who have levels of low-density lipoprotein (LDL) cholesterol of 130 mg per deciliter (3.4 mmol per liter) or more.1-3 However, about 40 percent of patients with coronary disease have LDL cholesterol levels below this value, and most of these patients also have low levels of high-density lipoprotein (HDL) cholesterol, with or without increased levels of triglycerides.4,5 Overall, low levels of HDL cholesterol without high levels of LDL cholesterol characterize 20 to 30 percent of patients with coronary disease, representing several million people in the United States.4,5 Observational studies indicate that low HDL cholesterol levels are strongly and independently associated with a higher risk of coronary heart disease.6-8
The optimal clinical approach is unknown for patients with coronary disease whose primary lipid abnormality is a low HDL cholesterol level, because no large-scale intervention trials with major clinical outcomes have been reported in this population. We report the results of a multicenter trial (the Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Cholesterol Intervention Trial [VA- HIT]), initiated in 1991 to address the hypothesis that therapy aimed at raising HDL cholesterol levels and lowering levels of triglycerides would reduce the incidence of death from coronary heart disease and nonfatal myocardial infarction in men with coronary heart disease who had low levels of both HDL cholesterol and LDL cholesterol. We chose the fibric acid derivative gemfibrozil for the intervention because we considered it the agent most likely to improve plasma HDL cholesterol and triglyceride values while having the least effect on plasma LDL cholesterol levels.
Methods
The protocol was approved by the Human Rights Committee of the Cooperative Studies Program Coordinating Center, by each center's institutional review board, and by the Cooperative Studies Program Evaluation Committee. All patients gave written informed consent.
Patients
We have described the study design in detail elsewhere.9 Briefly, men were recruited at 20 Veterans Affairs medical centers throughout the United States. Eligibility for the trial required a documented history of coronary heart disease (defined as a history of myocardial infarction, angina corroborated by objective evidence of ischemia, coronary revascularization, or angiographic evidence of stenosis greater than 50 percent of the luminal diameter in one or more major epicardial coronary arteries), an age of less than 74 years, an absence of serious coexisting conditions, an HDL cholesterol level of 40 mg per deciliter (1.0 mmol per liter) or less, an LDL cholesterol level of 140 mg per deciliter (3.6 mmol per liter) or less, and a triglyceride level of 300 mg per deciliter (3.4 mmol per liter) or less. To obtain a population whose lipid values were at or below these levels, we used a multistage lipid-screening method that included two lipid profiles obtained one to two weeks apart while the patients were fasting.9,10 The means of two additional fasting profiles were used for the base-line lipid values.
Treatment Regimen and Follow-up
After confirming the patients' eligibility with local personnel by telephone, the Cooperative Studies Program Coordinating Center randomly assigned patients to receive either gemfibrozil (1200 mg per day) or matching placebo, according to a permuted-block design with stratification according to center. Throughout the trial, all patients and local study personnel were blinded to treatment assignment.
From September 1991 through May 1995, patients received slow-release gemfibrozil (Lopid SR, Parke-Davis) at a dose of 1200 mg once daily or a matching placebo. On June 1, 1995, after the manufacturer discontinued production of Lopid SR, patients received regular gemfibrozil (Lopid, Parke-Davis) at a dose of 600 mg twice daily or matching placebo for the remainder of the study. The two formulations have been reported to have equivalent effects on plasma lipid levels,11 and we detected no changes in lipid levels after the substitution.
A study coordinator saw patients one month after randomization and then every three months for the duration of the study. At each follow-up visit, study staff provided counseling regarding adherence to the study regimen and asked about the occurrence of events and side effects since the previous visit, using a standard questionnaire that detailed specific symptoms. In addition, the staff provided instruction in the American Heart Association Step 1 diet and advised each patient to consult with his primary physician about an appropriate exercise regimen. An electrocardiogram was obtained annually, or more frequently if clinically indicated. Every six months for the first half of the study, and then annually, blood for lipid analysis was drawn while patients were fasting and was processed according to a standardized protocol. Plasma total cholesterol, HDL cholesterol, and triglycerides were measured by standardized automated enzymatic methods9 at a National Heart, Lung, and Blood Institute–Centers for Disease Control and Prevention regional network reference lipid laboratory. The LDL cholesterol level was calculated by the Friedewald formula.12 All patients were asked to attend regular follow-up visits whether or not they were still taking the study medication. All were followed until death, refusal of further visits, or the conclusion of the study.
Outcomes
The primary outcome was the combined incidence of nonfatal myocardial infarction or death from coronary heart disease as determined by the end-points committee, which was blinded to treatment assignment and lipid results. The diagnosis of myocardial infarction was based on an algorithm that incorporated standard electrocardiographic and clinical-history criteria and serial determinations of cardiac enzymes. Clinically silent myocardial infarctions were included, as identified on the basis of the occurrence of new diagnostic Q waves on routine annual electrocardiography. Death from coronary heart disease included sudden death, death due to myocardial infarction, death due to congestive heart failure, and death as a complication of invasive cardiac procedures. All electrocardiograms were read at a central electrocardiographic coding center according to the Minnesota code.13 A stroke-adjudication committee composed of three neurologists who were blinded to treatment assignment and lipid levels used predefined criteria to review all suspected instances of stroke, a secondary outcome, on the basis of clinical and radiographic data. Other prespecified secondary outcomes were also assessed. They included death from any cause, transient ischemic attack, revascularization procedures, carotid endarterectomy, and hospitalization for unstable angina or congestive heart failure. With the exception of deaths and strokes, which were adjudicated as described, secondary outcomes were confirmed by the principal investigator at each medical center, using standardized definitions in the protocol.
Statistical Analysis
All analyses followed an intention-to-treat approach. Applying a method of Lakatos14 to projected event rates in the placebo and gemfibrozil groups, we calculated that, at a type I error rate of 0.05, the study would require 2500 subjects to detect a 20 percent reduction in the primary outcome with 90 percent power. The study had low power to detect a plausible reduction in total mortality (e.g., 20 percent power to detect a 10 percent reduction with a type I error rate of 0.05). Analyses of time-to-event data were performed with the log-rank test.15 Patients were removed from all time-to-event analyses at the time of death. Relative risks were calculated from Cox models16 with treatment as the single covariate. Adjustment for base-line variables in the Cox models had a trivial effect on the estimates of the hazard ratios. Since the effect of gemfibrozil did not become apparent for about two years, the reported relative risks should be interpreted as the average reduction in risk over roughly five years. The data monitoring board used conditional power calculations17 to guide recommendations about study termination. The Veterans Affairs Cooperative Studies Program Coordinating Center in West Haven, Connecticut, maintained exclusive control of all data.
Results
Between September 4, 1991, and December 31, 1993, we enrolled 2531 patients: 1264 were randomly assigned to receive gemfibrozil and 1267 to receive placebo. Final follow-up visits occurred between May 1 and July 31, 1998, as originally planned. The median follow-up was 5.1 years (range, 0 to 6.9). Overall compliance, defined as the number of days on which the patient took the study medication (as determined by pill counts) divided by the number of days he was supposed to take the medication, was 75 percent in both groups. Among patients who attended the last study visit, 71 percent in each treatment group were still taking their assigned medication. Only 2 percent of patients in the placebo group and less than 1 percent of those assigned to gemfibrozil had been treated for more than six months with an open-label lipid medication. During the study, 418 patients died; of those who were not known to have died during the study, all but 60 were followed until the conclusion of the study, and vital status was ascertained for all but 3.
Patients randomly assigned to the two treatment groups were similar at base line with respect to demographic and clinical variables (Table 1Table 1
Base-Line Characteristics of the Patients According to Treatment Group.). The population was characterized by low levels of HDL cholesterol (mean, 32 mg per deciliter [0.8 mmol per liter]), low levels of LDL and total cholesterol (mean, 111 and 175 mg per deciliter [2.9 and 4.5 mmol per liter], respectively), moderate levels of triglycerides (mean, 160 mg per deciliter [1.8 mmol per liter]), advanced age (mean, 64 years), a high prevalence of diabetes (25 percent) and hypertension (57 percent), and abdominal obesity (mean [±SD] waist-to-hip ratio, 0.96±0.05).Effects on Lipid Levels
One year after randomization, the mean HDL cholesterol level was 6 percent higher in the gemfibrozil group than in the placebo group (34 mg per deciliter [0.9 mmol per liter] vs. 32 mg per deciliter [0.8 mmol per liter], P<0.001); the mean total cholesterol level was 4 percent lower (170 mg per deciliter [4.4 mmol per liter] vs. 177 mg per deciliter [4.6 mmol per liter], P<0.001); and the mean triglyceride level was 31 percent lower (115 mg per deciliter [1.3 mmol per liter] vs. 166 mg per deciliter [1.9 mmol per liter], P<0.001). Significant differences between treatment groups for these three lipids persisted throughout the study (Figure 1Figure 1
Lipid Concentrations According to Year of Study and Treatment Group.). The mean LDL cholesterol level was 113 mg per deciliter (2.9 mmol per liter) in both groups at one year and never differed significantly between groups.Outcomes
Overall, 275 patients (21.7 percent) in the placebo group and 219 patients (17.3 percent) in the gemfibrozil group had a primary event (Table 2Table 2
Major Cardiovascular Events According to Treatment Group.). Thus, gemfibrozil was associated with a reduction of 22 percent (95 percent confidence interval, 7 to 35 percent) in the rate of death from coronary heart disease or nonfatal myocardial infarction (P=0.006). The effect was consistent for both components of the primary outcome, with a 22 percent reduction in death from coronary heart disease (95 percent confidence interval, –2 to 41 percent [the negative number indicates an increase]; P=0.07) and a 23 percent reduction in nonfatal myocardial infarction (95 percent confidence interval, 4 to 38 percent; P=0.02). The beneficial effect of gemfibrozil did not become apparent until about two years after randomization (Figure 2Figure 2Kaplan–Meier Estimates of the Incidence of Death from Coronary Heart Disease and Nonfatal Myocardial Infarction in the Gemfibrozil and Placebo Groups.).Table 2 also shows the incidence of secondary outcomes according to treatment group. Seventy-six patients taking placebo (6.0 percent) and 58 taking gemfibrozil (4.6 percent) had strokes (relative risk reduction, 25 percent; 95 percent confidence interval, –6 to 47 percent; P=0.10). Since several recent secondary-prevention trials reported investigator-designated strokes rather than strokes confirmed by an adjudication committee, we also show such data in Table 2.1,2 Gemfibrozil resulted in a relative risk reduction of 24 percent for the combined outcome of death from coronary heart disease, nonfatal myocardial infarction, or confirmed stroke (95 percent confidence interval, 11 to 36 percent; P<0.001). Gemfibrozil also resulted in a statistically significant 59 percent reduction in transient ischemic attacks (95 percent confidence interval, 33 to 75 percent; P< 0.001) and a statistically significant 65 percent reduction in carotid endarterectomy (95 percent confidence interval, 37 to 80 percent; P<0.001). The rates of coronary revascularization and hospitalization for unstable angina did not differ significantly between the groups.
Subgroup Analyses
Although the study was not designed to have adequate power for subgroup analyses, we performed exploratory analyses in predefined subgroups, using the expanded outcome of death from coronary heart disease, nonfatal myocardial infarction, or confirmed adjudicated stroke. Gemfibrozil was associated with relative risk reductions ranging from 11 percent to 42 percent in all subgroups except for current smokers (Table 3Table 3
Effect of Gemfibrozil on Death Due to Coronary Heart Disease, Nonfatal Myocardial Infarction, and Confirmed Stroke in Prespecified Subgroups.).Adverse Events
As shown in Table 4Table 4
Incidence of Death from Various Causes and Incidence of Newly Diagnosed Cancers According to Treatment Group., there were 220 deaths in the placebo group (17.4 percent) and 198 in the gemfibrozil group (15.7 percent). There was no significant difference between the two groups in the rate of death from any specific cause. Cancer was diagnosed during the study in 263 patients, 138 in the placebo group and 125 in the gemfibrozil group.The study medication was generally well tolerated. The only symptom reported more commonly by patients receiving the active treatment was dyspepsia, which occurred in 40 percent of patients taking gemfibrozil and 34 percent of those taking placebo (P=0.002). Seven percent of patients in both treatment groups had biliary disease. More patients assigned to gemfibrozil underwent abdominal surgery, but the difference was not statistically significant (5.4 percent vs. 4.3 percent, P=0.19). The number of patients with elevations in either creatine kinase or aspartate aminotransferase levels did not differ significantly between the groups. Table 5Table 5
Reasons for Discontinuation of the Study Medication. shows the reasons for the discontinuation of the study medication.Discussion
In this trial, among men with coronary heart disease and low HDL cholesterol levels but without high-risk LDL cholesterol levels, gemfibrozil safely reduced the risk of death from coronary heart disease or nonfatal myocardial infarction by 22 percent. Gemfibrozil also resulted in a 24 percent reduction in the combined outcome of death from coronary heart disease, nonfatal myocardial infarction, or stroke, an effect that was consistent within nearly all of the prespecified subgroups we analyzed. The 29 percent reduction in investigator-designated stroke is similar to the 30 percent reported in trials of statins.1,2 Thus, the results of this study suggest that raising HDL cholesterol and lowering triglyceride levels, even without lowering the LDL cholesterol level, reduces major coronary events in patients whose primary lipid abnormality is a low HDL cholesterol level.
For the primary outcome, death from coronary heart disease or nonfatal myocardial infarction, the absolute risk reduction was 4.4 percent (21.7 percent for the placebo group minus 17.3 percent for the gemfibrozil group). Thus, in a population similar to the one in this study, 23 patients would need to be treated with gemfibrozil for five years to prevent one nonfatal myocardial infarction or death due to coronary heart disease (the “five-year number needed to treat”). The magnitude of the benefit of gemfibrozil in this population is similar to that of pravastatin in populations with average-to-moderately-high levels of LDL cholesterol. For example, in the Cholesterol and Recurrent Events (CARE) study (average LDL cholesterol level, 139 mg per deciliter [3.6 mmol per liter]) and the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study (average LDL cholesterol level, 150 mg per deciliter [3.9 mmol per liter]), the five-year numbers needed to treat to prevent one nonfatal myocardial infarction or death from coronary heart disease were 33 and 28, respectively.2,3 The low numbers needed to treat to prevent major cardiovascular events in our study suggest that gemfibrozil, an inexpensive medication, may prove highly cost effective, if not cost saving, for the treatment of patients with coronary heart disease who have this particular lipid profile.19,20 Formal cost-effectiveness analysis will be necessary to evaluate this question further.
Several possible mechanisms, including an increase in HDL cholesterol, improvement in triglyceride metabolism, and favorable effects on the size and composition of LDL and on hemostasis, might explain the observed clinical benefit. The 22 percent reduction in major cardiac events (relative to placebo) associated with a 6 percent increase in HDL cholesterol is consistent with an analysis of the results of the Helsinki Heart Study, a primary-prevention trial with gemfibrozil, which suggested that an 8 percent increase in HDL cholesterol would be expected to result in a 23 percent reduction in such events.21 HDL is thought to exert an antiatherogenic effect through its role in “reverse cholesterol transport,” in which cholesterol from peripheral tissues, including the arterial wall, is transported back to the liver for excretion.22 HDL may also act to prevent atherosclerosis by transporting antioxidants to LDL, thus making LDL less susceptible to oxidation within the endothelium.23 Furthermore, a low HDL cholesterol level is often accompanied by a cluster of other abnormalities that predispose the patient to the development of atherosclerotic disease.24,25 Often referred to as the metabolic syndrome, these abnormalities, usually seen in the context of abdominal obesity and insulin resistance, include hypertension, diabetes, persistence of highly atherogenic postprandial triglyceride-rich remnant lipoproteins, a preponderance of dense, highly oxidizable LDL particles, and a procoagulant state.24,26,27 Gemfibrozil may have favorable effects on these lipid abnormalities; specifically, it decreases the fraction of dense, more oxidizable LDL particles and improves the clearance, and hence the fasting and postprandial levels, of triglyceride-rich lipoproteins, including very-low-density lipoproteins and chylomicrons.28-30 These mechanisms may have contributed to the favorable clinical effect of gemfibrozil in the population we studied, which was characterized by a high prevalence of features of the metabolic syndrome.
Gemfibrozil use was not associated with any major adverse events in this trial. The overall incidence of cancer was slightly lower among patients receiving gemfibrozil, and no specific type of cancer was significantly more common in the gemfibrozil group. In fact, melanoma was significantly less common, a finding also reported in a recent trial of lovastatin.31 Gemfibrozil was also associated with an 11 percent reduction in overall mortality (95 percent confidence interval, –8 to 27 percent; P=0.23). Although this reduction is not statistically significant, as anticipated on the basis of the sample size, it is reassuring that the trend favors gemfibrozil and that deaths due to cancer and violence were less common in the gemfibrozil group. It should be noted, however, that although gemfibrozil proved safe and effective in this population, concern about a possible increase in cancer-related deaths has been aroused by prior studies of fibrates.32,33 Ongoing follow-up of the population in this study will provide additional useful information about the long-term safety of gemfibrozil.
Gemfibrozil was generally well tolerated in this population of elderly men with multiple coexisting illnesses. Although significantly more patients who received gemfibrozil reported gastrointestinal upset, compliance with study medication was not significantly affected; by the end of the study, 71 percent of the patients in both treatment groups were still taking their assigned study medications. This rate compares favorably with compliance in most other long-term primary-prevention trials, including those with statins,31,34 but is lower than that reported from recent secondary-prevention studies.1-3 Compliance may have been lower in our study than in other secondary-prevention studies because our patients had more coexisting illnesses and were probably taking more concomitant medications.
In conclusion, our study and other recent secondary-prevention trials give clinicians the data necessary to provide evidence-based lipid therapy for individual patients with coronary disease according to their predominant lipid abnormality. For patients with moderate or high levels of LDL cholesterol, the Scandinavian Simvastatin Survival Study and the CARE and LIPID studies demonstrate that statins reduce the incidence of major coronary events.1-3 It is uncertain, however, whether statins are beneficial for patients with LDL cholesterol levels of less than 130 mg per deciliter; secondary analyses from recent trials yield conflicting results.35-37 For such patients who also have low HDL cholesterol levels, our study demonstrates that gemfibrozil results in a significant reduction in the risk of major cardiovascular events. Moreover, the 22 percent relative reduction in the risk of major coronary events observed with gemfibrozil in this population is similar to the reduction of 23 to 24 percent in risk in the two recent secondary-prevention trials of pravastatin in patients with moderate levels of LDL cholesterol.2,3 Thus, for patients with coronary heart disease whose primary lipid abnormality is a low HDL cholesterol level — a finding that often occurs in the context of central obesity, diabetes, and other features of the metabolic syndrome — gemfibrozil is effective for the prevention of myocardial infarction and death from coronary heart disease.
Supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development and by a supplemental grant from Parke-Davis, a division of Warner-Lambert.
Dr. Schaefer is a consultant for Parke-Davis and Warner-Lambert. Dr. Faas is a shareholder in Warner-Lambert. Drs. Anderson, Schaefer, and Schectman receive grant support from the Parke-Davis Division of Warner-Lambert.
We are indebted to Mary Bauer and Lucy Kraml for assistance with the preparation of the manuscript.
Source Information
From the Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center, Minneapolis (H.B.R., T.J.W.); the Department of Medicine, Boston University School of Medicine, Boston (S.J.R.); the Department of Veterans Affairs Cooperative Studies Program Coordinating Center, West Haven, Conn. (D.C.); the Clinical Research Pharmacy Coordinating Center, Albuquerque, N.M. (C.L.F.); the Medicine Service, Veterans Affairs Medical Center, Lexington, Ky. (J.W.A.); the Medicine Service, Veterans Affairs Medical Center, Memphis, Tenn. (M.B.E.); the Medicine Service, Veterans Affairs Medical Center, Little Rock, Ark. (F.H.F.); the Medicine Service, Veterans Affairs Medical Center, San Juan, P.R. (E.L.); the Lipid Research Laboratory, Tufts University School of Medicine, Boston (E.J.S.); the Medicine Service, Veterans Affairs Medical Center, Milwaukee (G.S.); and Statistics Collaborative, Washington, D.C. (J.W.).
Address reprint requests to Dr. Rubins at the Section of General Internal Medicine (111O), Veterans Affairs Medical Center, Minneapolis, MN 55417, or at bloom013@tc.umn.edu.
The members of the study group are listed in the Appendix.
Appendix
The following persons participated in the VA-HIT trial (asterisks indicate principal investigators): Ann Arbor, Mich. — W. Kou,* G.B.J. Mancini,* S. Sample, and N. Champagne; Boston — W.E. Boden,* H. Kleinman,* C. Chapin, D. Gilroy-Fanaras, N. Aicardi, L. Kerry, and D. LeFebvre; Chicago — M.A. Papp,* R. Molokie,* S. Stanford, K. Oberg, T. Redmond, S. Monreal, and H. Thomas; Cincinnati — L.F. Wexler,* J. Shaffer,* E. Snow, M. Story, and K. Johnson; Fresno, Calif. — P.C. Deedwania,* E. Murphy, E. Bugay, K. Marshall, L. Cleary, J. King, K. Butler, and R. Kanefield; Houston — D.L. Mann,* P. Kuo,* C. Tyler, D. Espadas, and A. Chee; Huntington, W.Va. — R.C. Touchon,* S. Cansino, K. Peart, C. Harless, and M. Babb; Lexington, Ky. — B. Smith, L. Buchanan, K. Cox, J.E. Logan, and P. Boggs; Little Rock, Ark. — S. Thomas, J. Washam, C. Jones, L. Frazier, D. Holderfield, M. Sanders, and K. Ridings; Long Beach, Calif. — M.L. Kashyap,* J. Hagar,* N. Downey, R. Knight, J.R. Saleh, P. Rahimi, and J. Wallis; Louisville, Ky. — S.A. Joseph,* E. Samols,* S. Wagner,* D. Kinny, L. Pignatora, and T. Sugg; Manchester, N.H. — M. Mayo-Smith,* M. Carson, L. Lavoie, D. Gillie, D. Havron, and H. Croteau; Memphis, Tenn. — G. Rutan,* L. Harris (deceased), J. Pinson, R. Childress, R. Manning, and M. Jones; Milwaukee — S. Ristow, C. Brandt, and C. Parker; Minneapolis — J. Karvonen, L. Schlasner, M. Nelson, and D. Rootes; Portland, Oreg. — H. DeMots,* E. Murphy,* L. Gray, K. Martin, S. Bagnoli, T. Tucker, K. Moran, and J. Guzman; Salem, Va. — A. Iranmanesh,* D.C. Russell,* S. Clary, C. Stephens, L. Wertz, and L. Plichta; San Juan, P.R. — M.S. Velazquez and M. De Lourdes Cruz; Washington, D.C. — V. Papademetriou,* M. Metcalfe, and P. Dandenau; West Los Angeles, Calif. — J.M. Hershman,* B.N. Singh,* P. McCloy, D. Kistner, and K. Goddart; Veterans Affairs Cooperative Studies Program Coordinating Center, West Haven, Conn. — P.N. Peduzzi, M.K. Iwane, P. Antonelli, R. Bartozzi, C. Cushing, R. Kilstrom, R. Vinisko, J. Derrico, J. Brennan, J. Pritchett, and C. Harris; Veterans Affairs Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, N.M. — M.R. Sather, W.H. Gagne, C.A. Badgett, F. Lueddeke, J.D. Recio, Jr., and C. Sanchez; Veterans Affairs Cooperative Studies Program Headquarters, Washington, D.C. — J.R. Feussner, D. Deykin, P.C. Huang, and J. Gold; Central Lipid Laboratory, Boston — J.R. McNamara, C. Huang, T. Massov, and C. DeLuca; Electrocardiographic Coding Center, Minneapolis — R.S. Crow, M. McDonald, C. Swanson, C. Christianson, and J. Watchke; Nutrition Consultant, Richmond, Va. — K. Smith; Committees — Data Monitoring Board: T.A. Pearson, A.M. Gotto, K.R. Bailey, B.R. Davis, A.F. Parisi, B.M. Rifkind, and R. Zelis; Other committee members: D.J. Gordon, R. Lakshman, J. Davenport, V. Babikian, and L. Brass.
- References
References
1
Scandinavian Simvastatin Survival Study Group
Web of Science | Medline2
Sacks FM ,Pfeffer MA ,Moye LA , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009
Full Text | Web of Science | Medline3
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Full Text | Web of Science | Medline4
Rubins HB ,Robins SJ ,Collins D , et al. Distribution of lipids in 8,500 men with coronary artery disease. Am J Cardiol 1995;75:1196-1201
CrossRef | Web of Science | Medline5
Genest JJ ,McNamara JR ,Salem DN ,Schaefer EJ . Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991;67:1185-1189
CrossRef | Web of Science | Medline6
Pekkanen J ,Linn S ,Heiss G , et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-1707
Full Text | Web of Science | Medline7
Gordon DJ ,Rifkind BM . High-density lipoprotein -- the clinical implications of recent studies. N Engl J Med 1989;321:1311-1316
Full Text | Web of Science | Medline8
Goldbourt U ,Yaari S ,Medalie JH . Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-113
CrossRef | Web of Science | Medline9
Rubins HB ,Robins SJ ,Iwane MK , et al. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Am J Cardiol 1993;71:45-52
CrossRef | Web of Science | Medline10
Iwane MK ,Wittes J ,Collins DE ,Rubins HB . Simultaneous screening for three correlated lipids in the VA HDL Intervention Trial. J Clin Epidemiol 1999;52:685-693
CrossRef | Web of Science | Medline11
Schaefer EJ ,Lamon-Fava S ,Cole T , et al. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. Atherosclerosis 1996;127:113-122
CrossRef | Web of Science | Medline12
Friedewald WT ,Levy RI ,Frederickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
Web of Science | Medline13
Prineas RJ, Crow RS, Blackburn H. The Minnesota code manual of electrocardiographic findings: standards and procedures for measurement and classification. Boston: John Wright/PSG, 1982.
14
Lakatos E . Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Control Clin Trials 1986;7:189-199
CrossRef | Medline15
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;3:163-17016
Cox DR . Regression models and life-tables. J R Stat Soc [B] 1972;34:187-20217
Lan KKG ,Wittes J . The B-value: a tool for monitoring data. Biometrics 1988;44:579-585
CrossRef | Web of Science | Medline18
Rubins HB ,Robins SJ ,Collins D . The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am J Cardiol 1996;78:572-575
CrossRef | Web of Science | Medline19
Miller DB . Secondary prevention for ischemic heart disease: relative numbers needed to treat with different therapies. Arch Intern Med 1997;157:2045-2052
CrossRef | Web of Science | Medline20
Goldman L ,Gordon DJ ,Rifkind BM , et al. Cost and health implications of cholesterol lowering. Circulation 1992;85:1960-1968
Web of Science | Medline21
Manninen V ,Elo MO ,Frick MH , et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-651
CrossRef | Web of Science | Medline22
Hill SA ,McQueen MJ . Reverse cholesterol transport -- a review of the process and its clinical implications. Clin Biochem 1997;30:517-525
CrossRef | Web of Science | Medline23
Mackness MI ,Abbott CA ,Arrol S ,Durrington PN . The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J 1993;294:829-834
Web of Science | Medline24
Grundy SM . Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95:1-4
Web of Science | Medline25
Ginsberg HN . Is hypertriglyceridemia a risk factor for atherosclerotic cardiovascular disease? A simple question with a complicated answer. Ann Intern Med 1997;126:912-914
Web of Science | Medline26
Zavaroni I ,Bonora E ,Pagliara M , et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989;320:702-706
Full Text | Web of Science | Medline27
Lamarche B ,Tchernof A ,Mauriege P , et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279:1955-1961
CrossRef | Web of Science | Medline28
Yuan J ,Tsai MY ,Hunninghake DB . Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy. Atherosclerosis 1994;110:1-11
CrossRef | Web of Science | Medline29
Weintraub MS ,Eisenberg S ,Breslow JL . Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals: effects of treatment with cholestyramine and gemfibrozil. J Clin Invest 1987;79:1110-1119
CrossRef | Web of Science | Medline30
Bhatnagar D ,Durrington PN ,Mackness MI ,Arrol S ,Winocour PH ,Prais H . Effects of treatment of hypertriglyceridaemia with gemfibrozil on serum lipoproteins and the transfer of cholesteryl ester from high density lipoproteins to low density lipoproteins. Atherosclerosis 1992;92:49-57
CrossRef | Web of Science | Medline31
Downs JR ,Clearfield M ,Weis S , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;79:1615-1622
CrossRef | Web of Science32
A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate: report from the Committee of Principal Investigators
CrossRef | Web of Science | Medline33
Huttunen JK ,Heinonen OP ,Manninen V , et al. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med 1994;235:31-39
CrossRef | Web of Science | Medline34
Shepherd J ,Cobbe SM ,Ford I , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307
Full Text | Web of Science | Medline35
Sacks FM ,Moye LA ,Davis BR , et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation 1998;97:1446-1452
Web of Science | Medline36
Pedersen TR ,Olsson AG ,Faergeman O , et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-1460
Web of Science | Medline37
Grundy SM . Statin trials and goals of cholesterol-lowering therapy. Circulation 1998;97:1436-1439
Web of Science | Medline
- Citing Articles (1023)
Citing Articles
1
Sayuri N. Friedland, Aaron Leong, Kristian B. Filion, Jacques Genest, Iliana C. Lega, Salvatore Mottillo, Paul Poirier, Jennifer Reoch, Mark J. Eisenberg. (2012) The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists. The American Journal of Medicine 125:2, 126-133
CrossRef2
Elena Salmoirago-Blotcher, Sybil Crawford, Ira Ockene. (2012) The Reply. The American Journal of Medicine 125:2, e7-e8
CrossRef3
Elvin Tyrone Price, Gregory James Welder, Issam Zineh. (2012) Modulatory Effect of Fenofibrate on Endothelial Production of Neutrophil Chemokines IL-8 and ENA-78. Cardiovascular Drugs and Therapy
CrossRef4
Tsan Yang, Chien-An Sun, Ching-Chuan Chen, Szu-Hsien Wu, Tieh-Chi Chung, Yu-Ching Chou. (2012) The Association between Metabolic Syndrome-Related Indicators and Ten-Year Risk of Cardiovascular Disease: An Epidemiologic Assessment. ISRN Public Health 2012, 1-7
CrossRef5
Takahiro Kuwashiro, Hiroshi Sugimori, Tetsuro Ago, Masahiro Kamouchi, Takanari Kitazono. (2012) Risk Factors Predisposing to Stroke Recurrence within One Year of Non-Cardioembolic Stroke Onset: The Fukuoka Stroke Registry. Cerebrovascular Diseases 33:2, 141-149
CrossRef6
I. Kouroumichakis, N. Papanas, P. Zarogoulidis, V. Liakopoulos, E. Maltezos, D.P. Mikhailidis. (2012) Fibrates: Therapeutic potential for diabetic nephropathy?. European Journal of Internal Medicine
CrossRef7
Nikhil Tandon, Mohammed K. Ali, K.M. Venkat Narayan. (2012) Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus. American Journal Cardiovascular Drugs1
CrossRef8
Aiming Liu, Julin Yang, Xiaoli Huang, Jingfang Xiong, Ada Hang-Heng Wong, Lan Chang, Renke Dai. (2012) Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs. Vascular Pharmacology
CrossRef9
2011. Frontmatter. , i-xxxvi.
CrossRef10
2011. Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling. , 423-523.
CrossRef11
The AIM-HIGH Investigators. (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. New England Journal of Medicine 365:24, 2255-2267
Full Text12
Željko Reiner, Alberico L. Catapano, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegría, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) Guía de la ESC/EAS sobre el manejo de las dislipemias. Revista Española de Cardiología 64:12, 1168.e1-1168.e60
CrossRef13
Benoit J Arsenault, Jean-Pierre Després, S Matthijs Boekholdt. (2011) Hypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle?. Clinical Lipidology 6:6, 639-651
CrossRef14
Zachary Bloomgarden, Yehuda Handelsman, Daniel Einhorn. (2011) Comprehensive diabetes cardiovascular treatment = sugar + blood pressure + lipids. Journal of Diabetes 3:4, 257-260
CrossRef15
E. Bruckert, J. Ferrières, M. Farnier. (2011) HDL-cholestérol et approche thérapeutique. Archives of Cardiovascular Diseases Supplements 3:4, 273-279
CrossRef16
Uchechukwu K. Sampson, Sergio Fazio, MacRae F. Linton. (2011) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports
CrossRef17
Sidney C. Smith, Emelia J. Benjamin, Robert O. Bonow, Lynne T. Braun, Mark A. Creager, Barry A. Franklin, Raymond J. Gibbons, Scott M. Grundy, Loren F. Hiratzka, Daniel W. Jones, Donald M. Lloyd-Jones, Margo Minissian, Lori Mosca, Eric D. Peterson, Ralph L. Sacco, John Spertus, James H. Stein, Kathryn A. Taubert. (2011) AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. Journal of the American College of Cardiology 58:23, 2432-2446
CrossRef18
Manfredi Rizzo, Gerald H Tomkin, Angelo Maria Patti, Ilenia Pepe, Maria Rosa Valerio, Salvatore Di Rosa, Giovam Battista Rini, Gaetana Di Fede. (2011) Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes. Clinical Lipidology 6:5, 539-547
CrossRef19
James E. McLaren, Daryn R. Michael, Tim G. Ashlin, Dipak P. Ramji. (2011) Cytokines, macrophage lipid metabolism and foam cells: Implications for cardiovascular disease therapy. Progress in Lipid Research 50:4, 331-347
CrossRef20
Per Torger Skretteberg, Irene Grundvold, Sverre E. Kjeldsen, Jan E. Erikssen, Leiv Sandvik, Knut Liestøl, Gunnar Erikssen, Terje R. Pedersen, Johan Bodegard. (2011) HDL-cholesterol and prediction of coronary heart disease: Modified by physical fitness?. Atherosclerosis
CrossRef21
B. Simic, M. Hermann, S. G. Shaw, L. Bigler, U. Stalder, C. Dorries, C. Besler, T. F. Luscher, F. Ruschitzka. (2011) Torcetrapib impairs endothelial function in hypertension. European Heart Journal
CrossRef22
M. K. Rutter, R. W. Nesto. (2011) Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. European Heart Journal 32:18, 2247-2255
CrossRef23
Jesús Millán Núñez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Sala. (2011) Riesgo residual vascular de origen lipídico. Estrategias para el tratamiento del riesgo residual por dislipidemia aterogénica. Clínica e Investigación en Arteriosclerosis 23:5, 230-239
CrossRef24
Babasaheb P. Bandgar, Rajendra J. Sarangdhar, Fruthous Khan, Jeyamurugan Mookkan, Pranesha Shetty, Gajendra Singh. (2011) Synthesis and Biological Evaluation of Orally Active Hypolipidemic Agents. Journal of Medicinal Chemistry 54:16, 5915-5926
CrossRef25
Markolf Hanefeld, Ulrike Schatz, Frank Schaper. 2011. Treatments for the Metabolic Syndrome. , 327-346.
CrossRef26
Goldfine, Allison B., Kaul, Sanjay, Hiatt, William R., . (2011) Fibrates in the Treatment of Dyslipidemias — Time for a Reassessment. New England Journal of Medicine 365:6, 481-484
Full Text27
Sandeep A. Saha, Rohit R. Arora. (2011) Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology 22:4, 270-276
CrossRef28
Nadia Khoury, Anne Carol Goldberg. (2011) The Use of Fibric Acid Derivatives in Cardiovascular Prevention. Current Treatment Options in Cardiovascular Medicine 13:4, 335-342
CrossRef29
Philip Joseph, Koon Teo. (2011) Optimal Medical Therapy, Lifestyle Intervention, and Secondary Prevention Strategies for Cardiovascular Event Reduction in Ischemic Heart Disease. Current Cardiology Reports 13:4, 287-295
CrossRef30
Meng Lee, Jeffrey L. Saver, Amytis Towfighi, Jessica Chow, Bruce Ovbiagele. (2011) Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis. Atherosclerosis 217:2, 492-498
CrossRef31
Klaus G Parhofer. (2011) Pathophysiology of diabetic dyslipidemia: implications for atherogenesis and treatment. Clinical Lipidology 6:4, 401-411
CrossRef32
Protasio L da Luz, Raul C Maranhão. (2011) Novel aspects of HDL level and function in a clinical setting. Clinical Lipidology 6:4, 357-360
CrossRef33
Madhan Shanmugasundaram, Vinny K. Ram, Ulrich C. Luft, Molly Szerlip, Joseph S. Alpert. (2011) Peripheral Arterial Disease-What Do We Need to Know?. Clinical Cardiology 34:8, 478-482
CrossRef34
Theodosios D Filippatos, Moses S Elisaf. (2011) Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opinion on Pharmacotherapy 12:12, 1945-1958
CrossRef35
T. A. Jacobson. (2011) Opening a New Lipid "Apo-thecary": Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk. Mayo Clinic Proceedings 86:8, 762-780
CrossRef36
, , Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, , J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 32:14, 1769-1818
CrossRef37
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217:1, 3-46
CrossRef38
Jean-Louis Chiasson, Sophie Bernard. (2011) Reducing cardiovascular risk factors in patients with prediabetes. Diabetes Management 1:4, 423-438
CrossRef39
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217, 1-44
CrossRef40
Bernhard Föger. (2011) Lipid lowering therapy in type 2 diabetes. Wiener Medizinische Wochenschrift 161:11-12, 289-296
CrossRef41
R A Wilke. (2011) High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome. The Pharmacogenomics Journal 11:3, 162-173
CrossRef42
Bruno Vergès. (2011) Combination lipid therapy in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:9, 1393-1403
CrossRef43
Macan Marija, Konjevoda Paško, Lovrić Jasna, Koprivanac Marijan, Kelava Marta, Vrkić Nada, Bradamante Vlasta. (2011) The Influence of Gemfibrozil on Malondialdehyde Level and Paraoxonase 1 Activity in Wistar and Fisher Rats. Basic & Clinical Pharmacology & Toxicology 108:6, 428-435
CrossRef44
M. J. Chapman, H. N. Ginsberg, P. Amarenco, F. Andreotti, J. Boren, A. L. Catapano, O. S. Descamps, E. Fisher, P. T. Kovanen, J. A. Kuivenhoven, P. Lesnik, L. Masana, B. G. Nordestgaard, K. K. Ray, Z. Reiner, M.-R. Taskinen, L. Tokgozoglu, A. Tybjaerg-Hansen, G. F. Watts, . (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 32:11, 1345-1361
CrossRef45
Gissette Reyes-Soffer, Carlos Rondon-Clavo, Henry N Ginsberg. (2011) Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:9, 1429-1438
CrossRef46
Annett Stahn, Markolf Hanefeld. (2011) Multimodale Therapie von Fettstoffwechselstörungen. Clinical Research in Cardiology Supplements 6:S1, 10-16
CrossRef47
Jiao Guo, Weijian Bei, Yinming Hu, Chunping Tang, Wei He, Xiaobo Liu, Lihua Huang, Yang Cao, Xuguang Hu, Xunlong Zhong, Le Cao. (2011) A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats. Journal of Ethnopharmacology 135:2, 299-307
CrossRef48
Peter M Rothwell, Ale Algra, Pierre Amarenco. (2011) Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. The Lancet 377:9778, 1681-1692
CrossRef49
Carl J. Lavie, Richard V. Milani, James H. OʼKeefe. (2011) Dyslipidemia Intervention in Metabolic Syndrome: Emphasis on Improving Lipids and Clinical Event Reduction. The American Journal of the Medical Sciences 341:5, 388-393
CrossRef50
D. John Betteridge. (2011) Lipid control in patients with diabetes mellitus. Nature Reviews Cardiology 8:5, 278-290
CrossRef51
Preeti Raval, Mukul Jain, Amitgiri Goswami, Sujay Basu, Archana Gite, Atul Godha, Harikishore Pingali, Saurin Raval, Suresh Giri, Dinesh Suthar, Maanan Shah, Pankaj Patel. (2011) Revisiting glitazars: Thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents. Bioorganic & Medicinal Chemistry Letters 21:10, 3103-3109
CrossRef52
Najindra Maharjan, Updesh Bedi, Rohit Arora, Sanjay Bhandari, Pradeep Dahal, Sandeep Khosla. (2011) Impact of Statins on Cardiovascular Outcomes in Renal Transplant Recipients: A Systematic Review. American Journal of Therapeutics 18:3, e48-e54
CrossRef53
Shao Hong, -Quan Chen Li, Xu Jun. (2011) Treatment of dyslipidemia in the elderly. Journal of Geriatric Cardiology 8:1, 55-64
CrossRef54
A. S. Wierzbicki. (2011) Niacin: the only vitamin that reduces cardiovascular events. International Journal of Clinical Practice 65:4, 379-385
CrossRef55
Carlos G Santos-Gallego, Francisco Torres, Juan José Badimón. (2011) The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. Clinical Lipidology 6:2, 181-208
CrossRef56
Amanda N. Long, Samuel Dagogo-Jack. (2011) Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection. The Journal of Clinical Hypertension 13:4, 244-251
CrossRef57
D. S. H. Bell, F. Al Badarin, J. H. O’Keefe. (2011) Therapies for diabetic dyslipidaemia. Diabetes, Obesity and Metabolism 13:4, 313-325
CrossRef58
Stephen J. Nicholls, Allan Gordon, Jan Johansson, Kathy Wolski, Christie M. Ballantyne, John J.P. Kastelein, Allen Taylor, Marilyn Borgman, Steven E. Nissen. (2011) Efficacy and Safety of a Novel Oral Inducer of Apolipoprotein A-I Synthesis in Statin-Treated Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology 57:9, 1111-1119
CrossRef59
Paul Muntner, Fleur Lee, Brad C. Astor. (2011) Association of High-Density Lipoprotein Cholesterol With Coronary Heart Disease Risk Across Categories of Low-Density Lipoprotein Cholesterol: The Atherosclerosis Risk in Communities Study. The American Journal of the Medical Sciences 341:3, 173-180
CrossRef60
Christoph H Saely, Veronika Drexel, Alexander Vonbank, Heinz Drexel. (2011) Lipid management in Type 2 diabetes: the case for combination therapy?. Therapy 8:2, 129-141
CrossRef61
(2011) The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol. American Heart Journal 161:3, 471-477.e2
CrossRef62
Zachary T. Bloomgarden, Andrew Drexler. (2011) Fibrate use in diabetes: New concepts. Journal of Diabetes 3:1, 1-2
CrossRef63
Lawrence A. Leiter, David H. Fitchett, Richard E. Gilbert, Milan Gupta, G.B. John Mancini, Philip A. McFarlane, Robert Ross, Hwee Teoh, Subodh Verma, Sonia Anand, Kathryn Camelon, Chi-Ming Chow, Jafna L. Cox, Jean-Pierre Després, Jacques Genest, Stewart B. Harris, David C.W. Lau, Richard Lewanczuk, Peter P. Liu, Eva M. Lonn, Ruth McPherson, Paul Poirier, Shafiq Qaadri, Rémi Rabasa-Lhoret, Simon W. Rabkin, Arya M. Sharma, Andrew W. Steele, James A. Stone, Jean-Claude Tardif, Sheldon Tobe, Ehud Ur. (2011) Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group. Canadian Journal of Cardiology 27:2, e1-e33
CrossRef64
Ariel Brautbar, Christie M. Ballantyne. (2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology
CrossRef65
Margrit Schwarz, Jae B. Kim. 2011. Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL. , 199-234.
CrossRef66
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary. Journal of the American College of Cardiology 57:8, 1002-1044
CrossRef67
Rai Ajit K. Srivastava, Shirley He, Roger S. Newton. (2011) Differential regulation of human apolipoprotein AI and high-density lipoprotein by fenofibrate in hapoAI and hapoAI–CIII–AIV transgenic mice. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1811:2, 76-83
CrossRef68
Aysha Inankur, Stephen J. Nicholls, Anisa Jahangiri. (2011) High-Density Lipoprotein: Is the Good Cholesterol Turning Bad?. Current Cardiovascular Risk Reports 5:1, 18-28
CrossRef69
Marshall Elam, Laura C Lovato, Henry Ginsberg. (2011) Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective. Current Opinion in Lipidology 22:1, 55-61
CrossRef70
Steven E. Nissen. (2011) Atherosclerosis in 2010: New therapeutic insights. Nature Reviews Cardiology 8:2, 70-72
CrossRef71
B. Karamanos, A. Thanopoulou, V. Drossinos, E. Charalampidou, S. Sourmeli, A. Archimandritis. (2011) Study comparing the effect of pioglitazone in combination with either metformin or sulphonylureas on lipid profile and glycaemic control in patients with type 2 diabetes (ECLA). Current Medical Research and Opinion 27:2, 303-313
CrossRef72
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease. Journal of the American College of Cardiology 57:8, e16-e94
CrossRef73
Eric Bruckert, Julien Labreuche, Dominique Deplanque, Pierre-Jean Touboul, Pierre Amarenco. (2011) Fibrates Effect on Cardiovascular Risk Is Greater in Patients With High Triglyceride Levels or Atherogenic Dyslipidemia Profile: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology 57:2, 267-272
CrossRef74
Marshall Elam, Laura Lovato, Henry Ginsberg. (2011) The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clinical Lipidology 6:1, 9-20
CrossRef75
Michael Clearfield. (2011) Combination Lipid Therapy in Type 2 Diabetes. Current Atherosclerosis Reports 13:1, 1-3
CrossRef76
Hao Wang, Dao-Quan Peng. (2011) New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids in Health and Disease 10:1, 176
CrossRef77
Vivencio Barrios Alonso, Carlos Escobar Cervantes. (2011) Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. Revista Española de Cardiología Suplementos 11, 29-35
CrossRef78
Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John D. Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan B. Fowler, Gary Friday, Vicki S. Hertzberg, E. Bruce McIff, Wesley S. Moore, Peter D. Panagos, Thomas S. Riles, Robert H. Rosenwasser, Allen J. Taylor, Alice K. Jacobs, Sidney C. Smith, Jeffery L. Anderson, Cynthia D. Adams, Nancy Albert, Christopher E. Buller, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Sharon Ann Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick A. Nishimura, E. Magnus Ohman, Richard L. Page, Barbara Riegel, William G. Stevenson, Lynn G. Tarkington, Clyde W. Yancy. (2011) 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive summary. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef79
Jerome L. Fleg, Wilbert S. Aronow, William H. Frishman. (2011) Cardiovascular drug therapy in the elderly: benefits and challenges. Nature Reviews Cardiology 8:1, 13-28
CrossRef80
Sung-Tae Kim, Byung-Joon Kim, Dong-Mee Lim, In-Geol Song, Jang-Han Jung, Kang-Woo Lee, Keun-Young Park, Youn-Zoo Cho, Dae-Ho Lee, Gwan-Pyo Koh. (2011) Basal C-peptide Level as a Surrogate Marker of Subclinical Atherosclerosis in Type 2 Diabetic Patients. Diabetes & Metabolism Journal 35:1, 41
CrossRef81
Alexandros Vakalopoulos, Carsten Schmeck, Michael Thutewohl, Volkhart Li, Hilmar Bischoff, Klemens Lustig, Olaf Weber, Holger Paulsen, Harry Elias. (2011) Chromanol derivatives—A novel class of CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 21:1, 488-491
CrossRef82
Donovan McGrowder, Cliff Riley, Errol Y. St. A. Morrison, Lorenzo Gordon. (2011) The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer. Cholesterol 2011, 1-9
CrossRef83
T. A. Jacobson. (2011) ‘Trig-onometry’: non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia. International Journal of Clinical Practice 65:1, 82-101
CrossRef84
Hye Jin Kim, Hyun Ah Park, Young Gyu Cho, Jae Heon Kang, Kyoung Woo Kim, Joo Ho Kang, Nu-Ri Kim, Won-Chin Chung, Cheol Hwan Kim, Dong Hee Whang, Jin Kyun Park. (2011) Gender Difference in the Level of HDL Cholesterol in Korean Adults. Korean Journal of Family Medicine 32:3, 173
CrossRef85
Ines Kämmerer, Robert Ringseis, Klaus Eder. (2011) Feeding a thermally oxidised fat inhibits atherosclerotic plaque formation in the aortic root of LDL receptor-deficient mice. British Journal of Nutrition 105:02, 190-199
CrossRef86
Li Lin, Hui Gong, Jingyi Ge, Guoliang Jiang, Ning Zhou, Lei Li, Yong Ye, Guoping Zhang, Junbo Ge, Yunzeng Zou. (2011) High density lipoprotein downregulates angiotensin II type 1 receptor and inhibits angiotensin II-induced cardiac hypertrophy. Biochemical and Biophysical Research Communications 404:1, 28-33
CrossRef87
Ines Kammerer, Robert Ringseis, Ronald Biemann, Gaiping Wen, Klaus Eder. (2011) 13-hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophages. Lipids in Health and Disease 10:1, 222
CrossRef88
Antonio Pérez, Cintia González Blanco, Miguel Ángel Hernández-Presa, José Chaves. (2011) Therapeutic approach to dyslipidemia and goal achievement in a Spanish population with type 2 diabetes without cardiovascular disease. Endocrinología y Nutrición (English Edition) 58:6, 283-290
CrossRef89
Michel Farnier, Qian Dong, Arvind Shah, Amy O Johnson-Levonas, Philippe Brudi. (2011) Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. Lipids in Health and Disease 10:1, 212
CrossRef90
Joseph E. Thomas, Andrew M. Tershakovec, Charlotte Jones-Burton, Reza A. Sayeed, JoAnne M. Foody. (2010) Lipid Lowering for Secondary Prevention of Cardiovascular Disease in Older Adults. Drugs & Aging 27:12, 959-972
CrossRef91
Satyam Sarma, Hossein Ardehali, Mihai Gheorghiade. (2010) Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure. Heart Failure Reviews
CrossRef92
M. Rizzo, K. Berneis, S. Koulouris, S. Pastromas, G. B. Rini, D. Sakellariou, A. S. Manolis. (2010) Should we measure routinely oxidised and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?. International Journal of Clinical Practice 64:12, 1632-1642
CrossRef93
Rohit Seth Loomba, Rohit Arora. (2010) Prevention of Cardiovascular Disease Utilizing Fibrates-A Pooled Meta-analysis. American Journal of Therapeutics 17:6, e182-e188
CrossRef94
Barry H. Greenberg, Denise D. Barnard. 2010. Preventing Heart Failure. , 1-26.
CrossRef95
Christine Dawczynski, Lena Martin, Andreas Wagner, Gerhard Jahreis. (2010) n−3 LC-PUFA-enriched dairy products are able to reduce cardiovascular risk factors: A double-blind, cross-over study. Clinical Nutrition 29:5, 592-599
CrossRef96
Terry A Jacobson, Peter H Jones, Eli M Roth. (2010) Combination therapy with rosuvastatin and fenofibric acid for mixed dyslipidemia: overview of efficacy and safety. Clinical Lipidology 5:5, 627-649
CrossRef97
Peter T.W. Cheng, Ellen Kick, Ranjan Mukherjee. 2010. Nuclear Hormone Receptor Medicinal Chemistry. .
CrossRef98
James, W. Philip T., Caterson, Ian D., Coutinho, Walmir, Finer, Nick, Van Gaal, Luc F., Maggioni, Aldo P., Torp-Pedersen, Christian, Sharma, Arya M., Shepherd, Gillian M., Rode, Richard A., Renz, Cheryl L., . (2010) Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. New England Journal of Medicine 363:10, 905-917
Full Text99
Chris J Packard. (2010) Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology 3:5, 649-661
CrossRef100
Stephen J. Nicholls, Kiyoko Uno, E. Murat Tuzcu, Steven E. Nissen. (2010) Lessons from Coronary Intravascular Ultrasound on the Importance of Raising High-Density Lipoprotein Cholesterol. Current Atherosclerosis Reports 12:5, 301-307
CrossRef101
Justin MS Lee, Robin P Choudhury. (2010) Atherosclerosis regression and high-density lipoproteins. Expert Review of Cardiovascular Therapy 8:9, 1325-1334
CrossRef102
Anthony S. Wierzbicki, Jonathan Morrell, Deborah Hemsley, Zofia McMahon, Martin A. Crook, Richard Wray. (2010) The effect of fibrate–statin combination therapy on cardiovascular events: a retrospective cohort analysis. Current Medical Research and Opinion 26:9, 2141-2146
CrossRef103
Julien Labreuche, Dominique Deplanque, Pierre-Jean Touboul, Eric Bruckert, Pierre Amarenco. (2010) Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis. Atherosclerosis 212:1, 9-15
CrossRef104
Matthew A. Cavender, A. Michael Lincoff. (2010) Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist. American Journal Cardiovascular Drugs 10:4, 209-216
CrossRef105
Kunal N. Bhatt, Bryan J. Wells, Laurence S. Sperling, Jefferson T. Baer. (2010) High-Density Lipoprotein Therapy: Is There Hope?. Current Treatment Options in Cardiovascular Medicine 12:4, 315-328
CrossRef106
Ishwarlal Jialal, William Amess, Manpreet Kaur. (2010) Management of Hypertriglyceridemia in the Diabetic Patient. Current Diabetes Reports 10:4, 316-320
CrossRef107
J.C. Fruchart, F.M. Sacks, M.P. Hermans. (2010) Implications of the ACCORD Lipid study: perspective from the Residual Risk Reduction Initiative (R 3 i). Current Medical Research and Opinion 26:8, 1793-1797
CrossRef108
Anthony S Wierzbicki. (2010) Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Current Opinion in Lipidology 21:4, 352-358
CrossRef109
Peter M. Nilsson, Adie Viljoen, Anthony S. Wierzbicki. 2010. Cardiovascular Risk Factors. , 657-683.
CrossRef110
Alan J. Sinclair. 2010. Diabetes in Old Age. , 922-939.
CrossRef111
Timo E Strandberg. (2010) Lipid-lowering drugs and heart failure: where do we go after the statin trials?. Current Opinion in Cardiology 25:4, 385-393
CrossRef112
Mariam Farhad, Kasipathy Kailasapathy, Jyoti Tamang. 2010. Health Aspects of Fermented Foods. , 391-414.
CrossRef113
Xavier Pintó, Jesús Millán, Anna Muñoz, Emili Corbella, Antonio Hernández-Mijares, Manuel Zuñiga, Alipio Mangas, Juan Pedro-Botet. (2010) A Very High Prevalence of Low HDL Cholesterol in Spanish Patients With Acute Coronary Syndromes. Clinical Cardiology 33:7, 418-423
CrossRef114
Pit Sertznig, Markus Seifert, Wolfgang Tilgen, Jörg Reichrath. (2010) Peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) signaling pathways in melanoma cells: Promising new therapeutic targets?. The Journal of Steroid Biochemistry and Molecular Biology 121:1-2, 383-386
CrossRef115
Carl J. Fichtenbaum, Tzu-Min Yeh, Scott R. Evans, Judith A. Aberg. (2010) Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087. Journal of Clinical Lipidology 4:4, 279-287
CrossRef116
Jesús Millán Nú˜ez-Cortés, Juan Pedro-Botet Montoya, Xavier Pintó Sala. (2010) Riesgo vascular residual: recomendaciones de la Iniciativa Espa˜ola para la Reducción del Riesgo Residual. Medicina Clínica 135:4, 165-171
CrossRef117
M Fisher. (2010) Half full, half empty, or negative? Results of recent clinical trials. Practical Diabetes International 27:5, 174-175
CrossRef118
Haseeb Jafri, Alawi A. Alsheikh-Ali, Richard H. Karas. (2010) Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. Journal of the American College of Cardiology 55:25, 2846-2854
CrossRef119
Jennifer G. Robinson. (2010) Low High-Density Lipoprotein Cholesterol and Chronic Disease Risk. Journal of the American College of Cardiology 55:25, 2855-2857
CrossRef120
D Sanoudou, A Duka, K Drosatos, K C Hayes, V I Zannis. (2010) Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice. The Pharmacogenomics Journal 10:3, 165-179
CrossRef121
Eric Bruckert, Julien Labreuche, Pierre Amarenco. (2010) Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 210:2, 353-361
CrossRef122
M. John Chapman, Jan S. Redfern, Mark E. McGovern, Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, 314-345
CrossRef123
Matthew A. Cavender, Stephen J. Nicholls, A. Michael Lincoff. (2010) Strategies for the development of new PPAR agonists in diabetes. European Journal of Cardiovascular Prevention & Rehabilitation 17, S32-S37
CrossRef124
Bart Staels. (2010) Fibrates in CVD: a step towards personalised medicine. The Lancet 375:9729, 1847-1848
CrossRef125
Stephen J. Nicholls, Pia Lundman, Jean-Claude Tardif. (2010) Diabetic dyslipidemia: extending the target beyond LDL cholesterol. European Journal of Cardiovascular Prevention & Rehabilitation 17, S20-S24
CrossRef126
Min Jun, Celine Foote, Jicheng Lv, Bruce Neal, Anushka Patel, Stephen J Nicholls, Diederick E Grobbee, Alan Cass, John Chalmers, Vlado Perkovic. (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. The Lancet 375:9729, 1875-1884
CrossRef127
Anthony D. Goei, Laura K. Findeiss, Ahmad M. Slim. (2010) Medical Management in Peripheral Arterial Disease: A Systematic Approach to Medical Therapy. Journal of Vascular and Interventional Radiology 21:5, 603-605
CrossRef128
Sandeep A. Saha, Rohit R. Arora. (2010) Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus – A pooled meta-analysis of randomized placebo-controlled clinical trials. International Journal of Cardiology 141:2, 157-166
CrossRef129
David Lewis, Richard Haynes, Martin J. Landray. (2010) LIPIDS IN CHRONIC KIDNEY DISEASE. Journal of Renal Care 36, 27-33
CrossRef130
Wilbert S. Aronow, William H. Frishman. (2010) Management of Hypercholesterolemia in Older Persons for the Prevention of Cardiovascular Disease. Cardiology in Review 18:3, 132-140
CrossRef131
The ACCORD Study Group. (2010) Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine 362:17, 1563-1574
Full Text132
Justin W. Timbie, Rodney A. Hayward, Sandeep Vijan. (2010) Diminishing Efficacy of Combination Therapy, Response-Heterogeneity, and Treatment Intolerance Limit the Attainability of Tight Risk Factor Control in Patients with Diabetes. Health Services Research 45:2, 437-456
CrossRef133
Gerald W. Smetana, Jane S. Sillman. (2010) Update in New Medications for Primary Care. Journal of General Internal Medicine 25:3, 261-269
CrossRef134
Khalid Alwaili, Zuhier Awan, Ali Alshahrani, Jacques Genest. (2010) High-density lipoproteins and cardiovascular disease: 2010 update. Expert Review of Cardiovascular Therapy 8:3, 413-423
CrossRef135
Masaki Yoshida, Nagakatsu Harada, Keiko Yoshida, Tadahiko Nakagawa, Takaaki Shimohata, Kazuaki Mawatari, Akira Takahashi, Hiroshi Sakaue, Yutaka Nakaya. (2010) High density lipoprotein inhibits the activation of sterol regulatory element-binding protein-1 in cultured cells. FEBS Letters 584:6, 1217-1222
CrossRef136
Juan José Badimón, Borja Ibáñez. (2010) Incremento de las HDL como arma terapéutica en la aterotrombosis. Revista Española de Cardiología 63:3, 323-333
CrossRef137
Fredrick L. Dunn. (2010) Management of dyslipidemia in people with type 2 diabetes mellitus. Reviews in Endocrine and Metabolic Disorders 11:1, 41-51
CrossRef138
Pradeep Natarajan, Kausik K. Ray, Christopher P. Cannon. (2010) High-Density Lipoprotein and Coronary Heart Disease. Journal of the American College of Cardiology 55:13, 1283-1299
CrossRef139
N.F. Nguemaim, J. Mbuagbaw, T. Nkoa, G. Teto, G.R. Njitchouan, D.J. Pouomogne, A. Same-Ekobo, T. Asonganyi. (2010) Changes in Lipid Profiles in Two Groups of HIV-1 Infected Patients in Cameroon on Two Treatment Regimens with Either Efavirenz or Nevirapine, in Association with Reverse Transcriptase Inhibitors. Journal of Medical Sciences(Faisalabad) 10:2, 25-33
CrossRef140
M. J. Chapman, W. Le Goff, M. Guerin, A. Kontush. (2010) Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. European Heart Journal 31:2, 149-164
CrossRef141
Kiyoko Uno, Stephen J. Nicholls. (2010) Statin Effects on Both Low-Density Lipoproteins and High-Density Lipoproteins: Is There a Dual Benefit?. Current Atherosclerosis Reports 12:1, 14-19
CrossRef142
Vasilisa Sazonov, Joel Beetsch, Hemant Phatak, Chuck Wentworth, Marc Evans. (2010) Association between dyslipidemia and vascular events in patients treated with statins: Report from the UK General Practice Research Database. Atherosclerosis 208:1, 210-216
CrossRef143
Shepard D. Weiner, LeRoy E. Rabbani. (2010) Secondary prevention strategies for coronary heart disease. Journal of Thrombosis and Thrombolysis 29:1, 8-24
CrossRef144
Michael L. Cunningham, Bradley J. Collins, Milton R. Hejtmancik, Ronald A. Herbert, Gregory S. Travlos, Molly K. Vallant, Matthew D. Stout. (2010) Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism. PPAR Research 2010, 1-14
CrossRef145
Juan José Badimón, Carlos G. Santos-Gallego, Lina Badimón. (2010) Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos?. Revista Española de Cardiología 63, 20-35
CrossRef146
Maryam Rakhshandehroo, Bianca Knoch, Michael Müller, Sander Kersten. (2010) Peroxisome Proliferator-Activated Receptor Alpha Target Genes. PPAR Research 2010, 1-20
CrossRef147
Christoph H. Saely, Heinz Drexel. (2010) Bedeutung der Lipidtherapie bei Diabetes. Wiener Medizinische Wochenschrift 160:1-2, 25-29
CrossRef148
Robert S. Rosenson. (2009) Management of non-high-density lipoprotein abnormalities. Atherosclerosis 207:2, 328-335
CrossRef149
Peter H Jones. (2009) Fenofibric acid plus statin combination therapy for the treatment of mixed dyslipidemia. Clinical Lipidology 4:6, 699-711
CrossRef150
B. Singh, S. Arora, B. Goswami, V. Mallika. (2009) Metabolic syndrome: A review of emerging markers and management. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 3:4, 240-254
CrossRef151
Koichi Aizawa, Takahiro Inakuma. (2009) Dietary capsanthin, the main carotenoid in paprika ( Capsicum annuum), alters plasma high-density lipoprotein-cholesterol levels and hepatic gene expression in rats. British Journal of Nutrition 102:12, 1760
CrossRef152
Heinz Drexel. (2009) Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?. Fundamental & Clinical Pharmacology 23:6, 687-692
CrossRef153
Tiziana Sampietro, Federico Bigazzi, Mariarita Puntoni, Fabrizio Minichilli, Patrizia Landi, Beatrice Dal Pino, Clara Carpeggiani, Antonio LʼAbbate. (2009) Low high-density lipoprotein predicts death in patients with mild left ventricular dysfunction regardless of coronary atherosclerosis. Journal of Cardiovascular Medicine 10:12, 898-905
CrossRef154
Christina Voulgari, Nicholas Tentolouris. (2009) Combination of nateglinide with thiazolidinediones in Type 2 diabetes. Expert Review of Endocrinology & Metabolism 4:6, 537-552
CrossRef155
Farhan Aslam, Attiya Haque, L. Veronica Lee, JoAnne Foody. (2009) Hyperlipidemia in Older Adults. Clinics in Geriatric Medicine 25:4, 591-606
CrossRef156
Riccardo Candido, Stella Bernardi, Terri J Allen. (2009) Linking diabetes and atherosclerosis. Expert Review of Endocrinology & Metabolism 4:6, 603-624
CrossRef157
Christine T. Cigolle, Caroline S. Blaum, Jeffrey B. Halter. (2009) Diabetes and Cardiovascular Disease Prevention in Older Adults. Clinics in Geriatric Medicine 25:4, 607-641
CrossRef158
Elizabeth Morse, Erin Selim, Robyn Cunard. (2009) PPARα ligands cause lymphocyte depletion and cell cycle block and this is associated with augmented TRB3 and reduced Cyclin B1 expression. Molecular Immunology 46:16, 3454-3461
CrossRef159
Maurizio Paciaroni, Julien Bogousslavsky. (2009) Statins and stroke prevention. Expert Review of Cardiovascular Therapy 7:10, 1231-1243
CrossRef160
Jacques Genest, Ruth McPherson, Jiri Frohlich, Todd Anderson, Norm Campbell, André Carpentier, Patrick Couture, Robert Dufour, George Fodor, Gordon A. Francis, Steven Grover, Milan Gupta, Robert A. Hegele, David C. Lau, Lawrence Leiter, Gary F. Lewis, Eva Lonn, G.B. John Mancini, Dominic Ng, Glen J. Pearson, Allan Sniderman, James A. Stone, Ehud Ur. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Canadian Journal of Cardiology 25:10, 567-579
CrossRef161
R Olufadi, SH Wild, CD Byrne. 2009. Cholesterol Metabolism and Vascular Disease. .
CrossRef162
Henry N. Ginsberg, Paul R. MacCallum. (2009) The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: II. Therapeutic Management of Atherogenic Dyslipidemia. The Journal of Clinical Hypertension 11:9, 520-527
CrossRef163
M. Miller. (2009) Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM 102:9, 657-667
CrossRef164
Robert Berent, Serge P. von Duvillard, Johann Auer, Helmut Sinzinger, Peter Schmid. (2009) Lack of supervision after residential cardiac rehabilitation increases cardiovascular risk factors. European Journal of Cardiovascular Prevention & Rehabilitation1
CrossRef165
Christos D. Liapis, Efthimias D. Avgerinos, Nicholas P. Kadoglou, John D. Kakisis. (2009) Reply. Journal of Vascular Surgery 50:3, 707
CrossRef166
Derek J Hausenloy, Derek M Yellon. (2009) Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Current Opinion in Cardiology 24:5, 473-482
CrossRef167
J. E. Tomassini, T. Mazzone, R. B. Goldberg, J. R. Guyton, R. S. Weinstock, A. Polis, E. Jensen, A. M. Tershakovec. (2009) Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes, Obesity and Metabolism 11:9, 855-864
CrossRef168
Iwona Rudkowska, Christophe Garenc, Patrick Couture, Marie-Claude Vohl. (2009) Omega-3 fatty acids regulate gene expression levels differently in subjects carrying the PPARα L162V polymorphism. Genes & Nutrition 4:3, 199-205
CrossRef169
Terje R. Pedersen. (2009) Lipid-lowering drugs and risk for cancer. Current Atherosclerosis Reports 11:5, 350-357
CrossRef170
John A. Morrison, Charles J. Glueck, Paul S. Horn, Samrat Yeramaneni, Ping Wang. (2009) Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life. Metabolism 58:9, 1277-1284
CrossRef171
Terry A. Jacobson. (2009) Myopathy with statin–fibrate combination therapy: clinical considerations. Nature Reviews Endocrinology 5:9, 507-518
CrossRef172
Ambra Pozzi, Roy Zent. (2009) Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products. Wiley Interdisciplinary Reviews: Systems Biology and Medicine 1:2, 254-272
CrossRef173
T W Mahungu, D Nair, C J Smith, D Egan, M Youle, M A Johnson, S H Khoo, D J Back, A Owen. (2009) The Relationships of ABCB1 3435C>T and CYP2B6 516G>T With High-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Efavirenz. Clinical Pharmacology & Therapeutics 86:2, 204-211
CrossRef174
Diana R. Chirovsky, Veronika Fedirko, Yadong Cui, Vasilisa Sazonov, Philip Barter. (2009) Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. European Journal of Cardiovascular Prevention & Rehabilitation 16:4, 404-423
CrossRef175
Robert Berent, S. P. Duvillard, J. Auer, H. Sinzinger, P. Schmid. (2009) Patienten in der kardiovaskulären Rehabilitation - ein Erfolg nach 16 Monaten?. Sport- und Präventivmedizin 39:2, 22-28
CrossRef176
M. Hanefeld. (2009) The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes, Obesity and Metabolism 11:8, 742-756
CrossRef177
G. R. Hajer, Y. van der Graaf, M. L. Bots, A. Algra, F. L. J. Visseren, . (2009) Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c. European Journal of Clinical Investigation 39:8, 680-688
CrossRef178
Masaki Ogata, Maki Tsujita, Mohammad Anwar Hossain, Nobukatsu Akita, Frank J. Gonzalez, Bart Staels, Shogo Suzuki, Tatsuya Fukutomi, Genjiro Kimura, Shinji Yokoyama. (2009) On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis 205:2, 413-419
CrossRef179
William H. Smiley, Bobby V. Khan, Laurence S. Sperling. (2009) Management of the statin-intolerant patient. Current Treatment Options in Cardiovascular Medicine 11:4, 263-271
CrossRef180
Jean-Charles Fruchart. (2009) Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 205:1, 1-8
CrossRef181
Anthony S Wierzbicki. (2009) Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Current Opinion in Cardiology 24:4, 372-379
CrossRef182
Brian K Irons. (2009) Research Highlights. Therapy 6:4, 469-473
CrossRef183
Carlos Lahoz, José M. Mostaza. (2009) Colesterol ligado a lipoproteínas de alta densidad: de factor de riesgo a diana terapéutica. Medicina Clínica 133:6, 229-234
CrossRef184
Gerald M. Reaven, Jeffrey A. Lieberman, Gopalan Sethuraman, Helena Kraemer, John M. Davis, Christine Blasey, Ming T. Tsuang, Alan F. Schatzberg. (2009) In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. Journal of Psychiatric Research 43:11, 997-1002
CrossRef185
Xiushui Ren, Marina Trilesskaya, Damon M. Kwan, Kim Nguyen, Richard E. Shaw, Peter Y. Hui. (2009) Comparison of Outcomes Using Bare Metal Versus Drug-Eluting Stents in Coronary Artery Disease Patients With and Without Human Immunodeficiency Virus Infection. The American Journal of Cardiology 104:2, 216-222
CrossRef186
Kristina Lindemann, Lars J. Vatten, Marie Ellstrøm-Engh, Anne Eskild. (2009) Serum lipids and endometrial cancer risk: Results from the HUNT-II study. International Journal of Cancer 124:12, 2938-2941
CrossRef187
Emma Robinson, David J. Grieve. (2009) Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacology & Therapeutics 122:3, 246-263
CrossRef188
TD Filippatos, CS Derdemezis, MS Elisaf. (2009) Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors. Clinical Lipidology 4:3, 331-341
CrossRef189
Hiroshi Ashikaga, Roger S. Blumenthal, Steven R. Jones. (2009) Utility of Ezetimibe. The American Journal of Cardiology 103:9, 1321-1322
CrossRef190
Heiko Zettl, Michaela Dittrich, Ramona Steri, Ewgenij Proschak, Oliver Rau, Dieter Steinhilber, Gisbert Schneider, Michael Lämmerhofer, Manfred Schubert-Zsilavecz. (2009) Novel Pirinixic Acids as PPARα Preferential Dual PPARα/γ Agonists. QSAR & Combinatorial Science 28:5, 576-586
CrossRef191
Emmanuelle Jeanpierre, Thierry Le Tourneau, Christophe Zawadzki, Eric Van Belle, Frederic Mouquet, Sophie Susen, Michael D. Ezekowitz, Bart Staels, Brigitte Jude, Delphine Corseaux. (2009) Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits. Cardiovascular Pathology 18:3, 140-147
CrossRef192
A. Selcuk Adabag, Salima Mithani, Basel Al Aloul, Dorothea Collins, Stefan Bertog, Hanna E. Bloomfield. (2009) Efficacy of gemfibrozil in the primary prevention of atrial fibrillation in a large randomized controlled trial. American Heart Journal 157:5, 913-918
CrossRef193
Serge Rezzi, François-Pierre J. Martin, Dhanansayan Shanmuganayagam, Ricki J. Colman, Jeremy K. Nicholson, Richard Weindruch. (2009) Metabolic shifts due to long-term caloric restriction revealed in nonhuman primates. Experimental Gerontology 44:5, 356-362
CrossRef194
Ewa Dembowski, Michael H Davidson. (2009) Statin and ezetimibe combination therapy in cardiovascular disease. Current Opinion in Endocrinology, Diabetes and Obesity 16:2, 183-188
CrossRef195
Natacha Porta, Louis Vallée, Cécile Lecointe, Emmanuel Bouchaert, Bart Staels, Régis Bordet, Stéphane Auvin. (2009) Fenofibrate, a peroxisome proliferator-activated receptor-α agonist, exerts anticonvulsive properties. Epilepsia 50:4, 943-948
CrossRef196
Tamar Polonsky, Theodore Mazzone, Michael Davidson. (2009) The Clinical Implications of the CHICAGO Study for the Management of Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus. Trends in Cardiovascular Medicine 19:3, 94-99
CrossRef197
JWA Van Der Hoorn, JW Jukema, LM Havekes, E Lundholm, G Camejo, PCN Rensen, HMG Princen. (2009) The dual PPARα/γ agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. British Journal of Pharmacology 156:7, 1067-1075
CrossRef198
Julien Labreuche, Pierre-Jean Touboul, Pierre Amarenco. (2009) Plasma triglyceride levels and risk of stroke and carotid atherosclerosis: A systematic review of the epidemiological studies. Atherosclerosis 203:2, 331-345
CrossRef199
Subramaniam Tavintharan, Su Chi Lim, Chee Fang Sum. (2009) Effects of Niacin on Cell Adhesion and Early Atherogenesis: Biochemical and Functional Findings in Endothelial Cells. Basic & Clinical Pharmacology & Toxicology 104:3, 206-210
CrossRef200
Venkateshwar R. Polsani, Salim S. Virani, Vijay Nambi. (2009) Lipid management: Considerations in acute coronary syndrome. Current Atherosclerosis Reports 11:2, 149-156
CrossRef201
Manfredi Rizzo, Ali A. Rizvi, Giovam Battista Rini, Kaspar Berneis. (2009) The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. Acta Diabetologica 46:1, 1-11
CrossRef202
Arshag D Mooradian. (2009) Dyslipidemia in type 2 diabetes mellitus. Nature Clinical Practice Endocrinology & Metabolism 5:3, 150-159
CrossRef203
(2009) Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST. Revista Española de Cardiología 62:3, 293.e1-293.e47
CrossRef204
Joe F. Lau, Donald A. Smith. (2009) Advanced Lipoprotein Testing: Recommendations Based on Current Evidence. Endocrinology & Metabolism Clinics of North America 38:1, 1-31
CrossRef205
Ira J. Goldberg. (2009) Hypertriglyceridemia: Impact and Treatment. Endocrinology & Metabolism Clinics of North America 38:1, 137-149
CrossRef206
Peter P. Toth. (2009) Novel Therapies for Increasing Serum Levels of HDL. Endocrinology & Metabolism Clinics of North America 38:1, 151-170
CrossRef207
Eva Boes, Stefan Coassin, Barbara Kollerits, Iris M. Heid, Florian Kronenberg. (2009) Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: A systematic in-depth review. Experimental Gerontology 44:3, 136-160
CrossRef208
M. Reimann, E. Bonifacio, M. Solimena, P.E.H. Schwarz, B. Ludwig, M. Hanefeld, S.R. Bornstein. (2009) An update on preventive and regenerative therapies in diabetes mellitus. Pharmacology & Therapeutics 121:3, 317-331
CrossRef209
Suzanne Hughes. (2009) On the road to better dyslipidemia outcomes. The Nurse Practitioner 34:2, 14-21
CrossRef210
M. B. Davidson, T. Hu, Guven Sain, B. Hoar, C. Stevenson, B. J. Hoogwerf. (2009) The relationship of glycaemic control and triglycerides in patients with diabetes mellitus: a PreCIS Database Study. Diabetes, Obesity and Metabolism 11:2, 118-122
CrossRef211
Hemanth Neeli, Ram Gadi, Daniel J. Rader. (2009) Managing diabetic dyslipidemia: Beyond statin therapy. Current Diabetes Reports 9:1, 11-17
CrossRef212
Edip Ucar, Can Huzmeli, Oguz Guven, Nazan Savas, Murat Gullu, Sema Asilyoruk, Ceren Kuvandik, Aysegul Temizkan, Guven Kuvandik. (2009) Frequency of Metabolic Syndrome among Hemodialysis Patients According to NCEP-ATP III and IDF Definitions. Renal Failure 31:3, 221-228
CrossRef213
Dongsoon Shin. (2009) The effect of seamustard on blood lipid profiles and glucose level of rats fed diet with different energy composition. Nutrition Research and Practice 3:1, 31
CrossRef214
Jean-Claude Tardif, Therese Heinonen, Stephane Noble. (2009) High-density lipoprotein/apolipoprotein A-I infusion therapy. Current Atherosclerosis Reports 11:1, 58-63
CrossRef215
R. R. Holman, S. Paul, A. Farmer, L. Tucker, I. M. Stratton, H. A. W. Neil, . (2009) Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. Diabetologia 52:1, 50-59
CrossRef216
Frank Hermann, Frank Enseleit, Lukas E. Spieker, Daniel Périat, Isabella Sudano, Matthias Hermann, Roberto Corti, Georg Noll, Frank Ruschitzka, Thomas F. Lüscher. (2009) Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia. Thrombosis Research 123:3, 460-465
CrossRef217
Kathryn Z. Guyton, Weihsueh A. Chiu, Thomas F. Bateson, Jennifer Jinot, Cheryl Siegel Scott, Rebecca C. Brown, Jane C. Caldwell. (2009) A Reexamination of the PPAR-α Activation Mode of Action as a Basis for Assessing Human Cancer Risks of Environmental Contaminants. Environmental Health Perspectives
CrossRef218
Michael T. McDermott. 2009. Lipid Disorders. , 65-75.
CrossRef219
Robert Guthrie. (2009) Should we treat all primary prevention patients with statins?. Current Atherosclerosis Reports 11:1, 36-42
CrossRef220
Jennifer G. Robinson, Songfeng Wang, Brian J. Smith, Terry A. Jacobson. (2009) Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk. Journal of the American College of Cardiology 53:4, 316-322
CrossRef221
Carlos A. Alvarez, Nicole M. Russell, Krystal L. Edwards, R. Shane Greene, Lisa M. Chastain, Rick A. Weideman, Anthony J. Busti. (2008) Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population. Journal of Clinical Lipidology 2:6, 447-452
CrossRef222
Herbert D. Aronow, A. Michael Lincoff, Martin J. Quinn, A. Thomas McRae, Hitinder S. Gurm, Penny L. Houghtaling, Christopher B. Granger, Robert A. Harrington, Franz Van de Werf, Eric J. Topol, Michael S. Lauer. (2008) Relation Between Previous Lipid-Lowering Therapy and Infarct Size (Creatine Kinase-MB Level) in Patients Presenting With Acute Myocardial Infarction. The American Journal of Cardiology 102:9, 1119-1124
CrossRef223
Karam Kostner, Soneil Gupta. (2008) Niacin: a lipid polypill?. Expert Opinion on Pharmacotherapy 9:16, 2911-2920
CrossRef224
Alp Burak Catakoglu, Belgin Süsleyici Duman, Hilal Kurtoğlu, Melike Ersöz, Murat Şener, Hüseyin Çelebi, Penbe Çağatay, Vedat Aytekin, Saide Aytekin. (2008) Common Variants in the ATP-binding Cassette Transporter 1 Gene with Decreased HDL-Cholesterol Levels and Coronary Artery Disease. Archives of Medical Research 39:8, 735-742
CrossRef225
Ángel Rodríguez, Jesús Reviriego, Pepa Polavieja, Jordi Mesa. (2008) Efectividad y tolerabilidad a 6 meses de la pioglitazona en combinación con sulfonilureas o metformina en el tratamiento de la diabetes mellitus tipo 2. Medicina Clínica 131:19, 721-730
CrossRef226
Peter P. Toth. (2008) When high is low: Raising low levels of high-density lipoprotein cholesterol. Current Cardiology Reports 10:6, 488-496
CrossRef227
Robert S Rosenson. (2008) Fenofibrate: treatment of hyperlipidemia and beyond. Expert Review of Cardiovascular Therapy 6:10, 1319-1330
CrossRef228
, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, A. Kastrati, A. Rosengren, P. G. Steg, M. Tubaro, F. Verheugt, F. Weidinger, M. Weis, , A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S. D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J. L. Zamorano, , S. Silber, F. V. Aguirre, N. Al-Attar, E. Alegria, F. Andreotti, W. Benzer, O. Breithardt, N. Danchin, C. D. Mario, D. Dudek, D. Gulba, S. Halvorsen, P. Kaufmann, R. Kornowski, G. Y. H. Lip, F. Rutten. (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:. European Heart Journal 29:23, 2909-2945
CrossRef229
Theodosios Filippatos, Haralampos J Milionis. (2008) Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opinion on Investigational Drugs 17:10, 1599-1614
CrossRef230
Christopher M. Rembold. (2008) To statin or to non-statin in coronary disease-considering absolute risk is the answer. Atherosclerosis 200:2, 447
CrossRef231
William G. Henderson, Philip W. Lavori, Peter Peduzzi, Joseph F. Collins, Mike R. Sather, John R. Feussner. 2008. Cooperative Studies Program, US Department of Veterans Affairs. .
CrossRef232
Emile Mohler, Jay Giri. (2008) Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines. Current Medical Research and Opinion 24:9, 2509-2522
CrossRef233
M. Mastorikou, B. Mackness, Y. Liu, M. Mackness. (2008) Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabetic Medicine 25:9, 1049-1055
CrossRef234
Panupong Jiamsripong, Martina Mookadam, Mohsen S. Alharthi, Bijoy K. Khandheria, Farouk Mookadam. (2008) The Metabolic Syndrome and Cardiovascular Disease: Part 2. Preventive Cardiology 11:4, 223-229
CrossRef235
Bart Staels, Michel Maes, Alberto Zambon. (2008) Fibrates and future PPARα agonists in the treatment of cardiovascular disease. Nature Clinical Practice Cardiovascular Medicine 5:9, 542-553
CrossRef236
Julian O.M. Ormerod, Houman Ashrafian, Michael P. Frenneaux. (2008) Impaired energetics in heart failure — A new therapeutic target. Pharmacology & Therapeutics 119:3, 264-274
CrossRef237
Bin Zhang, Joe Menzin, Mark Friedman, Jonathan R. Korn, Russel T. Burge. (2008) Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination Survey. Current Medical Research and Opinion 24:9, 2711-2717
CrossRef238
Jonathan Belsey, Simon de Lusignan, Tom Chan, Jeremy van Vlymen, Nigel Hague. (2008) Abnormal lipids in high-risk patients achieving cholesterol targets: a cross-sectional study of routinely collected UK general practice data. Current Medical Research and Opinion 24:9, 2551-2560
CrossRef239
Gabriela Orasanu, Ouliana Ziouzenkova, Pallavi R. Devchand, Vedika Nehra, Osama Hamdy, Edward S. Horton, Jorge Plutzky. (2008) The Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-α–Dependent Manner In Vitro and In Vivo in Mice. Journal of the American College of Cardiology 52:10, 869-881
CrossRef240
Alice Y. Y. Cheng, Lawrence A. Leiter. (2008) PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease. Diabetes, Obesity and Metabolism 10:9, 691-698
CrossRef241
Raul D. Santos, Bela F. Asztalos, Lilton R.C. Martinez, Marcio H. Miname, Eliana Polisecki, Ernst J. Schaefer. (2008) Clinical presentation, laboratory values, and coronary heart disease risk in marked high-density lipoprotein–deficiency states. Journal of Clinical Lipidology 2:4, 237-247
CrossRef242
Fergus McTaggart, Peter Jones. (2008) Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit. Cardiovascular Drugs and Therapy 22:4, 321-338
CrossRef243
James K. Liao. (2008) Clinical trials report. Current Atherosclerosis Reports 10:4, 281-283
CrossRef244
Ekaterini Vourvouhaki, George V Dedoussis. (2008) Cholesterol ester transfer protein: a therapeutic target in atherosclerosis?. Expert Opinion on Therapeutic Targets 12:8, 937-948
CrossRef245
Zuhier Awan, Khalid Al. Waili, Khalid Alrasadi, Jacques Genest. (2008) Treatment of low high-density lipoprotein cholesterol. Canadian Journal of Cardiology 24, 27C-31C
CrossRef246
Fahim Abbasi, Helke M.F. Farin, Cindy Lamendola, Leigh McGraw, Tracey McLaughlin, Gerald M. Reaven. (2008) Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers. Metabolism 57:8, 1108-1114
CrossRef247
Handrean Soran, Paul Durrington. (2008) Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opinion on Pharmacotherapy 9:12, 2145-2160
CrossRef248
Nizal Sarrafzadegan, Katayoun Rabiei, Ali Kabir, Seddighe Asgary, Aliakbar Tavassoli, Alireza Khosravi, Hamid Chalian. (2008) Changes in lipid profile of patients referred to a cardiac rehabilitation program. European Journal of Cardiovascular Prevention & Rehabilitation 15:4, 467-472
CrossRef249
J. Lin, T.L. Hocker, M. Singh, H. Tsao. (2008) Genetics of melanoma predisposition. British Journal of Dermatology 159:2, 286-291
CrossRef250
Harikishore Pingali, Mukul Jain, Shailesh Shah, Pankaj Makadia, Pandurang Zaware, Ashish Goel, Megha Patel, Suresh Giri, Harilal Patel, Pankaj Patel. (2008) Design and synthesis of novel oxazole containing 1,3-Dioxane-2-carboxylic acid derivatives as PPAR α/γ dual agonists. Bioorganic & Medicinal Chemistry 16:15, 7117-7127
CrossRef251
Larry B. Goldstein. (2008) 10 Questions About Statins and Stroke. The Neurologist 14:4, 262-264
CrossRef252
Thomas P. Beyer, Yanqun Chen, Regina K. Porter, Deshun Lu, Robert J. Schmidt, Nathan B. Mantlo, Robert J. Konrad, Guoqing Cao. (2008) Peroxisome Proliferator-Activated Receptor α Agonists Regulate Cholesterol Ester Transfer Protein. Lipids 43:7, 611-618
CrossRef253
Fahim Abbasi, Yii-Der Ida Chen, Helke M.F. Farin, Cindy Lamendola, Gerald M. Reaven. (2008) Comparison of Three Treatment Approaches to Decreasing Cardiovascular Disease Risk in Nondiabetic Insulin-Resistant Dyslipidemic Subjects. The American Journal of Cardiology 102:1, 64-69
CrossRef254
Valmore Bermúdez, Raquel Cano, Clímaco Cano, Fernando Bermúdez, Nailet Arraiz, Luis Acosta, Freddy Finol, María Rebeca Pabón, Anilsa Amell, Nadia Reyna, Joaquin Hidalgo, Paúl Kendall, Velasco Manuel, Rafael Hernández. (2008) Pharmacologic Management of Isolated Low High-Density Lipoprotein Syndrome. American Journal of Therapeutics 15:4, 377-388
CrossRef255
Venkateshwar R. Polsani, Salim S. Virani, Vijay Nambi. (2008) Lipid management: Considerations in acute coronary syndrome. Current Cardiology Reports 10:4, 334-341
CrossRef256
Stephen J Nicholls, E Murat Tuzcu. (2008) High-density lipoprotein and atheroma monitoring. Current Opinion in Cardiology 23:4, 386-392
CrossRef257
John F. Oram, Jay W. Heinecke. (2008) When good cholesterol turns bad: The evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Current Diabetes Reports 8:3, 165-167
CrossRef258
Rebecca L Pollex, Tisha R Joy, Robert A Hegele. (2008) Emerging antidyslipidemic drugs. Expert Opinion on Emerging Drugs 13:2, 363-381
CrossRef259
László Szapáry, Beáta Horváth, Zsolt Márton, Gergely Fehér, Kálmán Tóth, Sámuel Komoly. (2008) Az atorvastatinkezelés haemorrheologiai és haemostaseologiai hatásai krónikus agyérbetegekben. Orvosi Hetilap 149:24, 1117-1123
CrossRef260
Carlos Calvo. (2008) Bases moleculares de las propiedades antiaterogénicas de las lipoproteínas de alta densidad. Clínica e Investigación en Arteriosclerosis 20:3, 116-125
CrossRef261
Padmini Manghat, Anthony S Wierzbicki. (2008) Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. Future Lipidology 3:3, 237-255
CrossRef262
Min-Jeong Shin, Alka M. Kanaya, Ronald M. Krauss. (2008) Polymorphisms in the peroxisome proliferator activated receptor α gene are associated with levels of apolipoprotein CIII and triglyceride in African-Americans but not Caucasians. Atherosclerosis 198:2, 313-319
CrossRef263
Nerses Sanossian, Nicholas E. Tarlov. (2008) HDL-C and LDL-C: Their role in stroke pathogenesis and implications for treatment. Current Treatment Options in Cardiovascular Medicine 10:3, 195-206
CrossRef264
Francisco Javier del Cañizo Gómez, María Natividad Moreira Andrés. (2008) Strict control of modifiable cardiovascular risk factors in patients with type 2 diabetes mellitus. Medicina Clínica 130:17, 641-644
CrossRef265
Inbal Avisar, J. Gerald Brook, Efrat Wolfovitz. (2008) Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. European Journal of Internal Medicine 19:3, 203-208
CrossRef266
Katsuyuki Nakajima, Yasuhiro Nakajima, Sanae Takeichi, Masaki Q. Fujita. (2008) Plasma remnant-like lipoprotein particles or LDL-C as major pathologic factors in sudden cardiac death cases. Atherosclerosis 198:1, 237-246
CrossRef267
JB Warren. (2008) Cholesterol—When Is Lower Better?. Clinical Pharmacology & Therapeutics 83:5, 777-780
CrossRef268
Joshua Remick, Howard Weintraub, Robert Setton, Joseph Offenbacher, Edward Fisher, Arthur Schwartzbard. (2008) Fibrate Therapy. Cardiology in Review 16:3, 129-141
CrossRef269
Socrates Pastromas, Angela-Beth Terzi, Dimitris Tousoulis, Spyridon Koulouris. (2008) Postprandial lipemia: An under-recognized atherogenic factor in patients with diabetes mellitus. International Journal of Cardiology 126:1, 3-12
CrossRef270
Malkhey Verma, Hans-Joerg Martin, Wahajul Haq, Timothy R. O'Connor, Edmund Maser, Ganesaratnam K. Balendiran. (2008) Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers. European Journal of Pharmacology 584:2-3, 213-221
CrossRef271
John D. Brunzell, Michael Davidson, Curt D. Furberg, Ronald B. Goldberg, Barbara V. Howard, James H. Stein, Joseph L. Witztum. (2008) Lipoprotein Management in Patients With Cardiometabolic Risk. Journal of the American College of Cardiology 51:15, 1512-1524
CrossRef272
C. P. Cannon. (2008) Combination therapy in the management of mixed dyslipidaemia. Journal of Internal Medicine 263:4, 353-365
CrossRef273
Farhan Majeed, Michael Miller. (2008) Low high-density lipoprotein cholesterol: an important consideration in coronary heart disease risk assessment. Current Opinion in Endocrinology, Diabetes and Obesity 15:2, 175-181
CrossRef274
K. Kotseva, M. Stagmo, D. De Bacquer, G. De Backer, D. Wood. (2008) Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: Findings from the EUROASPIRE II survey. Atherosclerosis 197:2, 710-717
CrossRef275
J. Willeit, S. Kiechl, F. Aichner, K. Berek, H. Binder, M. Brainin, F. Fazekas, G. Fraedrich, H.P. Haring, S. Horner, B. Iglseder, P. Kapeller, W. Lang, E. Minar, K. Niederkorn, G. Noisternig, M. Schillinger, R. Schmidt, E. Schmutzhard, P. Waldenberger, H.W. Wege. (2008) Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13:2, 115-125
CrossRef276
Madiha Abdel-Maksoud, Vasilisa Sazonov, Stephen W Gutkin, John E Hokanson. (2008) Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes. Journal of Cardiovascular Pharmacology 51:4, 331-351
CrossRef277
Yasmine S Ali, MacRae F Linton, Sergio Fazio. (2008) Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. Current Opinion in Endocrinology, Diabetes and Obesity 15:2, 142-146
CrossRef278
Fadi Shamoun, Neethi Sural, George Abela. (2008) Peripheral artery disease: therapeutic advances. Expert Review of Cardiovascular Therapy 6:4, 539-553
CrossRef279
Jorge Plutzky. 2008. PPARs in Atherosclerosis. .
CrossRef280
Mohammad Anwar Hossain, Maki Tsujita, Frank J Gonzalez, Shinji Yokoyama. (2008) Effects of Fibrate Drugs on Expression of ABCA1 and HDL Biogenesis in Hepatocytes. Journal of Cardiovascular Pharmacology 51:3, 258-266
CrossRef281
Lisa R Tannock. (2008) Advances in the management of hyperlipidemia-induced atherosclerosis. Expert Review of Cardiovascular Therapy 6:3, 369-383
CrossRef282
Tina Banks, Adebayo Oyekan. (2008) Peroxisome proliferator-activated receptor α activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat. Journal of Hypertension 26:3, 468-477
CrossRef283
J. Willeit, S. Kiechl, F. Aichner, K. Berek, H. Binder, M. Brainin, F. Fazekas, G. Fraedrich, H.P. Haring, S. Horner, B. Iglseder, P. Kapeller, W. Lang, E. Minar, K. Niederkorn, G. Noisternig, M. Schillinger, R. Schmidt, E. Schmutzhard, P. Waldenberger, H.W. Wege. (2008) Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13:1, 31-41
CrossRef284
John A. Farmer. (2008) Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. Current Diabetes Reports 8:1, 71-77
CrossRef285
Tisha Joy, Robert A. Hegele. (2008) Is raising HDL a futile strategy for atheroprotection?. Nature Reviews Drug Discovery 7:2, 143-155
CrossRef286
Helene Glassberg, Daniel J. Rader. (2008) Management of Lipids in the Prevention of Cardiovascular Events. Annual Review of Medicine 59:1, 79-94
CrossRef287
Joseph E. Thomas, JoAnne M. Foody. 2008. Disorders of Lipid Metabolism. , 159-178.
CrossRef288
Sander J. Robins, Dorothea Collins, Judith R. McNamara, Hanna E. Bloomfield. (2008) Body weight, plasma insulin, and coronary events with gemfibrozil in the Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Atherosclerosis 196:2, 849-855
CrossRef289
Sergio Fazio. (2008) Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy. Clinical Therapeutics 30:2, 294-306
CrossRef290
Virginia Meza, Cecilia Ganduglia, Agustín Ciapponi, Virginia Meza. 2008. Combined therapy with statins and fibrates for people with dyslipidaemia. .
CrossRef291
Emil M. deGoma, Nicholas J. Leeper, Paul A. Heidenreich. (2008) Clinical Significance of High-Density Lipoprotein Cholesterol in Patients With Low Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 51:1, 49-55
CrossRef292
Carl J. Lavie, Richard V. Milani. (2008) Shedding Light on High-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology 51:1, 56-58
CrossRef293
Ilan Goldenberg, Michal Benderly, Uri Goldbourt. (2008) Secondary Prevention With Bezafibrate Therapy for the Treatment of Dyslipidemia. Journal of the American College of Cardiology 51:4, 459-465
CrossRef294
Mark L. De Buyzere, Denis L. Clement. (2008) Management of Hypertension in Peripheral Arterial Disease. Progress in Cardiovascular Diseases 50:4, 238-263
CrossRef295
Matthias W Riepe, Roman Huber. (2008) Secondary Stroke Prevention. CNS Drugs 22:2, 113-121
CrossRef296
Genovefa D Kolovou, Peggy M Kostakou, Katherine K Anagnostopoulou, Dennis V Cokkinos. (2008) Therapeutic Effects of Fibrates in Postprandial Lipemia. American Journal of Cardiovascular Drugs 8:4, 243-255
CrossRef297
Eliot A. Brinton. (2008) Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?. Current Atherosclerosis Reports 10:1, 25-32
CrossRef298
Vasilios Papademetriou. 2008. Management of Associated Cardiovascular Risk in Essential Hypertension. , 635-643.
CrossRef299
Pit Sertznig, Markus Seifert, Wolfgang Tilgen, Jörg Reichrath. (2008) Peroxisome Proliferator-Activated Receptors (PPARs) and the Human Skin. American Journal of Clinical Dermatology 9:1, 15-31
CrossRef300
Chi-Wen Chiang, Hui-Fen Chiu, Chi-Yu Chen, Hsin-Lung Wu, Chun-Yuh Yang. (2008) Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997–2003. Pharmacoepidemiology and Drug Safety 17:1, 62-69
CrossRef301
Magdalena Hałabiś, Elżbieta Kimak. (2008) HDL particle as a risk factor for cardiovascular diseases in healthy people. Annales UMCS, Pharmacia 21:1, 349-353
CrossRef302
Tetsuo Asaki, Tomiyoshi Aoki, Taisuke Hamamoto, Yukiteru Sugiyama, Shinji Ohmachi, Kenji Kuwabara, Kohji Murakami, Makoto Todo. (2008) Structure–activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor α (PPARα) agonists. Bioorganic & Medicinal Chemistry 16:2, 981-994
CrossRef303
Wimon Phuntuwate, Chuthamanee Suthisisang, Banhan Koanantakul, Preecha Chaloeiphap, Bharti Mackness, Mike Mackness. (2008) Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 196:1, 122-128
CrossRef304
Sander Kersten. (2008) Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism. PPAR Research 2008, 1-11
CrossRef305
Jennifer G. Robinson. (2008) Should We Use PPAR Agonists to Reduce Cardiovascular Risk?. PPAR Research 2008, 1-13
CrossRef306
Makoto Ayaori, Yukihiko Momiyama, Zahi A. Fayad, Atsushi Yonemura, Reiko Ohmori, Teruyoshi Kihara, Nobukiyo Tanaka, Kazuhiro Nakaya, Masatsune Ogura, Shojiro Sawada, Hiroaki Taniguchi, Masatoshi Kusuhara, Masayoshi Nagata, Haruo Nakamura, Fumitaka Ohsuzu. (2008) Effect of bezafibrate therapy on atherosclerotic aortic plaques detected by MRI in dyslipidemic patients with hypertriglyceridemia. Atherosclerosis 196:1, 425-433
CrossRef307
Sharon Cresci. (2008) PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease. PPAR Research 2008, 1-11
CrossRef308
Ambra Pozzi, Jorge H. Capdevila. (2008) PPARα Ligands as Antitumorigenic and Antiangiogenic Agents. PPAR Research 2008, 1-8
CrossRef309
L. Chepulis, N. Starkey. (2008) The Long-Term Effects of Feeding Honey Compared with Sucrose and a Sugar-Free Diet on Weight Gain, Lipid Profiles, and DEXA Measurements in Rats. Journal of Food Science 73:1, H1-H7
CrossRef310
L. Kennedy. (2008) Prevalence and Treatment of Low HDL Cholesterol Among Primary Care Patients With Type 2 Diabetes: An unmet challenge for cardiovascular risk reduction. Yearbook of Endocrinology 2008, 26-28
CrossRef311
Bela F. Asztalos, Dorothea Collins, Katalin V. Horvath, Hanna E. Bloomfield, Sander J. Robins, Ernst J. Schaefer. (2008) Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 57:1, 77-83
CrossRef312
Kuo-Liong Chien. 2007. Update in Hyperlipidemia Clinical Trials. .
CrossRef313
Barbara Gross, Bart Staels. (2007) PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, 687-710
CrossRef314
Masoor Kamalesh. (2007) Heart Failure in Diabetes and Related Conditions. Journal of Cardiac Failure 13:10, 861-873
CrossRef315
Julia M. Bottomley, Frank D. Raymond. (2007) Pharmaco-economic issues for diabetes therapy. Best Practice & Research Clinical Endocrinology & Metabolism 21:4, 657-685
CrossRef316
Joseph Francis, Jonathan B. Perlin. (2007) Improving performance through knowledge translation in the Veterans Health Administration. Journal of Continuing Education in the Health Professions 26:1, 63-71
CrossRef317
John F. Oram, Jay W. Heinecke. (2007) When good cholesterol turns bad: The evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Current Atherosclerosis Reports 9:6, 425-427
CrossRef318
M. A. Bouhlel, B. Staels, G. Chinetti-Gbaguidi. (2007) Peroxisome proliferator-activated receptors – from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease. Journal of Internal Medicine 0:0, 071203163533001-???
CrossRef319
M. Rizzo, K. Berneis. (2007) Who needs to care about small, dense low-density lipoproteins?. International Journal of Clinical Practice 61:11, 1949-1956
CrossRef320
Sayeeda Rahman, Tahminur Rahman, Aziz Al-Shafi Ismail, Abdul Rahman A Rashid. (2007) Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes, Obesity and Metabolism 9:6, 767-780
CrossRef321
Yuhua Sun, Yuejin Yang, Weidong Pei, Yongjian Wu, Jinglin Zhao. (2007) Is Elevated High-density Lipoprotein Cholesterol Always Good for Coronary Heart Disease?. Clinical Cardiology 30:11, 576-580
CrossRef322
Donald A. Smith. (2007) Treatment of the Dyslipidemia of Insulin Resistance. Medical Clinics of North America 91:6, 1185-1210
CrossRef323
Stephen A. Brietzke. (2007) Controversy in Diagnosis and Management of the Metabolic Syndrome. Medical Clinics of North America 91:6, 1041-1061
CrossRef324
Danielle Lann, Derek LeRoith. (2007) Insulin Resistance as the Underlying Cause for the Metabolic Syndrome. Medical Clinics of North America 91:6, 1063-1077
CrossRef325
D. C. Archer, J. T. Frkanec, J. Cromwell, P. Clopton, R. Cunard. (2007) WY14,643, a PPARα ligand, attenuates expression of anti-glomerular basement membrane disease. Clinical & Experimental Immunology 150:2, 386-396
CrossRef326
A. Vogt, U. Kassner, U. Hostalek, E. Steinhagen-Thiessen. (2007) Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan®). International Journal of Clinical Practice 61:11, 1914-1921
CrossRef327
Amy Z. Fan, James H. Dwyer. (2007) Sex differences in the relation of HDL cholesterol to progression of carotid intima-media thickness: The Los Angeles Atherosclerosis Study. Atherosclerosis 195:1, e191-e196
CrossRef328
Sharon Cresci. (2007) Pharmacogenetics of the PPAR genes and cardiovascular disease. Pharmacogenomics 8:11, 1581-1595
CrossRef329
Christopher M. Rembold. (2007) To statin or to non-statin in coronary disease—considering absolute risk is the answer. Atherosclerosis 195:1, 1-6
CrossRef330
Vasilios G. Athyros, Anna I. Kakafika, Athanasios A. Papageorgiou, Konstantinos Tziomalos, Athanasios Skaperdas, Efstathios Pagourelias, Athina Pirpasopoulou, Asterios Karagiannis, Dimitri P. Mikhailidis, . (2007) Atorvastatin Decreases Triacylglycerol-Associated Risk of Vascular Events in Coronary Heart Disease Patients. Lipids 42:11, 999-1009
CrossRef331
Lawrence A. Leiter, Robert S. Rosenson, Evan Stein, John P.D. Reckless, Karl-Ludwig Schulte, Margo Schleman, Paul Miller, Michael Palmer, Froukje Sosef. (2007) Efficacy and safety of rosuvastatin 40mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Atherosclerosis 194:2, e154-e164
CrossRef332
Toshio Hayashi, Koutaro Yokote, Yasushi Saito, Akihisa Iguchi. (2007) Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opinion on Pharmacotherapy 8:14, 2315-2327
CrossRef333
Francisco Javier del Cañizo Gómez, M. Natividad Moreira Andrés, Carmen Bohígas Roldán, Mercedes Herranz Puebla. (2007) Efecto, en la práctica clínica, de la fluvastatina de liberación prolongada en los lípidos séricos en pacientes con diabetes tipo 2 y dislipemia. Clínica e Investigación en Arteriosclerosis 19:5, 240-246
CrossRef334
Juan Ascaso, Pedro Gonzalez Santos, Antonio Hernández Mijares, Alipio Mangas Rojas, Luis Masana Marín, Jesús Millan Nuñez-Cortés, Luis Felipe Pallardo, Juan Pedro-Botet, Francisco Pérez Jimenez, Xavier Pintó, Ignacio Plaza, Juan Rubiés, Manuel Zúñiga. (2007) Dislipemia del síndrome metabólico. Documento sumario del Foro-HDL. Clínica e Investigación en Arteriosclerosis 19:5, 252-263
CrossRef335
Jens Kronborg, Trond Jenssen, Inger Njølstad, Ingrid Toft, Bjørn O. Eriksen. (2007) Metabolic risk factors associated with serum creatinine in a non-diabetic population. European Journal of Epidemiology 22:10, 707-713
CrossRef336
Brunzell, John D., . (2007) Hypertriglyceridemia. New England Journal of Medicine 357:10, 1009-1017
Full Text337
Helena Tenenbaum, Solomon Behar, Valentina Boyko, Yehuda Adler, Enrique Z. Fisman, David Tanne, Mordechai Lapidot, Ehud Schwammenthal, Micha Feinberg, Zipora Matas, Michael Motro, Alexander Tenenbaum. (2007) Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 194:1, 265-271
CrossRef338
Neil J Stone, Lowell R Schmeltz. (2007) Metabolic syndrome management. Expert Opinion on Pharmacotherapy 8:13, 2059-2075
CrossRef339
Angeliki Georgopoulos, Hanna Bloomfield, Dorothea Collins, Margaret E. Brousseau, Jose M. Ordovas, John J. O’Connor, Sander J. Robins, Ernest J. Schaefer. (2007) Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the veterans affairs HDL intervention trial (VA-HIT). Atherosclerosis 194:1, 169-174
CrossRef340
J. Shepherd. (2007) Dyslipidaemia in diabetic patients: time for a rethink. Diabetes, Obesity and Metabolism 9:5, 609-616
CrossRef341
Carolyn Jenkins, Maria Lopes-Virella. 2007. Nutrition in Diabetes Mellitus. , 785-813.
CrossRef342
David Conen, Paul M Ridker. (2007) Clinical significance of high-sensitivity C-reactive protein in cardiovascular disease. Biomarkers in Medicine 1:2, 229-241
CrossRef343
W. Ahmed, O. Ziouzenkova, J. Brown, P. Devchand, S. Francis, M. Kadakia, T. Kanda, G. Orasanu, M. Sharlach, F. Zandbergen, J. Plutzky. (2007) PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?. Journal of Internal Medicine 262:2, 184-198
CrossRef344
O. Wiklund, L. Håversen, C. Pettersson, L. M. Hultén. (2007) How can we prevent cardiovascular disease in diabetes. Journal of Internal Medicine 262:2, 199-207
CrossRef345
Stephen J Nicholls, Steven E Nissen. (2007) New targets of high-density lipoprotein therapy. Current Opinion in Lipidology 18:4, 421-426
CrossRef346
Petra Keul, Katherine Sattler, Bodo Levkau. (2007) HDL and its sphingosine-1-phosphate content in cardioprotection. Heart Failure Reviews 12:3-4, 301-306
CrossRef347
M. Bajaj, S. Suraamornkul, L. J. Hardies, L. Glass, N. Musi, R. A. DeFronzo. (2007) Effects of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 50:8, 1723-1731
CrossRef348
M.D. Mañas García, E. Marchán Carranza, J. Galiana Gómez del Pulgar. (2007) Descenso de lipoproteínas de alta densidad secundario al tratamiento con esteroides anabolizantes. Revista Clínica Española 207:7, 376-377
CrossRef349
Larry B. Goldstein. (2007) Statins for stroke prevention. Current Atherosclerosis Reports 9:4, 305-311
CrossRef350
Theodore Mazzone. (2007) HDL cholesterol and atherosclerosis. The Lancet 370:9582, 107-108
CrossRef351
Michiel L Bots, Frank L Visseren, Gregory W Evans, Ward A Riley, James H Revkin, Charles H Tegeler, Charles L Shear, William T Duggan, Ralph M Vicari, Diederick E Grobbee, John J Kastelein. (2007) Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. The Lancet 370:9582, 153-160
CrossRef352
Jose J. Lara, Maria Economou, A. Michael Wallace, Anne Rumley, Gordon Lowe, Christine Slater, Muriel Caslake, Naveed Sattar, Michael E.J. Lean. (2007) Benefits of salmon eating on traditional and novel vascular risk factors in young, non-obese healthy subjects. Atherosclerosis 193:1, 213-221
CrossRef353
Ingrid M. Jazet, Anton J. de Craen, Eveline M. van Schie, A. Edo Meinders. (2007) Sustained beneficial metabolic effects 18 months after a 30-day very low calorie diet in severely obese, insulin-treated patients with type 2 diabetes. Diabetes Research and Clinical Practice 77:1, 70-76
CrossRef354
John Carlquist, Jeffrey L Anderson. (2007) Inconsistencies in the genetic prediction of HDL cholesterol versus atherosclerosis. Current Opinion in Cardiology 22:4, 352-358
CrossRef355
Akihiko Fujii, Terri J. Allen, Paul J. Nestel. (2007) A 1,3-diacylglycerol-rich oil induces less atherosclerosis and lowers plasma cholesterol in diabetic apoE-deficient mice. Atherosclerosis 193:1, 55-61
CrossRef356
J Rumi Jaumdally, Chetan Varma, Gregory YH Lip. (2007) Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?. Expert Opinion on Pharmacotherapy 8:9, 1235-1243
CrossRef357
Terry A. Jacobson, Michael Miller, Ernst J. Schaefer. (2007) Hypertriglyceridemia and cardiovascular risk reduction. Clinical Therapeutics 29:5, 763-777
CrossRef358
James M McKenney, Domenic Sica. (2007) Role of Prescription Omega-3 Fatty Acids in the Treatment of Hypertriglyceridemia. Pharmacotherapy 27:5, 715-728
CrossRef359
Ling DING, Xing-guang LIANG, Yi-jia LOU. (2007) Time-dependence of cardiomyocyte differentiation disturbed by peroxisome proliferator-activated receptor ? inhibitor GW6471 in murine embryonic stem cells in vitro. Acta Pharmacologica Sinica 28:5, 634-642
CrossRef360
A. Lawrence Gould, Glenn M. Davies, Evo Alemao, Donald D. Yin, John R. Cook. (2007) Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clinical Therapeutics 29:5, 778-794
CrossRef361
Jeffrey J. Link, Anand Rohatgi, James A. de Lemos. (2007) HDL Cholesterol: Physiology, Pathophysiology, and Management. Current Problems in Cardiology 32:5, 268-314
CrossRef362
J. S. Rana, M. Nieuwdorp, J. W. Jukema, J. J. P. Kastelein. (2007) Cardiovascular metabolic syndrome ? an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes, Obesity and Metabolism 9:3, 218-232
CrossRef363
Cristina Bianchi, Giuseppe Penno, Fabiola Romero, Stefano Del Prato, Roberto Miccoli. (2007) Treating the metabolic syndrome. Expert Review of Cardiovascular Therapy 5:3, 491-506
CrossRef364
Jesús Millán. (2007) Tratamiento de la dislipemia en pacientes con síndrome metabólico o con diabetes mellitus. Medicina Clínica 128:20, 786-794
CrossRef365
(2007) Guías de práctica clínica sobre diabetes, prediabetes y enfermedades cardiovasculares: versión resumida. Revista Española de Cardiología 60:5, 525.e1-525.e64
CrossRef366
Kastelein, John J.P., van Leuven, Sander I., Burgess, Leslie, Evans, Greg W., Kuivenhoven, Jan A., Barter, Philip J., Revkin, James H., Grobbee, Diederick E., Riley, Ward A., Shear, Charles L., Duggan, William T., Bots, Michiel L., . (2007) Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. New England Journal of Medicine 356:16, 1620-1630
Full Text367
Shinichi Oikawa, Toru Kita, Hiroshi Mabuchi, Masunori Matsuzaki, Yuji Matsuzawa, Noriaki Nakaya, Yasushi Saito, Jun Sasaki, Kazuaki Shimamoto, Hiroshige Itakura. (2007) Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: Implication from Japan Lipid Intervention Trial (J-LIT). Atherosclerosis 191:2, 440-446
CrossRef368
Stanley H Hsia. (2007) Alternate approaches to managing lipid-associated cardiovascular risk. Future Lipidology 2:2, 157-163
CrossRef369
Anthony S. Wierzbicki. (2007) Lipid-Altering Therapies and the Progression of Atherosclerotic Disease. CardioVascular and Interventional Radiology 30:2, 155-160
CrossRef370
John A. Farmer. (2007) Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. Current Atherosclerosis Reports 9:2, 162-168
CrossRef371
John J. P. Kastelein, Sander I. van Leuven, Gregory W. Evans, Ward A. Riley, James H. Revkin, Charles L. Shear, Michiel L. Bots. (2007) Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*. Current Medical Research and Opinion 23:4, 885-894
CrossRef372
Alexander Tenenbaum, Yehuda Adler, Valentina Boyko, Helena Tenenbaum, Enrique Z. Fisman, David Tanne, Mordechai Lapidot, Ehud Schwammenthal, Micha S. Feinberg, Zipora Matas, Michael Motro, Solomon Behar. (2007) Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease. American Heart Journal 153:4, 559-565
CrossRef373
James M Backes, Cheryl A Gibson, Janelle F Ruisinger, Patrick M Moriarty. (2007) Fibrates: What Have We Learned in the Past 40 Years?. Pharmacotherapy 27:3, 412-424
CrossRef374
Xavier Pintó, Emili Corbella, Rosaura Figueras, Josefina Biarnés, Wifredo Ricart, Clotilde Morales, Liliana Falkon, Luis Masana. (2007) Factores predictivos del riesgo de enfermedad cardiovascular en los pacientes con diabetes tipo 2 e hipercolesterolemia. Estudio ESODIAH. Revista Española de Cardiología 60:3, 251-258
CrossRef375
G Y H Lip, A H Barnett, A Bradbury, F P Cappuccio, P S Gill, E Hughes, C Imray, K Jolly, K Patel. (2007) Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to management. Journal of Human Hypertension 21:3, 183-211
CrossRef376
Karam M. Kostner, Gerhard M. Kostner. (2007) Fibrate bei Lipidstoffwechselstörungen: Klinischer Stellenwert. Pharmazie in unserer Zeit 36:2, 114-119
CrossRef377
Nadia Reyna-Villasmil, Valmore Berm??dez-Pirela, Edgardo Mengual-Moreno, Nelly Arias, Cl??maco Cano-Ponce, Elliuz Leal-Gonzalez, Aida Souki, George E Inglett, Zafar H Israili, Rafael Hern??ndez-Hern??ndez, Manuel Valasco, Naikt Arraiz. (2007) Oat-derived ??-Glucan Significantly Improves HDLC and Diminishes LDLC and Non-HDL Cholesterol in Overweight Individuals With Mild Hypercholesterolemia. American Journal of Therapeutics 14:2, 203-212
CrossRef378
James M. McKenney. (2007) Effect of drugs on high-density lipoprotein. Journal of Clinical Lipidology 1:1, 74-87
CrossRef379
Jeff Geohas, Anne Daly, Vijaya Juturu, Manley Finch, James R. Komorowski. (2007) Chromium Picolinate and Biotin Combination Reduces Atherogenic Index of Plasma in Patients with Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-Blinded, Randomized Clinical Trial. The American Journal of the Medical Sciences 333:3, 145-153
CrossRef380
B. Greg Brown, Xue-Qiao Zhao, Marian C. Cheung. (2007) Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence. Journal of Clinical Lipidology 1:1, 88-94
CrossRef381
Herbert Schuster. (2007) The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Review of Cardiovascular Therapy 5:2, 177-193
CrossRef382
S. Tavintharan, M. Sivakumar, S.C. Lim, C.F. Sum. (2007) Niacin affects cell adhesion molecules and plasminogen activator inhibitor-1 in HepG2 cells. Clinica Chimica Acta 376:1-2, 41-44
CrossRef383
Xiayang Qiu, Anil Mistry, Mark J Ammirati, Boris A Chrunyk, Ronald W Clark, Yang Cong, Jeffrey S Culp, Dennis E Danley, Thomas B Freeman, Kieran F Geoghegan, Matthew C Griffor, Steven J Hawrylik, Cheryl M Hayward, Preston Hensley, Lise R Hoth, George A Karam, Maruja E Lira, David B Lloyd, Katherine M McGrath, Kim J Stutzman-Engwall, Ann K Subashi, Timothy A Subashi, John F Thompson, Ing-Kae Wang, Honglei Zhao, Andrew P Seddon. (2007) Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nature Structural & Molecular Biology 14:2, 106-113
CrossRef384
Peter Libby, Jorge Plutzky. (2007) Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists. The American Journal of Cardiology 99:4, 27-40
CrossRef385
Robert S. Rosenson. (2007) Effects of Peroxisome Proliferator-Activated Receptors on Lipoprotein Metabolism and Glucose Control in Type 2 Diabetes Mellitus. The American Journal of Cardiology 99:4, 96-104
CrossRef386
Seung Hwan Han, Michael J Quon, Kwang Kon Koh. (2007) Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Current Opinion in Lipidology 18:1, 58-65
CrossRef387
Rakesh K. Mishra, Craig T. Basson. (2007) Treatment goals for the management of lipids and inflammation for patients with coronary artery disease. Current Treatment Options in Cardiovascular Medicine 9:1, 3-10
CrossRef388
Michael H. Davidson. (2007) Global Risk Management in Patients with Type 2 Diabetes Mellitus. The American Journal of Cardiology 99:4, 41-50
CrossRef389
Anthony S. Wierzbicki. (2007) Lipid-Altering Therapies and the Progression of Atherosclerotic Disease. CardioVascular and Interventional Radiology 30:2, 155
CrossRef390
L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, F.G.R. Fowkes. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery 45:1, S5-S67
CrossRef391
Intekhab Ahmed, Kevin Furlong, Jeremy Flood, Vanita P Treat, Barry J Goldstein. (2007) Dual PPAR ??/?? Agonists: Promises and Pitfalls in Type 2 Diabetes. American Journal of Therapeutics 14:1, 49-62
CrossRef392
Paul Stang, Lisa Morris, Judy Kempf, Scott Henderson, Marianne Ulcickas Yood, Susan Oliveria. (2007) The CoPrescription of Contraindicated Drugs With Statins: Continuing Potential for Increased Risk of Adverse Events. American Journal of Therapeutics 14:1, 30-40
CrossRef393
Jamie J. O’Brien, Denise M. Ray, Sherry L. Spinelli, Neil Blumberg, Mark B. Taubman, Charles W. Francis, Steven D. Wittlin, Richard P. Phipps. (2007) The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARγ ligands. Prostaglandins & Other Lipid Mediators 82:1-4, 68-76
CrossRef394
Manfredi Rizzo, Kaspar Berneis. (2007) Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes/Metabolism Research and Reviews 23:1, 14-20
CrossRef395
James M. McKenney, John A. Hoekstra. (2007) Will torcetrapib be the next big thing in coronary heart disease risk reduction?. Current Atherosclerosis Reports 9:1, 48-56
CrossRef396
Michael H. Davidson. (2007) Clinical trials report. Current Atherosclerosis Reports 9:1, 45-47
CrossRef397
Alexander Chernobelsky, M. Dominique Ashen, Roger S Blumenthal, Neil L. Coplan. (2007) High-Density Lipoprotein Cholesterol: A Potential Therapeutic Target for Prevention of Coronary Artery Disease. Preventive Cardiology 10:1, 26-30
CrossRef398
Eric R. Bates, Joseph D. Babb, Donald E. Casey, Christopher U. Cates, Gary R. Duckwiler, Ted E. Feldman, William A. Gray, Kenneth Ouriel, Eric D. Peterson, Kenneth Rosenfield, John H. Rundback, Robert D. Safian, Michael A. Sloan, Christopher J. White, Robert A. Harrington, Jonathan Abrams, Jeffrey L. Anderson, Eric R. Bates, Mark J. Eisenberg, Cindy L. Grines, Mark A. Hlatky, Robert C. Lichtenberg, Jonathan R. Lindner, Gerald M. Pohost, Richard S. Schofield, Samuel J. Shubrooks, James H. Stein, Cynthia M. Tracy, Robert A. Vogel, Deborah J. Wesley. (2007) ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting. Journal of the American College of Cardiology 49:1, 126-170
CrossRef399
Peter P. Toth. (2007) Reducing cardiovascular risk by targeting high-density lipoprotein cholesterol. Current Atherosclerosis Reports 9:1, 81-88
CrossRef400
H. M. F. Farin, F. Abbasi, S. H. Kim, C. Lamendola, T. McLaughlin, G. M. Reaven. (2007) The relationship between insulin resistance and dyslipidaemia in cigarette smokers. Diabetes, Obesity and Metabolism 9:1, 65-69
CrossRef401
L. Norgren, W.R. Hiatt, J.A. Dormandy, M.R. Nehler, K.A. Harris, F.G.R. Fowkes. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). European Journal of Vascular and Endovascular Surgery 33:1, S1-S75
CrossRef402
Juan Ascaso, Pedro Gonzalez Santos, Antonio Hernandez Mijares, Alipio Mangas Rojas, Luis Masana, Jesus Millan, Luis Felipe Pallardo, Juan Pedro-Botet, Francisco Perez Jimenez, Xavier Pint??, Ignacio Plaza, Juan Rubi??s, Manuel Z????iga. (2007) Management of Dyslipidemia in the Metabolic Syndrome. American Journal of Cardiovascular Drugs 7:1, 39-58
CrossRef403
Young-Ran Kang, Choong-Hwan Kwak, Jin-Yong Hwang. (2007) Safety and Efficacy of Peroxisome Proliferator-Activated Receptor-α Agonist for Treating Cardiovascular Disease. Korean Circulation Journal 37:12, 599
CrossRef404
Jennifer G. Robinson. (2007) Update on PPAR agonists: The clinical significance of FIELD and PROACTIVE. Current Atherosclerosis Reports 9:1, 64-71
CrossRef405
Andrea Kassai, László Illyés, Hossein Z. Mirdamadi, Ildiko Seres, Tímea Kalmár, Mária Audikovszky, György Paragh. (2007) The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clinical Biochemistry 40:1-2, 1-5
CrossRef406
Michael H. Davidson, H. Daniel Yannicelli. (2006) New Concepts in Dyslipidemia in the Metabolic Syndrome and Diabetes. Metabolic Syndrome and Related Disorders 4:4, 299-314
CrossRef407
J-P Montani, A K Viecelli, A Prévot, A G Dulloo. (2006) Weight cycling during growth and beyond as a risk factor for later cardiovascular diseases: the ‘repeated overshoot’ theory. International Journal of Obesity 30, S58-S66
CrossRef408
Claudio Napoli, Filomena de Nigris, Sharon Williams-Ignarro, Orlando Pignalosa, Vincenzo Sica, Louis J. Ignarro. (2006) Nitric oxide and atherosclerosis: An update. Nitric Oxide 15:4, 265-279
CrossRef409
Bruno Vergès. (2006) Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD. Current Opinion in Lipidology 17:6, 653-658
CrossRef410
Kenneth L Jones. (2006) The dilemma of the metabolic syndrome in children and adolescents: disease or distraction?. Pediatric Diabetes 7:6, 311-321
CrossRef411
B Greg Brown, Karen Hinckley Stukovsky, Xue-Qiao Zhao. (2006) Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Current Opinion in Lipidology 17:6, 631-636
CrossRef412
Benjamin Ansell, F. D. Richard Hobbs. (2006) The potential for CETP inhibition to reduce cardiovascular disease risk. Current Medical Research and Opinion 22:12, 2467-2478
CrossRef413
Stuart M Grieve, Jean-Claude Ansquer, Anthony C Keech. (2006) Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. Future Cardiology 2:6, 635-646
CrossRef414
S. R. Freeman, A. L. Drake, L. F. Heilig, M. Graber, K. McNealy, L. M. Schilling, R. P. Dellavalle. (2006) Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis. JNCI Journal of the National Cancer Institute 98:21, 1538-1546
CrossRef415
Lawrence Blonde, Judith Dempster, Joanne M. Gallivan, Elizabeth Warren-Boulton. (2006) Reducing cardiovascular disease risk in patients with diabetes: A message from the National Diabetes Education Program. Journal of the American Academy of Nurse Practitioners 18:11, 524-533
CrossRef416
Andries J. Gilde, Jean-Charles Fruchart, Bart Staels. (2006) Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease. Journal of the American College of Cardiology 48:9, A24-A32
CrossRef417
Aviv Shaish, Ayelet Harari, Lea Hananshvili, Hofit Cohen, Rafael Bitzur, Tamar Luvish, Esfir Ulman, Moria Golan, Ami Ben-Amotz, Dov Gavish, Zeev Rotstein, Dror Harats. (2006) 9-cis β-carotene-rich powder of the alga Dunaliella bardawil increases plasma HDL-cholesterol in fibrate-treated patients. Atherosclerosis 189:1, 215-221
CrossRef418
Gérald Luc, Patrick Duriez, Jean-Charles Fruchart. 2006. Triglycerides and Risk for Atherosclerotic Disease. , 341-388.
CrossRef419
Charles Reasner. 2006. The Metabolic Syndrome: Identification and Management of the Patient at High Risk for Cardiovascular Disease. , 409-440.
CrossRef420
Ronald Goldberg. 2006. Type 2 Diabetes. , 187-254.
CrossRef421
Sander J Robins, Hanna E Bloomfield. (2006) Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Current Opinion in Internal Medicine 5:5, 510-518
CrossRef422
Shyam Prabhakaran, Bernardo Liberato, Ralph L. Sacco. 2006. Stroke Prevention. , 545-584.
CrossRef423
Peter P Toth, Antonio M Gotto. 2006. High-Density Lipoprotein Cholesterol. , 295-340.
CrossRef424
Robert E. Heinig. (2006) The patient with diabetes: Preventing cardiovascular complications. Clinical Cardiology 29:S2, 13-20
CrossRef425
Michael H Hoskins, Terry A Jacobson. (2006) Combination use of statins and omega-3 fatty acids: an emerging therapy for combined hyperlipidemia. Future Lipidology 1:5, 579-591
CrossRef426
Wan Sub Shim, Mi Young Do, Soo Kyung Kim, Hae Jin Kim, Kyu Yeon Hur, Eun Seok Kang, Chul Woo Ahn, Sung Kil Lim, Hyun Chul Lee, Bong Soo Cha. (2006) The long-term effects of rosiglitazone on serum lipid concentrations and body weight. Clinical Endocrinology 65:4, 453-459
CrossRef427
A. H. Barnett, A. N. Dixon, S. Bellary, M. W. Hanif, J. P. O’Hare, N. T. Raymond, S. Kumar. (2006) Type 2 diabetes and cardiovascular risk in the UK south Asian community. Diabetologia 49:10, 2234-2246
CrossRef428
Glen J. Pearson, Gordon A. Francis, Jacques S. Romney, Dawna M. Gilchrist, Andrea Opgenorth, Gabor T. Gyenes. (2006) The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. Canadian Journal of Cardiology 22:11, 939-945
CrossRef429
Jia Liu, Kambiz Kalantarinia, Mitchell H. Rosner. (2006) Endocrinology and Dialysis: Management of Lipid Abnormalities Associated with End-Stage Renal Disease. Seminars in Dialysis 19:5, 391-401
CrossRef430
Tina J. Chahil, Henry N. Ginsberg. (2006) Diabetic Dyslipidemia. Endocrinology & Metabolism Clinics of North America 35:3, 491-510
CrossRef431
Tamara Darsow, David Kendall, David Maggs. (2006) Is the metabolic syndrome a real clinical entity and should it receive drug treatment?. Current Diabetes Reports 6:5, 357-364
CrossRef432
Achikam Grinberg, Kyung W Park. (2006) Nuclear Peroxisome Proliferator-Activated Receptors and Thiazolidinediones. International Anesthesiology Clinics 43:2, 1-21
CrossRef433
Thomas Dayspring, Gregory Pokrywka. (2006) Fibrate therapy in patients with metabolic syndrome and diabetes mellitus. Current Atherosclerosis Reports 8:5, 356-364
CrossRef434
M. John Chapman. (2006) Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacology & Therapeutics 111:3, 893-908
CrossRef435
James F. Tobin, Leonard P. Freedman. (2006) Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy. Trends in Endocrinology & Metabolism 17:7, 284-290
CrossRef436
Ingrid Pruimboom-Brees, Mehrdad Haghpassand, Lori Royer, Dominique Brees, Charles Aldinger, William Reagan, Jatinder Singh, Roy Kerlin, Christopher Kane, Scott Bagley, Cheryl Hayward, James Loy, Peter O'Brien, Omar L. Francone. (2006) A Critical Role for Peroxisomal Proliferator-Activated Receptor-α Nuclear Receptors in the Development of Cardiomyocyte Degeneration and Necrosis. The American Journal of Pathology 169:3, 750-760
CrossRef437
Murat Suher, Eyüp Koç, Berrin Çamur, Önder Sava. (2006) Comparison of effects of fibrates in patients with hypertriglyceridemia. Advances in Therapy 23:5, 793-798
CrossRef438
Christian A. Schneider. (2006) Improving macrovascular outcomes in type 2 diabetes: outcome studies in cardiovascular risk and metabolic control. Current Medical Research and Opinion 22:s2, S15-S26
CrossRef439
Moti Haim, Michal Benderly, Valentina Boyko, Ilan Goldenberg, David Tanne, Alex Battler, Uri Goldbourt, Solomon Behar. (2006) Decrease in triglyceride level by bezafibrate is related to reduction of recurrent coronary events: a Bezafibrate Infarction Prevention substudy. Coronary Artery Disease 17:5, 455-461
CrossRef440
Ibrahim R. Hanna, Brent Heeke, Heather Bush, Lynne Brosius, Diane King-Hageman, Samuel C. Dudley, John F. Beshai, Jonathan J. Langberg. (2006) Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 3:8, 881-886
CrossRef441
Jacques Genest. (2006) Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Canadian Journal of Cardiology 22:10, 863-868
CrossRef442
Liam R. Brunham, Roshni R. Singaraja, Michael R. Hayden. (2006) Variations on a Gene: Rare and Common Variants in ABCA1 and Their Impact on HDL Cholesterol Levels and Atherosclerosis. Annual Review of Nutrition 26:1, 105-129
CrossRef443
Stephen D Wiviott, Christopher P Cannon. (2006) Update on lipid-lowering therapy and LDL-cholesterol targets. Nature Clinical Practice Cardiovascular Medicine 3:8, 424-436
CrossRef444
Juan Pedro-Botet. (2006) Importancia de la prevención cardiovascular en la diabetes mellitus: un reto pendiente. Clínica e Investigación en Arteriosclerosis 18:4, 139-145
CrossRef445
Steven G. Chrysant, Mohammad Ibrahim. (2006) Niacin-ER/Statin Combination for the Treatment of Dyslipidemia: Focus on Low High-Density Lipoprotein Cholesterol. The Journal of Clinical Hypertension 8:7, 493-501
CrossRef446
William L. Isley. (2006) Low-density lipoprotein cholesterol lowering in the prevention of CHD: How low should we go?. Current Treatment Options in Cardiovascular Medicine 8:4, 289-297
CrossRef447
Michel R. Langlois, Victor H. Blaton. (2006) Historical milestones in measurement of HDL-cholesterol: Impact on clinical and laboratory practice. Clinica Chimica Acta 369:2, 168-178
CrossRef448
Peter H. Jones. (2006) Dyslipidemia in Older Adults. The American Journal of Geriatric Cardiology 15:4, 239-244
CrossRef449
Aaron Vinik, Henri Parson, Jagdeesh Ullal. (2006) The role of PPARs in the microvascular dysfunction in diabetes. Vascular Pharmacology 45:1, 54-64
CrossRef450
A. Rees. (2006) FIELD study. Diabetic Medicine 23:s3, 6-12
CrossRef451
Gary F Lewis. (2006) Determinants of plasma HDL concentrations and reverse cholesterol transport. Current Opinion in Cardiology 21:4, 345-352
CrossRef452
E. Shyong Tai, Dorothea Collins, Sander J. Robins, John J. O’Connor, Hanna E. Bloomfield, Jose M. Ordovas, Ernst J. Schaefer, Margaret E. Brousseau. (2006) The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: The Veterans Affairs HDL Intervention Trial (VA-HIT). Atherosclerosis 187:1, 153-160
CrossRef453
Isabella Sudano, Lukas E. Spieker, Frank Hermann, Andreas Flammer, Roberto Corti, Georg Noll, Thomas F. L??scher. (2006) Protection of Endothelial Function: Targets for Nutritional and Pharmacological Interventions. Journal of Cardiovascular Pharmacology 47:Supplement 2, S136-S150
CrossRef454
James M McKenney. (2006) When it comes to the FIELD study, what is...is. Future Lipidology 1:3, 275-281
CrossRef455
F. Civeira, E. Bustamante, E. Jarauta, E. Meriño-Ibarra. (2006) Lipoproteínas clásicas, terapéuticas modernas. Farmacología de las lipoproteínas de alta densidad. Clínica e Investigación en Arteriosclerosis 18, 10-19
CrossRef456
Manoj D. Patel, Paul D. Thompson. (2006) Phytosterols and vascular disease. Atherosclerosis 186:1, 12-19
CrossRef457
Warren H. Capell, Robert H. Eckel. (2006) Treatment of hypertriglyceridemia. Current Diabetes Reports 6:3, 230-240
CrossRef458
George A. Kelley, Kristi S. Kelley, Barry Franklin. (2006) Aerobic Exercise and Lipids and Lipoproteins in Patients With Cardiovascular Disease. Journal of Cardiopulmonary Rehabilitation 26:3, 131-139
CrossRef459
Maria P. Solano, Ronald B. Goldberg. (2006) Management of Dyslipidemia in Diabetes. Cardiology in Review 14:3, 125-135
CrossRef460
Philip T Rodgers, Dawn C Fuke. (2006) New and Emerging Strategies for Reducing Cardiometabolic Risk Factors. Pharmacotherapy 26:5part2, 13S-31S
CrossRef461
Harold E. Lebovitz. (2006) Insulin resistance - a common link between type 2 diabetes and cardiovascular disease. Diabetes, Obesity and Metabolism 8:3, 237-249
CrossRef462
Laurence Duvillard, Philippe Gambert. (2006) Evaluation of the VITROS® chemistry products dHDL slides for direct measurement of high density lipoprotein cholesterol. Clinica Chimica Acta 366:1-2, 130-136
CrossRef463
A. S. Wierzbicki. (2006) FIELDS of dreams, fields of tears: a perspective on the fibrate trials. International Journal of Clinical Practice 60:4, 442-449
CrossRef464
A. C. Calkin, M. E. Cooper, K. A. Jandeleit-Dahm, T. J. Allen. (2006) Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 49:4, 766-774
CrossRef465
Michael Miller. (2006) Therapeutic modalities following low-density lipoprotein cholesterol goal attainment. Future Lipidology 1:2, 131-133
CrossRef466
Gregg D Simonson, David M Kendall. (2006) Different actions of peroxisome proliferator-activated receptors: molecular mechanisms and clinical importance. Current Opinion in Endocrinology & Diabetes 13:2, 162-170
CrossRef467
Sabin Allemann, Peter Diem, Matthias Egger, Emanuel R. Christ, Christoph Stettler. (2006) Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials. Current Medical Research and Opinion 22:3, 617-623
CrossRef468
Marta Marchesi, Cesare R Sirtori. (2006) Therapeutic use of the high-density lipoprotein protein and peptides. Expert Opinion on Investigational Drugs 15:3, 227-241
CrossRef469
Carolyn M. Hutter, Melissa A. Austin, Federico M. Farin, Hannah-Malia Viernes, Karen L. Edwards, Donna L. Leonetti, Marguerite J. McNeely, Wilfred Y. Fujimoto. (2006) Association of endothelial lipase gene (LIPG) haplotypes with high-density lipoprotein cholesterol subfractions and apolipoprotein AI plasma levels in Japanese Americans. Atherosclerosis 185:1, 78-86
CrossRef470
M Davis, P Durrington, W Hanif, J Morrell, S Mughal, T Mehrali, AH Barnett, J Shepherd. (2006) Lipid treatment strategies for metabolic syndrome in established cardiovascular disease: a consensus guideline. Practical Diabetes International 23:2, 78-85
CrossRef471
Alan T. Hirsch, Ziv J. Haskal, Norman R. Hertzer, Curtis W. Bakal, Mark A. Creager, Jonathan L. Halperin, Loren F. Hiratzka, William R.C. Murphy, Jeffrey W. Olin, Jules B. Puschett, Kenneth A. Rosenfield, David Sacks, James C. Stanley, Lloyd M. Taylor, Christopher J. White, John White, Rodney A. White, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Jonathan L. Halperin, Loren F. Hiratzka, Sharon A. Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): Executive Summary A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery,
AAVS/SVS when Guideline initiated, now merged into SVS Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Journal of the American College of Cardiology 47:6, 1239-1312
CrossRef472
Alan T. Hirsch, Ziv J. Haskal, Norman R. Hertzer, Curtis W. Bakal, Mark A. Creager, Jonathan L. Halperin, Loren F. Hiratzka, William R.C. Murphy, Jeffrey W. Olin, Jules B. Puschett, Kenneth A. Rosenfield, David Sacks, James C. Stanley, Lloyd M. Taylor, Christopher J. White, John White, Rodney A. White, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Raymond J. Gibbons, Jonathan L. Halperin, Loren F. Hiratzka, Sharon A. Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery,
CrossRef473
Cinzia Sarti, John Gallagher. (2006) The metabolic syndrome. Journal of Diabetes and its Complications 20:2, 121-132
CrossRef474
Sheila A Doggrell. (2006) Inhibitors of cholesteryl ester transfer protein – a new approach to coronary artery disease. Expert Opinion on Investigational Drugs 15:2, 99-106
CrossRef475
W. Dallas Hall, Laurence O. Watkins, Jackson T. Wright, Nanette K. Wenger, Shiriki K. Kumanyika, James R. Gavin, Keith C. Ferdinand, Karol Watson, Luther T. Clark, John M. Flack, James W. Reed, Ella W. Horton, Elijah Saunders. (2006) The Metabolic Syndrome: Recognition and Management. Disease Management 9:1, 16-33
CrossRef476
Rakesh S Birjmohun, Erik SG Stroes, John JP Kastelein. (2006) Raising high-density lipoprotein cholesterol for better prevention of cardiovascular disease. Future Lipidology 1:1, 47-54
CrossRef477
Gregory A. Nichols, Carol E. Koro, Wiley Chan, Steven J. Bowlin, Dennis L. Sprecher. (2006) The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: A retrospective chart review involving up to 8 years of follow-up. Clinical Therapeutics 28:2, 243-250
CrossRef478
Jeffrey T Kuvin, Alawi A Alsheikh-Ali, Richard H Karas. (2006) High-Density Lipoprotein Cholesterol-Raising Strategies. Journal of Cardiovascular Pharmacology 47:2, 196-204
CrossRef479
Gerd Schmitz, Thomas Langmann. (2006) Pharmacogenomics of cholesterol-lowering therapy. Vascular Pharmacology 44:2, 75-89
CrossRef480
Andrew C. Li, Wulf Palinski. (2006) PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS: How Their Effects on Macrophages Can Lead to the Development of a New Drug Therapy Against Atherosclerosis. Annual Review of Pharmacology and Toxicology 46:1, 1-39
CrossRef481
Amie D McCord. (2006) Clinical Impact of a Pharmacist-Managed Diabetes Mellitus Drug Therapy Management Service. Pharmacotherapy 26:2, 248-253
CrossRef482
Simon W. Beaven, Peter Tontonoz. (2006) Nuclear Receptors in Lipid Metabolism: Targeting the Heart of Dyslipidemia. Annual Review of Medicine 57:1, 313-329
CrossRef483
Yu-Hua Sun, Yue-Jin Yang, Wei-Dong Pei, Yong-Jian Wu, Run-Lin Gao. (2006) Patients With Low High-Density Lipoprotein-Cholesterol or Smoking are More Likely to Develop Myocardial Infarction Among Subjects With a Visible Lesion or Stenosis in Coronary Artery. Circulation Journal 70:12, 1602-1605
CrossRef484
Udho Thadani. (2006) Selection of optimal therapy for chronic stable angina. Current Treatment Options in Cardiovascular Medicine 8:1, 23-35
CrossRef485
Tiziana Sampietro, Federico Bigazzi, Mariarita Puntoni, Alberto Bionda. (2006) HDL inflammation and atherosclerosis: current and future perspectives. Future Cardiology 2:1, 37-48
CrossRef486
Terry A. Jacobson, Franklin H. Zimmerman. (2006) Fibrates in Combination With Statins in the Management of Dyslipidemia. The Journal of Clinical Hypertension 8:1, 35-41
CrossRef487
Anup K. Sabharwal, Jeffrey B. Boord. (2006) Low-density lipoprotein reduction: Is the risk worth the benefit?. Current Atherosclerosis Reports 8:1, 19-25
CrossRef488
Gary M. Coppola, Robert E. Damon, J. Bruce Eskesen, Dennis S. France, James R. Paterniti. (2006) Biological evaluation of 1-alkyl-3-phenylthioureas as orally active HDL-elevating agents. Bioorganic & Medicinal Chemistry Letters 16:1, 113-117
CrossRef489
Anna C Calkin, Terri J Allen. (2006) Diabetes Mellitus-Associated Atherosclerosis. American Journal of Cardiovascular Drugs 6:1, 15-40
CrossRef490
Paul J. Garcia, Craig W. Spellman. (2006) Should all diabetic patients receive statins?. Current Atherosclerosis Reports 8:1, 13-18
CrossRef491
Wilbert S Aronow. (2006) Managing Hyperlipidaemia in the Elderly. Drugs & Aging 23:3, 181-189
CrossRef492
Harrihar A Pershadsingh. (2006) Dual Peroxisome Proliferator-Activated Receptor-??/?? Agonists. Treatments in Endocrinology 5:2, 89-99
CrossRef493
Ruth Penn, Robert X. Williams, Dilip K. Guha-Ray, William G. Sawyers, Sandra L. Braun, Keith T. Rains. (2006) An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery®-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. Clinical Therapeutics 28:1, 45-54
CrossRef494
Danielle Duffy, Daniel J. Rader. (2006) High-Density Lipoprotein Cholesterol Therapies. Journal of Cardiopulmonary Rehabilitation 26:1, 1-8
CrossRef495
Francesca Giovannelli, Speranza Rubattu. (2006) The Role of Cardiac Rehabilitation in the Treatment and Secondary Prevention of Cardiovascular Disease. High Blood Pressure & Cardiovascular Prevention 13:1, 21-27
CrossRef496
Konstantinos Tziomalos, Vasilios G Athyros. (2006) Fenofibrate: a novel formulation (Triglide?) in the treatment of lipid disorders: a review. International Journal of Nanomedicine 1:2, 129-147
CrossRef497
Wan-Sub Shim, Mi-Young Do, Soo-Kyung Kim, Hae-Jin Kim, Kyu-Yeon Hur, Eun-Seok Kang, Yu-Mie Rhee, Chul-Woo Ahn, Sung-Kil Lim, Kyung-Rae Kim, Hyun-Chul Lee, Bong-Soo Cha. (2006) The long term effects of rosiglitazone on serum lipid concentration and body weight. The Journal of Korean Diabetes Association 30:1, 17
CrossRef498
Stephen J. Nicholls, Ilke Sipahi, E. Murat Tuzcu. (2006) Evaluación de la progresión y la regresión de la aterosclerosis coronaria mediante ecografía intravascular. ¿Un nuevo cambio de paradigma?. Revista Española de Cardiología 59:1, 57-66
CrossRef499
A. Steinmetz. (2006) Chronische Therapie des metabolischen Syndroms bei herzoperierten Diabetikern. Clinical Research in Cardiology 95:S1, i110-i116
CrossRef500
Abu R. Vasudevan, Peter H. Jones. (2006) Effective use of combination lipid therapy. Current Atherosclerosis Reports 8:1, 76-84
CrossRef501
Vid Stanulovic, Mirjana Djeric, Jovan Popovic. (2006) Clinical trials of statins and fibrates: A meta-analysis. Medicinski pregled 59:5-6, 213-218
CrossRef502
Sachin Navare, Paul Thompson. 2005. Pharmacological Treatments of Lipid Abnormalities. , 183-212.
CrossRef503
William Kannel. 2005. Cardiovascular Risk Assessment. , 12-30.
CrossRef504
Saad Hafidh, Neelavathi Senkottaiyan, Daniel Villarreal, Martin A. Alpert. (2005) Management of the Metabolic Syndrome. The American Journal of the Medical Sciences 330:6, 343-351
CrossRef505
John Betteridge. (2005) Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. The American Journal of Medicine 118:12, 10-15
CrossRef506
Y.-D. Jiang, C.-J. Yen, W.-L. Chou, S.-S. Kuo, K.-C. Lee, K. C. Chiu, L.-M. Chuang. (2005) Interaction of the G182C polymorphism in the APOA5 gene and fasting plasma glucose on plasma triglycerides in Type 2 diabetic subjects. Diabetic Medicine 22:12, 1690-1695
CrossRef507
Eric Bruckert, Marie Baccara-Dinet, Fran McCoy, John Chapman. (2005) High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Current Medical Research and Opinion 21:12, 1927-1934
CrossRef508
Sharon Cresci. (2005) The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics. Expert Opinion on Pharmacotherapy 6:15, 2577-2591
CrossRef509
Robert Menuet, Carl J. Lavie, Richard V. Milani. (2005) Importance and Management of Dyslipidemia in the Metabolic Syndrome. The American Journal of the Medical Sciences 330:6, 295-302
CrossRef510
Zachary T. Bloomgarden. (2005) Cardiovascular Complications of Insulin Resistance. Metabolic Syndrome and Related Disorders 3:4, 305-315
CrossRef511
Michael Schachter. (2005) Strategies for Modifying High-Density Lipoprotein Cholesterol: A Role for Nicotinic Acid. Cardiovascular Drugs and Therapy 19:6, 415-422
CrossRef512
Richard A Krasuski. (2005) HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. Current Opinion in Lipidology 16:6, 652-657
CrossRef513
C. Verny. (2005) Management of dyslipidemia in elderly diabetic patients. Diabetes & Metabolism 31, 5S74-5S81
CrossRef514
Benjamin J. Ansell, Karol E. Watson, Alan M. Fogelman, Mohamad Navab, Gregg C. Fonarow. (2005) High-Density Lipoprotein Function. Journal of the American College of Cardiology 46:10, 1792-1798
CrossRef515
Thomas D. Giles, Gary E. Sander. (2005) Pathophysiologic, Diagnostic, and Therapeutic Aspects of the Metabolic Syndrome. The Journal of Clinical Hypertension 7:11, 669-678
CrossRef516
Florence Gizard, Carole Amant, Olivier Barbier, Stefano Bellosta, Romain Robillard, Frédéric Percevault, Henry Sevestre, Paul Krimpenfort, Alberto Corsini, Jacques Rochette, Corine Glineur, Jean-Charles Fruchart, Gérard Torpier, Bart Staels. (2005) PPARα inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. Journal of Clinical Investigation 115:11, 3228-3238
CrossRef517
Sander J. Robins. (2005) Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome. Current Cardiology Reports 7:6, 457-464
CrossRef518
Mohammad Newaz, Ahmad Blanton, Paul Fidelis, Adebayo Oyekan. (2005) NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator activated receptor (PPAR)α-mediated cardiovascular effects. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 579:1-2, 163-171
CrossRef519
Robert S. Kirsner, Claudia C. Ramirez, Daniel G. Federman, Fangchao Ma. (2005) Lipid-lowering agents and risk of melanoma. International Journal of Cancer 117:2, 333-333
CrossRef520
Pål Aukrust, Arne Yndestad, Torgun Wæhre, Lars Gullestad, Bente Halvorsen, Jan Kristian Damås. (2005) Inflammation in coronary artery disease: potential role for immunomodulatory therapy. Expert Review of Cardiovascular Therapy 3:6, 1111-1124
CrossRef521
Weili Yan, Dongfeng Gu, Xiaoyan Yang, Jun Wu, Ling Kang, Li Zhang. (2005) High-density lipoprotein cholesterol levels increase with age, body mass index, blood pressure and fasting blood glucose in a rural Uygur population in China. Journal of Hypertension 23:11, 1985-1989
CrossRef522
Abu R. Vasudevan, Peter H. Jones. (2005) Effective use of combination lipid therapy. Current Cardiology Reports 7:6, 471-479
CrossRef523
Usha Panchapakesan, Xin-Ming Chen, Carol A Pollock. (2005) Drug Insight: thiazolidinediones and diabetic nephropathy—relevance to renoprotection. Nature Clinical Practice Nephrology 1:1, 33-43
CrossRef524
Daniel E. Rosenberg, Serge A. Jabbour, Barry J. Goldstein. (2005) Insulin resistance, diabetes and cardiovascular risk: approaches to treatment. Diabetes, Obesity and Metabolism 7:6, 642-653
CrossRef525
I. Gouni-Berthold, W. Krone. (2005) Hypertriglyceridemia—why, when and how should it be treated?. Zeitschrift für Kardiologie 94:11, 731-739
CrossRef526
Robert Dellavalle, Amanda Drake, Marla Graber, Lauren Heilig, Eric Hester, Kathryn Johnson, Kristie McNealy, Lisa Schilling, Robert Dellavalle. 2005. Statins and fibrates for preventing melanoma. .
CrossRef527
Grant H Skrepnek. (2005) Cost–effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD. Expert Review of Pharmacoeconomics & Outcomes Research 5:5, 603-623
CrossRef528
Antonio M. Gotto. (2005) Evolving Concepts of Dyslipidemia, Atherosclerosis, and Cardiovascular Disease. Journal of the American College of Cardiology 46:7, 1219-1224
CrossRef529
Peter Libby. (2005) The Forgotten Majority. Journal of the American College of Cardiology 46:7, 1225-1228
CrossRef530
George Steiner. (2005) Fibrates and coronary risk reduction. Atherosclerosis 182:2, 199-207
CrossRef531
Emily S van Aalst-Cohen, Angelique C M Jansen, S Matthijs Boekholdt, Michael W T Tanck, Marcel R Fontecha, Suzanne Cheng, Jia Li, Joep C Defesche, Jan Albert Kuivenhoven, John J P Kastelein. (2005) Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. European Journal of Human Genetics 13:10, 1137-1142
CrossRef532
Ashen, M. Dominique, Blumenthal, Roger S., . (2005) Low HDL Cholesterol Levels. New England Journal of Medicine 353:12, 1252-1260
Full Text533
Vishal Bhatia. (2005) Insulin Resistance in Polycystic Ovarian Disease. Southern Medical Journal 98:9, 902-909
CrossRef534
Obiamiwe C. Umeh, Judith S. Currier. (2005) Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Current HIV/AIDS Reports 2:3, 132-139
CrossRef535
David M. Kendall. (2005) The Truth about Lipid Effects of the Thiazolidinediones. Metabolic Syndrome and Related Disorders 3:3, 194-197
CrossRef536
Susan G. Lakoski, David M. Herrington. (2005) Effects of oestrogen receptor-active compounds on lipid metabolism. Diabetes, Obesity and Metabolism 7:5, 471-477
CrossRef537
Eric Van Ganse, Laurent Laforest, Evo Alemao, Glenn Davies, Stephen Gutkin, Don Yin. (2005) Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Current Medical Research and Opinion 21:9, 1389-1399
CrossRef538
Giulia Chinetti-Gbaguidi, Jean Charles Fruchart, Bart Staels. (2005) Pleiotropic effects of fibrates. Current Atherosclerosis Reports 7:5, 396-401
CrossRef539
Clay F Semenkovich. (2005) TZDs and diabetes: testing the waters. Nature Medicine 11:8, 822-824
CrossRef540
James B. Meigs. (2005) Prevention of coronary heart disease in diabetes. Current Treatment Options in Cardiovascular Medicine 7:4, 259-271
CrossRef541
L. A. CARLSON. (2005) Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. Journal of Internal Medicine 258:2, 94-114
CrossRef542
&NA;. (2005) There is a smorgasbord of options in the management of dyslipidaemia in visceral obesity. Drugs & Therapy Perspectives 21:8, 10-14
CrossRef543
Kenneth K. Wu, Tsuei-Ju Wu, Jayne Chin, Lyndon J. Mitnaul, Melba Hernandez, Tian-Quan Cai, Ning Ren, M. Gerard Waters, Samuel D. Wright, Kang Cheng. (2005) Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor. Atherosclerosis 181:2, 251-259
CrossRef544
William G. Henderson, Philip W. Lavori, Peter Peduzzi, Joseph F. Collins, Mike R. Sather, John R. Feussner. 2005. Cooperative Studies Program, US Department of Veterans Affairs. .
CrossRef545
C. Llor Vila. (2005) Manejo de las dislipemias en poblaciones especiales: tratamiento de la dislipemia diabética. Atención Primaria 36, 47-51
CrossRef546
A. Maiques Galán, M. Blasco Valle. (2005) Bases de la evidencia científica del tratamiento hipolipemiante. Factores que condicionan su efectividad e indicaciones en prevención cardiovascular. Atención Primaria 36, 31-39
CrossRef547
Danielle Duffy, Daniel J Rader. (2005) Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. Current Opinion in Cardiology 20:4, 301-306
CrossRef548
Robert S Rosenson. (2005) Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. Current Opinion in Cardiology 20:4, 313-317
CrossRef549
R. Mukhtar, J. P. D. Reckless. (2005) Dyslipidaemia in Type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone. Diabetic Medicine 22:s3, 6-10
CrossRef550
Robert S. Rosenson. (2005) HDL-C and the diabetic patient: Target for therapeutic intervention?. Diabetes Research and Clinical Practice 68, S36-S42
CrossRef551
Alawi A. Alsheikh-Ali, Jeffrey T. Kuvin, Richard H. Karas. (2005) High-density lipoprotein cholesterol in the cardiovascular equation: Does the “good” still count?. Atherosclerosis 180:2, 217-223
CrossRef552
J. Tuomilehto, J. Lindstrom, Q. Qiao. (2005) Strategies for the prevention of type 2 diabetes and cardiovascular disease. European Heart Journal Supplements 7:Suppl D, D18-D22
CrossRef553
A. Pérez, L. Sojo. (2005) Diabetes mellitus tipo 2. ¿Cómo tratar la dislipemia diabética?. Clínica e Investigación en Arteriosclerosis 17, 40-51
CrossRef554
M. Vázquez Carrera. (2005) Receptores activados por proliferadores peroxisómicos tipo gamma en el síndrome metabólico: ¿amigos o enemigos?. Clínica e Investigación en Arteriosclerosis 17, 59-69
CrossRef555
James Shepherd, John Betteridge, Luc Van Gaal. (2005) Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Current Medical Research and Opinion 21:5, 665-682
CrossRef556
Stuart A Cook, Tim Aitman, Rossi P Naoumova. (2005) Therapy Insight: heart disease and the insulin-resistant patient. Nature Clinical Practice Cardiovascular Medicine 2:5, 252-260
CrossRef557
Daniel Schneider, Judith Hsia. (2005) Coronary heart disease prevention in menopausal women. Expert Opinion on Pharmacotherapy 6:5, 695-705
CrossRef558
Kwang Kon Koh, Michael J. Quon, Seung Hwan Han, Wook-Jin Chung, Jeong Yeal Ahn, Yiel-Hea Seo, In Suck Choi, Eak Kyun Shin. (2005) Additive Beneficial Effects of Fenofibrate Combined With Atorvastatin in the Treatment of Combined Hyperlipidemia. Journal of the American College of Cardiology 45:10, 1649-1653
CrossRef559
Henry N. Ginsberg, Yuan-Li Zhang, Antonio Hernandez-Ono. (2005) Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes. Archives of Medical Research 36:3, 232-240
CrossRef560
Prakash Deedwania, Natalia Volkova. (2005) Dyslipidemia and lipid-lowering therapy in the elderly. Expert Review of Cardiovascular Therapy 3:3, 453-463
CrossRef561
(2005) A Comparison of Lipid Variables as Predictors of Cardiovascular Disease in the Asia Pacific Region. Annals of Epidemiology 15:5, 405-413
CrossRef562
T.W. MEADE. (2005) Fibrinogen measurement to assess the risk of arterial thrombosis in individual patients: yes. Journal of Thrombosis and Haemostasis 3:4, 632-634
CrossRef563
James M Backes, Cheryl A Gibson, Patricia A Howard. (2005) Optimal lipid modification: the rationale for combination therapy. Vascular Health and Risk Management 1:4, 317-331
CrossRef564
Patrick Linsel-Nitschke, Alan R. Tall. (2005) HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nature Reviews Drug Discovery 4:3, 193-205
CrossRef565
Marie-France Demierre, Vernon K. Sondak. (2005) Cutaneous melanoma: pathogenesis and rationale for chemoprevention. Critical Reviews in Oncology/Hematology 53:3, 225-239
CrossRef566
Rakesh S Birjmohun, Erik SG Stroes, John JP Kastelein. (2005) Future strategies in the management of dyslipidemia. Future Cardiology 1:2, 127-130
CrossRef567
Kai-Chien Yang, Cheng-Chung Fang, Ta-Chen Su, Yuan-Teh Lee. (2005) Treatment of fibrate-induced rhabdomyolysis with plasma exchange in ESRD. American Journal of Kidney Diseases 45:3, e57-e60
CrossRef568
B. Vergès. (2005) Diabetic dyslipidaemia: insights for optimizing patient management. Current Medical Research and Opinion 21:s1, S29-S40
CrossRef569
W. B. Chan, P. C. Y. Tong, C. C. Chow, W. Y. So, M. C. Y. Ng, R. C. W. Ma, R. Osaki, C. S. Cockram, J. C. N. Chan. (2005) Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients. Diabetes/Metabolism Research and Reviews 21:2, 183-188
CrossRef570
M. John Chapman. (2005) Beyond the Statins: New Therapeutic Perspectives in Cardiovascular Disease Prevention. Cardiovascular Drugs and Therapy 19:2, 135-139
CrossRef571
Karen L Andrews, Malarvannan Pannirselvam, Todd J Anderson, Alicia J Jenkins, Chris R Triggle, Michael A Hill. (2005) The vascular endothelium in diabetes: a practical target fordrug treatment?. Expert Opinion on Therapeutic Targets 9:1, 101-117
CrossRef572
Anthony S. Wierzbicki. (2005) Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. Current Medical Research and Opinion 21:2, 299-305
CrossRef573
Michel de Lorgeril, Patricia Salen, Annabelle Guiraud, Sabrina Zeghichi, François Boucher, Joël de Leiris. (2005) Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease. Nutrition, Metabolism and Cardiovascular Diseases 15:1, 36-41
CrossRef574
Gary M. Coppola, Robert E. Damon, J. Bruce Eskesen, Dennis S. France, James R. Paterniti. (2005) 1-Hydroxyalkyl-3-phenylthioureas as novel HDL-elevating agents. Bioorganic & Medicinal Chemistry Letters 15:3, 809-812
CrossRef575
Susan Cheng, Judith H. Lichtman, Joan M. Amatruda, Grace L. Smith, Jennifer A. Mattera, Sarah A. Roumanis, Harlan M. Krumholz. (2005) Knowledge of Cholesterol Levels and Targets in Patients With Coronary Artery Disease. Preventive Cardiology 8:1, 11-17
CrossRef576
Richard J Woodman, Gerard T Chew, Gerald F Watts. (2005) Mechanisms, Significance and Treatment of Vascular Dysfunction in Type 2 Diabetes Mellitus. Drugs 65:1, 31-74
CrossRef577
Richard W Nesto. (2005) Beyond Low-Density Lipoprotein. American Journal of Cardiovascular Drugs 5:6, 379-387
CrossRef578
Amit Khera, Darren K McGuire. (2005) Management of Diabetic Dyslipidemia. American Journal of Cardiovascular Drugs 5:2, 83-91
CrossRef579
Jean-François Mauger, Patrick Couture, Marie-Eve Paradis, Benoît Lamarche. (2005) Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. Atherosclerosis 178:1, 157-163
CrossRef580
Benjamin J. Ansell. (2005) Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Current Atherosclerosis Reports 7:1, 29-33
CrossRef581
Thomas C. Wascher. (2005) The Era of Statins – Is There Still a Place for Other Classes of Lipid-Lowering Drugs?. Heart Drug 5:1, 34-38
CrossRef582
Gerd Assmann. (2005) Beyond statin therapy: why we need new thinking. Current Medical Research and Opinion 21:s6, S3-S8
CrossRef583
Rukmini Rajagopalan, Shrividya Iyer, Mehmood Khan. (2005) Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials*. Current Medical Research and Opinion 21:1, 163-172
CrossRef584
L Brian Cross, Andrea S Franks. (2005) Clinical Outcomes Associated with Pharmacist Involvement in Patients with Dyslipidemia. Disease Management & Health Outcomes 13:1, 31-42
CrossRef585
Zdenek Kucera, Jiri Vlcek, Miroslava Hejdova. (2005) Theoretical exposure of chronically treated patients to lipid lowering agents. Pharmacoepidemiology and Drug Safety 14:1, 61-67
CrossRef586
Richard L. Dunbar, Daniel J. Rader. (2005) Current drug options for raising HDL cholesterol. Current Treatment Options in Cardiovascular Medicine 7:1, 15-23
CrossRef587
José Vivancos-Mora, Antonio C. Gil-Núñez. (2005) Lipids and Stroke: The Opportunity of Lipid-Lowering Treatment. Cerebrovascular Diseases 20:2, 53-67
CrossRef588
Joel W Hay, Kimberly L Sterling. (2005) Cost Effectiveness of Treating Low HDL-Cholesterol in the Primary Prevention of Coronary Heart Disease. PharmacoEconomics 23:2, 133-141
CrossRef589
Udho Thadani. (2005) Modified-Release Formulation of Trimetazidine for Exceptional Control of Angina Pectoris. American Journal of Cardiovascular Drugs 5:5, 331-334
CrossRef590
George Steiner. (2005) A New Perspective in the Treatment of Dyslipidemia. Treatments in Endocrinology 4:5, 311-317
CrossRef591
Peter M. Rothwell. (2005) Prevention of Stroke in Patients with Diabetes mellitus and the Metabolic Syndrome. Cerebrovascular Diseases 20:1, 24-34
CrossRef592
David Brieger, S Benedict Freedman, Leonard Kritharides, Harry Lowe. 2004. Treatment of Vulnerable Plaques. , 164-202.
CrossRef593
J. Nigro, M. L. Ballinger, R. J. Dilley, G. L. R. Jennings, T. N. Wight, P. J. Little. (2004) Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding. Diabetologia 47:12, 2105-2113
CrossRef594
Terje R Pedersen, Jonathan A Tobert. (2004) Simvastatin: a review. Expert Opinion on Pharmacotherapy 5:12, 2583-2596
CrossRef595
William L. Isley. (2004) What Did PROVE-IT Prove?. Diabetes Technology & Therapeutics 6:6, 864-867
CrossRef596
Yong S. K. Moon, Moti L. Kashyap. (2004) Pharmacologic Treatment of Type 2 Diabetic Dyslipidemia. Pharmacotherapy 24:12, 1692-1713
CrossRef597
MM Thompson, SC Reed, GW Cockerill. (2004) Therapeutic approaches to raising plasma HDL-cholesterol levels. Nature Clinical Practice Cardiovascular Medicine 1:2, 84-89
CrossRef598
J. David Curb, Robert D. Abbott, Beatriz L. Rodriguez, Kamal Masaki, Jordan Popper, Randi Chen, Helen Petrovitch, Patricia Blanchette, Irwin Schatz, Katsuhiko Yano. (2004) Prospective Association Between Low and High Total and Low-Density Lipoprotein Cholesterol and Coronary Heart Disease in Elderly Men. Journal of the American Geriatrics Society 52:12, 1975-1980
CrossRef599
Shui-Ping Zhao, Jie Wu, Da-Qing Zhang, Hui-Jun Ye, Ling Liu, Jie-Qi Li. (2004) Fenofibrate enhances CD36 mediated endocytic uptake and degradation of oxidized low density lipoprotein in adipocytes from hypercholesterolemia rabbit. Atherosclerosis 177:2, 255-262
CrossRef600
Antonio Castrillo, Peter Tontonoz. (2004) PPARs in atherosclerosis: the clot thickens. Journal of Clinical Investigation 114:11, 1538-1540
CrossRef601
Emma A. Meagher. (2004) Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story. Current Cardiology Reports 6:6, 457-463
CrossRef602
Juan F Viles-Gonzalez, Brian G Choi, Valentin Fuster, Juan J Badimon. (2004) Peroxisome proliferator-activated receptor ligands in atherosclerosis. Expert Opinion on Investigational Drugs 13:11, 1393-1403
CrossRef603
A.S. Wierzbicki. (2004) Lipid-altering agents: the future. International Journal of Clinical Practice 58:11, 1063-1072
CrossRef604
Kathie L. Hermayer. (2004) Treatment of lipids and type 2 diabetes. Current Cardiology Reports 6:6, 443-450
CrossRef605
Marcello Tonelli, Dorothea Collins, Sander Robins, Hanna Bloomfield, Gary C. Curhan. (2004) Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. American Journal of Kidney Diseases 44:5, 832-839
CrossRef606
Antonio Castrillo, Peter Tontonoz. (2004) NUCLEAR RECEPTORS IN MACROPHAGE BIOLOGY: At the Crossroads of Lipid Metabolism and Inflammation. Annual Review of Cell and Developmental Biology 20:1, 455-480
CrossRef607
Anthony S Wierzbicki. (2004) Lipid-lowering therapies in development. Expert Opinion on Investigational Drugs 13:11, 1405-1418
CrossRef608
G. De Angelis. (2004) The influence of statin characteristics on their safety and tolerability. International Journal of Clinical Practice 58:10, 945-955
CrossRef609
Lauri I. Kajosaari, Janne T. Backman, Mikko Neuvonen, Jouko Laitila, Pertti J. Neuvonen. (2004) Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. British Journal of Clinical Pharmacology 58:4, 390-396
CrossRef610
G. Kees Hovingh, Alison Brownlie, Radjesh J. Bisoendial, Marie Pierre Dube, Johannes H.M. Levels, Wilma Petersen, Robin P.F. Dullaart, Erik S.G. Stroes, Aeilko H. Zwinderman, Eric de Groot, Michael R. Hayden, Jan Albert Kuivenhoven, John J.P. Kastelein. (2004) A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. Journal of the American College of Cardiology 44:7, 1429-1435
CrossRef611
A. H. Barnett, A. W. Bradbury, J. Brittenden, B. Crichton, R. Donnelly, S. Homer-Vanniasinkam, D. P. Mikhailidis, G. Stansby. (2004) The role of cilostazol in the treatment of intermittent claudication. Current Medical Research and Opinion 20:10, 1661-1670
CrossRef612
Sheila A Doggrell. (2004) Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein – a new approach to coronary artery disease. Expert Opinion on Investigational Drugs 13:10, 1365-1368
CrossRef613
P. Gervois, J.-C. Fruchart, B. Staels. (2004) Inflammation, dyslipidaemia, diabetes and PPARs: pharmacological interest of dual PPARα and PPARγ agonists. International Journal of Clinical Practice 58, 22-29
CrossRef614
Sanjaya Khanal, Omar Obeidat, Mei Lu, Lori Douthat, Michael P. Hudson, Adam B. Greenbaum, Aaron Kugelmass, W. Douglas Weaver. (2004) Dyslipidemia in patients with angiographically confirmed coronary artery disease-an opportunity for improvement. Clinical Cardiology 27:10, 577-580
CrossRef615
Yki-Järvinen, Hannele, . (2004) Thiazolidinediones. New England Journal of Medicine 351:11, 1106-1118
Full Text616
Anthony S. Wierzbicki. (2004) Raising high-density lipoprotein. International Journal of Clinical Practice 58:9, 817-819
CrossRef617
T. A. Jacobson, C. C. Case, S. Roberts, A. Buckley, K. M. Murtaugh, J. C. Y. Sung, D. Gause, C. Varas, C. M. Ballantyne. (2004) Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes, Obesity and Metabolism 6:5, 353-362
CrossRef618
John Morgan, Christina Carey, Anne Lincoff, David Capuzzi. (2004) High-density lipoprotein subfractions and risk of coronary artery disease. Current Atherosclerosis Reports 6:5, 359-365
CrossRef619
Robert S Rosenson, Charles A Reasner. (2004) Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes. Current Opinion in Cardiology 19:5, 480-487
CrossRef620
J. Jaime Caro, K. Jack Ishak, Ingrid Caro, Kristen Migliaccio-Walle, Wendy S. Klittich. (2004) Comparing Medications in a Therapeutic Area Using an NNT Model. Value in Health 7:5, 585-594
CrossRef621
Gloria Lena Vega. (2004) Management of atherogenic dyslipidemia of the metabolic syndrome: evolving rationale for combined drug therapy. Endocrinology & Metabolism Clinics of North America 33:3, 525-544
CrossRef622
Parin Parikh, Rahul Garg, Andrew Atiemo, Chandrasekhar R. Vasamreddy, Vicki Chan, Roger S. Blumenthal. (2004) The Metabolic Syndrome: What to Treat, How to Treat, What Are the Goals?. The American Heart Hospital Journal 2:4, 191-197
CrossRef623
George Steiner. (2004) Fibrates in the metabolic syndrome and in diabetes. Endocrinology & Metabolism Clinics of North America 33:3, 545-555
CrossRef624
Marcello Tonelli, Dorothea Collins, Sander Robins, Hanna Bloomfield, Gary C. Curhan, . (2004) Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney International 66:3, 1123-1130
CrossRef625
T Damci, H Kultursay, A Oguz, S Pehlivanoglu, L Tokgozoglu. (2004) Sub-optimal drug treatment of diabetes and cardiovascular risk in diabetic patients in Turkey. A countrywide survey. Diabetes & Metabolism 30:4, 327-333
CrossRef626
M. Laakso. (2004) The relative importance of cardiovascular risk factors in type 2 diabetes. International Journal of Clinical Practice 58, 20-24
CrossRef627
Kathleen L. Wyne. (2004) Management of Type 2 Diabetes Mellitus: Is It Time for a Paradigm Shift?. Metabolic Syndrome and Related Disorders 2:4, 251-262
CrossRef628
Liviu Klein, Mihai Gheorghiade. (2004) Coronary artery disease and prevention of heart failure. Medical Clinics of North America 88:5, 1209-1235
CrossRef629
Daniel J. Rader. (2004) Inhibition of cholesteryl ester transfer protein activity: A new therapeutic approach to raising high-density lipoprotein. Current Atherosclerosis Reports 6:5, 398-405
CrossRef630
Thierry Claudel, Ekkehard Sturm, Folkert Kuipers, Bart Staels. (2004) The farnesoid X receptor: a novel drug target?. Expert Opinion on Investigational Drugs 13:9, 1135-1148
CrossRef631
M. John Chapman, Gerd Assmann, Jean-Charles Fruchart, James Shepherd, Cesare Sirtori. (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid – a position paper developed by the European Consensus Panel on HDL-C*. Current Medical Research and Opinion 20:8, 1253-1268
CrossRef632
Francisco Javier del Cañizo-Gómez, Marı́a Natividad Moreira-Andrés. (2004) Cardiovascular risk factors in patients with type 2 diabetes. Diabetes Research and Clinical Practice 65:2, 125-133
CrossRef633
Scott M. Grundy, James I. Cleeman, C. Noel Bairey Merz, H. Bryan Brewer, Luther T. Clark, Donald B. Hunninghake, Richard C. Pasternak, Sidney C. Smith, Neil J. Stone. (2004) Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 44:3, 720-732
CrossRef634
Abhinav Goyal, John L. Petersen, Kenneth W. Mahaffey. (2004) The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes. Current Cardiology Reports 6:4, 300-307
CrossRef635
Ronald M Krauss, Patty W Siri. (2004) Dyslipidemia in type 2 diabetes. Medical Clinics of North America 88:4, 897-909
CrossRef636
Marc Evans, Phil McEwan, John R. Peters, Craig J. Currie. (2004) Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate.. Diabetes, Obesity and Metabolism 6:4, 299-307
CrossRef637
Cynthia F. Corbett, Dave Cook. (2004) Diabetes ABCs. Home Healthcare Nurse: The Journal for the Home Care and Hospice Professional 22:7, 452-459
CrossRef638
Michael Miller, Adrian Dobs, Zhong Yuan, Wendy P. Battisti, Hannah Borisute, Joanne Palmisano. (2004) Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. Current Medical Research and Opinion 20:7, 1087-1094
CrossRef639
Maryam Sadat Farvid, Fereydoun Siassi, Mahmoud Jalali, Mostafa Hosseini, Navid Saadat. (2004) The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes. Diabetes Research and Clinical Practice 65:1, 21-28
CrossRef640
Xavier Girerd, Philippe Giral. (2004) Risk stratification for the prevention of cardiovascular complications of hypertension. Current Medical Research and Opinion 20:7, 1137-1142
CrossRef641
Gerald Reaven. (2004) The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinology & Metabolism Clinics of North America 33:2, 283-303
CrossRef642
Paul T Williams. (2004) The relationships of vigorous exercise, alcohol, and adiposity to low and high high-density lipoprotein-cholesterol levels. Metabolism 53:6, 700-709
CrossRef643
Maja Grabacka, Wojciech Placha, Przemyslaw M. Plonka, Stanislawa Pajak, Krystyna Urbanska, Piotr Laidler, Andrzej Slominski. (2004) Inhibition of melanoma metastases by fenofibrate. Archives of Dermatological Research 296:2, 54-58
CrossRef644
Gerd Assmann, Jerzy-Roch Nofer, Helmut Schulte. (2004) Cardiovascular risk assessment in metabolic syndrome: view from PROCAM. Endocrinology & Metabolism Clinics of North America 33:2, 377-392
CrossRef645
Otto Mayer, Jaroslav ??imon, Lubo?? Holubec, Richard Pikner, Ivana Vobrubov??, Ladislav Trefil. (2004) Fibrate treatment and prevalence risk of mild hyperhomocysteinaemia in clinical coronary heart disease patients. European Journal of Cardiovascular Prevention & Rehabilitation 11:3, 244-249
CrossRef646
Julie P. Sutherland, Benjamin McKinley, Robert H. Eckel. (2004) The Metabolic Syndrome and Inflammation. Metabolic Syndrome and Related Disorders 2:2, 82-104
CrossRef647
Kwang Kon Koh, Jeong Yeal Ahn, Seung Hwan Han, Dong Kyu Jin, Hyung Sik Kim, Kyung Cheon Lee, Eak Kyun Shin, Ichiro Sakuma. (2004) Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis. Atherosclerosis 174:2, 379-383
CrossRef648
Thomas W Doebber, Linda J Kelly, Gaochao Zhou, Roger Meurer, Chhabi Biswas, Ying Li, Margaret S Wu, Marc C Ippolito, Yu-Sheng Chao, Pei-Ran Wang, Samuel D Wright, David E Moller, Joel P Berger. (2004) MK-0767, a novel dual PPARα/γ agonist, displays robust antihyperglycemic and hypolipidemic activities. Biochemical and Biophysical Research Communications 318:2, 323-328
CrossRef649
Vasilios G. Athyros, Dimitri P. Mikhailidis, Athanasios A. Papageorgiou, Athanasios N. Symeonidis, Bodosakis R. Mercouris, Anthimos N. Pehlivanidis, Vasilios I. Bouloukos, Moses Elisaf. (2004) Effect of atorvastatin on highdensity lipoprotein cholesteroland its relationship withcoronary events: a subgroupanalysis of the GREekAtorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Current Medical Research and Opinion 20:5, 627-637
CrossRef650
J. D. Lee, J. R. Morrissey, V. Patel. (2004) Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine). Current Medical Research and Opinion 20:5, 765-772
CrossRef651
Peter Schwandt, Adrian JB Brady. (2004) Achieving lipid goals in Europe: how large is the treatment gap?. Expert Review of Cardiovascular Therapy 2:3, 431-449
CrossRef652
Paul N. Durrington, Jaakko Tuomilehto, Andreas Hamann, David Kallend, Karen Smith. (2004) Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Research and Clinical Practice 64:2, 137-151
CrossRef653
Ranjan Chakrabarti, Parimal Misra, Reeba K Vikramadithyan, Mamnoor Premkumar, Jagadheshan Hiriyan, Srinivas R Datla, Ravi K.B Damarla, Juluri Suresh, Ramanujam Rajagopalan. (2004) Antidiabetic and hypolipidemic potential of DRF 2519—a dual activator of PPAR-α and PPAR-γ. European Journal of Pharmacology 491:2-3, 195-206
CrossRef654
F Bonnet, E Balestre, R Thiebaut, P Mercie, M Dupon, P Morlat, F Dabis, . (2004) Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Medicine 5:3, 133-139
CrossRef655
Michel Marcil, Brian O'Connell, Larbi Krimbou, Jacques Genest Jr. (2004) High-density lipoproteins: multifunctional vanguards of the cardiovascular system. Expert Review of Cardiovascular Therapy 2:3, 417-430
CrossRef656
Alan J. Sinclair. 2004. Aging and Diabetes Mellitus. .
CrossRef657
B. Charbonnel, B. Bouhanick, C. Le Feuvre. (2004) Recommandations SFC/ALFEDIAM sur la prise en charge du patient diabétique vu par le cardiologue. Diabetes & Metabolism 30:2, 2S9-2S24
CrossRef658
J. Puel, P. Valensi, G. Vanzetto, V. Lassmann-Vague, J.-L. Monin, Ph. Moulin, Ch. Ziccarelli, H. Mayaudon, M. Ovize, S. Bernard, E. Van Belle, S. Halimi. (2004) Identification of myocardial ischemia in the diabetic patient Joint ALFEDIAM and SFC recommendations. Diabetes & Metabolism 30:2, 3S3-3S18
CrossRef659
Richard Chudleigh, Julia Platts. (2004) Clinical therapy and trials. Current Opinion in Lipidology 15:2, 235-237
CrossRef660
James R. Gavin. (2004) Slowing Cardiovascular Disease Progression in African-American Patients: Diabetes Management. The Journal of Clinical Hypertension 6:s4, 26-33
CrossRef661
Clyde W. Yancy. (2004) Improving Outcomes in the Post-Myocardial Infarction Setting. The Journal of Clinical Hypertension 6:s4, 34-41
CrossRef662
&NA;. (2004) Screening for Type 2 Diabetes Mellitus in Adults: Recommendations and Rationale. AJN, American Journal of Nursing 104:3, 83-90
CrossRef663
Christine E. Young, Richard H. Karas, Jeffrey T. Kuvin. (2004) High-Density Lipoprotein Cholesterol and Coronary Heart Disease. Cardiology in Review 12:2, 107-119
CrossRef664
Sergio Fazio, MacRae F. Linton. (2004) The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy. Current Atherosclerosis Reports 6:2, 148-157
CrossRef665
Bartlomiej Piechowski-Jozwiak, Julien Bogousslavsky. (2004) Stroke prevention with lipid-lowering therapy. Expert Review of Neurotherapeutics 4:2, 233-239
CrossRef666
Kristy L. West, Maria Fernandez. (2004) Guinea Pigs as Models to Study the Hypocholesterolemic Effects of Drugs. Cardiovascular Drug Reviews 22:1, 55-70
CrossRef667
Arati Wagh, Neil J Stone. (2004) Treatment of metabolic syndrome. Expert Review of Cardiovascular Therapy 2:2, 213-228
CrossRef668
J. B. Buse, M. H. Tan, M. J. Prince, P. P. Erickson. (2004) The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 6:2, 133-156
CrossRef669
Antonio M. Gotto, Eliot A. Brinton. (2004) Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease. Journal of the American College of Cardiology 43:5, 717-724
CrossRef670
Philip W. Shaul, Chieko Mineo. (2004) HDL action on the vascular wall: is the answer NO?. Journal of Clinical Investigation 113:4, 509-513
CrossRef671
Marja-Riitta Taskinen. 2004. Hypolipidemic Agents and Their Role in the Therapy of Diabetes Mellitus. .
CrossRef672
The UK HDL-C Consensus Group. (2004) Role of fibrates in reducing coronary risk: a UK Consensus. Current Medical Research and Opinion 20:2, 241-247
CrossRef673
B Vergès. (2004) Clinical interest of PPARs ligands. Diabetes & Metabolism 30:1, 7-12
CrossRef674
Terry Meriden. (2004) Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clinical Therapeutics 26:2, 177-190
CrossRef675
Patrick C Choy, Yaw L Siow, David Mymin, Karmin O. (2004) Lipids and atherosclerosis. Biochemistry and Cell Biology 82:1, 212-224
CrossRef676
Anne L. Peters Harmel, David M. Kendall, John B. Buse, Patrick J. Boyle, Albert Marchetti, Helen Lau. (2004) Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes*. Current Medical Research and Opinion 20:2, 215-223
CrossRef677
Cameron C. Lindsey, Maqual R. Graham, Thomas P. Johnston, Chelsea G. Kiroff, Anna Freshley. (2004) A Clinical Comparison of Calculated versus Direct Measurement of Low-Density Lipoprotein Cholesterol Level. Pharmacotherapy 24:2, 167-172
CrossRef678
John C. LaRosa. (2004) New and emerging data from clinical trials of statins. Current Atherosclerosis Reports 6:1, 12-19
CrossRef679
Frank van Leth, Prahpan Phanuphak, Erik Stroes, Brian Gazzard, Pedro Cahn, François Raffi, Robin Wood, Mark Bloch, Christine Katlama, John J. P. Kastelein, Mauro Schechter, Robert L. Murphy, Andrzej Horban, David B. Hall, Joep M. A. Lange, Peter Reiss. (2004) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1. PLoS Medicine 1:1, e19
CrossRef680
Kohji Shirai. (2004) Obesity as the core of the metabolic syndrome and the management of coronary heart disease. Current Medical Research and Opinion 20:3, 295-304
CrossRef681
Dick C Chan, Hugh P R Barrett, Gerald F Watts. (2004) Dyslipidemia in Visceral Obesity. American Journal of Cardiovascular Drugs 4:4, 227-246
CrossRef682
Richard W Grant, James B Meigs. (2004) Should the Insulin Resistance Syndrome be Treated in the Elderly?. Drugs & Aging 21:3, 141-151
CrossRef683
Shung Chull Chae. (2004) Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease. Journal of the Korean Medical Association 47:8, 704
CrossRef684
Juan F Ascaso, Arturo Fern??ndez-Cruz, Pedro Gonz??lez Santos, Antonio Hern??ndez Mijares, Alipio Mangas Rojas, Jesus Mill??n, Luis Felipe Pallardo, Juan Pedro-Botet, Francisco P??rez-Jim??nez, Gonzalo P??a, Xavier Pint??, Ignacio Plaza, Juan Rubi??s-Prat. (2004) Significance of High Density Lipoprotein-Cholesterol in Cardiovascular Risk Prevention. American Journal of Cardiovascular Drugs 4:5, 299-314
CrossRef685
Cathie Sudlow, Charles P. Warlow. 2004. Long-Term Medical Management of Ischemic Stroke and Transient Ischemic Attack Due to Arterial Disease. , 1129-1150.
CrossRef686
Kenneth J. Mukamal. (2004) Alcohol Consumption and Abnormalities of Brain Structure and Vasculature. The American Journal of Geriatric Cardiology 13:1, 22-28
CrossRef687
Alexander Tenenbaum, Enrique Z Fisman. (2004) Impaired Glucose Metabolism in Patients with Heart Failure. American Journal of Cardiovascular Drugs 4:5, 269-280
CrossRef688
Sander J Robins. (2003) Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?. Current Opinion in Lipidology 14:6, 575-583
CrossRef689
Guy De Backer, Ettore Ambrosioni, Knut Broch-Johnsen, Carlos Brotons, Renata Cifkova, Jean Dallongeville, Shah Ebrahim, Ole Faergeman, Ian Graham, Guiseppe Mancia, Volkert Manger Cats, Kristina Orth-Gom??r, Joep Perk, Kalevi Py??r??l??, Jos?? L. Rodicio, Susana Sans, Vedat Sansoy, Udo Sechtem, Sigmund Silber, Troels Thomsen, David Wood. (2003) European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation 10:Supplement 1, S1-S78
CrossRef690
S. Haffner, H. B. Cassells. (2003) Metabolic syndrome - a new risk factor of coronary heart disease?. Diabetes, Obesity and Metabolism 5:6, 359-370
CrossRef691
Andrew Neil. (2003) Diabetes and cardiovascular disease. Diabetes, Obesity and Metabolism 5:s1, s11-s18
CrossRef692
David S. H. Bell. (2003) Dyslipidemia in Type 2 Diabetes and the Effects of Thiazolidinediones. The Endocrinologist 13:6, 496-504
CrossRef693
Michael H. Davidson, Leiv Ose, Jiri Frohlich, Russell S. Scott, Carlos A. Dujovne, Ivan D. Escobar, Marcelo C. Bertolami, Frank Cihon, Darbie L. MacCubbin, Michele Mercuri. (2003) Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups. Clinical Cardiology 26:11, 509-514
CrossRef694
Harold Bays, Evan A Stein. (2003) Pharmacotherapy for dyslipidaemia – current therapies and future agents. Expert Opinion on Pharmacotherapy 4:11, 1901-1938
CrossRef695
Anthony S Wierzbicki. (2003) New lipid-lowering agents. Expert Opinion on Emerging Drugs 8:2, 365-376
CrossRef696
Ranjan Chakrabarti, Reeba K Vikramadithyan, Parimal Misra, Jagadheshan Hiriyan, Suryaprakash Raichur, Ravi K Damarla, Cynthia Gershome, Juluri Suresh, Ramanujam Rajagopalan. (2003) Ragaglitazar: a novel PPAR α & PPAR γ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. British Journal of Pharmacology 140:3, 527-537
CrossRef697
Rex W. Force. (2003) Evidence-Based Medicine and Information Mastery: Application for Acute Gastrointestinal Conditions. Pharmacotherapy 23:10 Part 2, 61S-67S
CrossRef698
Amale A. Lteif, Kieren J. Mather, Charles M. Clark. (2003) Diabetes and Heart Disease. Cardiology in Review 11:5, 262-274
CrossRef699
M. P. Dube, J. H. Stein, J. A. Aberg, C. J. Fichtenbaum, J. G. Gerber, K. T. Tashima, W. K. Henry, J. S. Currier, D. Sprecher, M. J. Glesby, . (2003) Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clinical Infectious Diseases 37:5, 613-627
CrossRef700
Otto Mayer, Jaroslav Šimon, Luboš Holubec, Richard Pikner, Ivan Šubrt. (2003) Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration. European Journal of Clinical Pharmacology 59:5-6, 367-371
CrossRef701
Ahmad Aljada, Priya Mohanty, Paresh Dandona. (2003) Lipids, Carbohydrates, and Heart Disease. Metabolic Syndrome and Related Disorders 1:3, 185-188
CrossRef702
Antonios M. Xydakis, Peter H. Jones. (2003) Toxicity of antilipidemic agents: Facts and fictions. Current Atherosclerosis Reports 5:5, 403-410
CrossRef703
Peter P. Toth. (2003) Reverse cholesterol transport: High-density lipoprotein’s magnificent mile. Current Atherosclerosis Reports 5:5, 386-393
CrossRef704
Daisuke Takada, Yoichi Ezura, Shuji Ono, Yasuhiko Iino, Yasuo Katayama, Yuanpei Xin, Lily L. Wu, Stacey Larringa-Shum, Susan H. Stephenson, Steven C. Hunt, Paul N. Hopkins, Mitsuru Emi. (2003) Growth hormone receptor variant (L526I) modifies plasma HDL cholesterol phenotype in familial hypercholesterolemia: Intra-familial association study in an eight-generation hyperlipidemic kindred. American Journal of Medical Genetics 121A:2, 136-140
CrossRef705
Leonardo Calza, Roberto Manfredi, Francesco Chiodo. (2003) Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. International Journal of Antimicrobial Agents 22:2, 89-99
CrossRef706
Paul Durrington. (2003) Dyslipidaemia. The Lancet 362:9385, 717-731
CrossRef707
Tsukasa Ishihara, Hirotoshi Kakuta, Hiroshi Moritani, Tohru Ugawa, Shuichi Sakamoto, Shin-ichi Tsukamoto, Isao Yanagisawa. (2003) Syntheses of 3-Ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels. Bioorganic & Medicinal Chemistry 11:17, 3735-3745
CrossRef708
David Alexander Leaf. (2003) The effect of physical exercise on reverse cholesterol transport. Metabolism 52:8, 950-957
CrossRef709
Lars H Lindholm, Mats Persson, Petar Alaupovic, Bo Carlberg, Anders Svensson, Ola Samuelsson. (2003) Metabolic outcome during 1 year in newly detected hypertensives. Journal of Hypertension 21:8, 1563-1574
CrossRef710
Jeffrey T. Kuvin, Richard H. Karas. (2003) The effects of LDL reduction and HDL augmentation on physiologic and inflammatory markers. Current Opinion in Cardiology 18:4, 295-300
CrossRef711
Seth Braunstein. (2003) New developments in type 2 diabetes mellitus: Combination therapy with a thiazolidinedione. Clinical Therapeutics 25:7, 1895-1917
CrossRef712
P. H. Winocour, M. Fisher. (2003) Prediction of cardiovascular risk in people with diabetes. Diabetic Medicine 20:7, 515-527
CrossRef713
Nicolaas C. Schaper, Peter J.E.M Kitslaar. 2003. Peripheral Vascular Disease in Diabetes. .
CrossRef714
Jaakko Tuomilehto. (2003) Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia. Diabetes Research and Clinical Practice 61, S27-S34
CrossRef715
Rosaire P. Gray, John S. Yudkin. 2003. Clinical Features and Treatment of Coronary Heart Disease in Diabetes. .
CrossRef716
William E. Boden. (2003) Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Current Opinion in Cardiology 18:4, 278-285
CrossRef717
Sunil Asnani, Emily Chan, S. N. Murthy, D. B. McNamara, Vivian A. Fonseca. (2003) Effect of Pharmacological Treatments for Diabetes on Homocysteine. Metabolic Syndrome and Related Disorders 1:2, 149-158
CrossRef718
Philip Barter, John Kastelein, Alistair Nunn, Richard Hobbs. (2003) High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 168:2, 195-211
CrossRef719
David M. Kendall, Burton E. Sobel, Ann M. Coulston, Anne L. Peters Harmel, Barry K. McLean, Virginia Peragallo-Dittko, John B. Buse, Vivian A. Fonseca, James O. Hill, Richard W. Nesto, Xavier F. Pi Sunyer. (2003) The insulin resistance syndrome and coronary artery disease. Coronary Artery Disease 14:4, 335-348
CrossRef720
A Fredenrich, P Bayer. (2003) Reverse cholesterol transport, high density lipoproteins and HDL cholesterol: recent data. Diabetes & Metabolism 29:3, 201-205
CrossRef721
Hanna Zowall, Steven A Grover. (2003) Costs of dyslipidemia. Expert Review of Pharmacoeconomics & Outcomes Research 3:3, 273-281
CrossRef722
&NA;. (2003) Bibliography. Coronary Artery Disease 14:4, 349-352
CrossRef723
M. Miller. (2003) Niacin as a Component of Combination Therapy for Dyslipidemia. Mayo Clinic Proceedings 78:6, 735-742
CrossRef724
Christopher J Packard, Allan Gaw, James Shepherd. 2003. Cholesterol-lowering Agents and their Use. .
CrossRef725
Samaha, Frederick F., Iqbal, Nayyar, Seshadri, Prakash, Chicano, Kathryn L., Daily, Denise A., McGrory, Joyce, Williams, Terrence, Williams, Monica, Gracely, Edward J., Stern, Linda, . (2003) A Low-Carbohydrate as Compared with a Low-Fat Diet in Severe Obesity. New England Journal of Medicine 348:21, 2074-2081
Full Text726
Care California Healthcare FoundationAme. (2003) Guidelines for Improving the Care of the Older Person with Diabetes Mellitus. Journal of the American Geriatrics Society 51:5s, 265-280
CrossRef727
Robert P. Dellavalle, M. Kelly Nicholas, Lisa M. Schilling. (2003) Melanoma Chemoprevention: A Role for Statins or Fibrates?. American Journal of Therapeutics 10:3, 203-210
CrossRef728
Shaista Malik, Moti L Kashyap. (2003) Dyslipidemia treatment: current considerations and unmet needs. Expert Review of Cardiovascular Therapy 1:1, 121-134
CrossRef729
David A Playford, Gerald F Watts, Kevin D Croft, Valerie Burke. (2003) Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes. Atherosclerosis 168:1, 169-179
CrossRef730
Chad R. Worz, Michael Bottorff. (2003) Treating Dyslipidemic Patients with Lipid-Modifying and Combination Therapies. Pharmacotherapy 23:5, 625-637
CrossRef731
Kathleen L. Wyne, David S.H. Bell, Seth Braunstein, Andrew J. Drexler, Jeffrey L. Miller, James G. Nuckolls. (2003) Trends in Management of Type 2 Diabetes. The Endocrinologist 13:Sup 1, S1-S21
CrossRef732
K. Empen, H.-C. Geiss, M. Lehrke, C. Otto, P. Schwandt, K.G. Parhofer. (2003) Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia. Nutrition, Metabolism and Cardiovascular Diseases 13:2, 87-92
CrossRef733
Kenneth J. Mukamal. (2003) Alcohol Use and Prognosis in Patients With Coronary Heart Disease. Preventive Cardiology 6:2, 93-98
CrossRef734
Henry Ginsberg, Anton Stalenhoef. (2003) Journal of Cardiovascular Risk 10:2, 121-128
CrossRef735
H. Bryan Brewer. (2003) New features of the national cholesterol education program adult treatment panel III lipid-lowering guidelines. Clinical Cardiology 26:S3, 19-24
CrossRef736
Leonardo Calza, Roberto Manfredi, Francesco Chiodo. (2003) Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 17:6, 851-859
CrossRef737
Gerd Schmitz, Wolfgang Drobnik. (2003) Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy. Clinical Chemistry and Laboratory Medicine 41:4, 581-589
CrossRef738
R. S. Weinstock. (2003) Treating Type 2 Diabetes Mellitus: A Growing Epidemic. Mayo Clinic Proceedings 78:4, 411-413
CrossRef739
D. R. Sullivan. (2003) Recent trends in lipid management: raising the bar and shifting the goalposts?. Internal Medicine Journal 33:3, 95-102
CrossRef740
Gerald Reaven, Philip S Tsao. (2003) Insulin resistance and compensatory hyperinsulinemia. Journal of the American College of Cardiology 41:6, 1044-1047
CrossRef741
Jonathan L. Isaacsohn, James LaSalle, George Chao, Leonard Gonasun. (2003) Comparison of treatment with fluvastatin extended-release 80-mg tablets and immediate-release 40-mg capsules in patients with primary hypercholesterolemia. Clinical Therapeutics 25:3, 904-918
CrossRef742
Joseph M. Keenan. (2003) Treatment of Patients with Lipid Disorders in the Primary Care Setting: New Treatment Guidelines and their Implications. Southern Medical Journal 96:3, 266-275
CrossRef743
K. Borch-Johnsen, T. Lauritzen, C. Glumer, A. Sandbaek. (2003) Screening for Type 2 diabetes-should it be now?. Diabetic Medicine 20:3, 175-181
CrossRef744
Eric Bruckert. (2003) New lipid-modifying therapies. Expert Opinion on Investigational Drugs 12:3, 325-335
CrossRef745
GEORGIOS I. PAPAIOANNOU, GARY V. HELLER. (2003) Risk Assessment by Myocardial Perfusion Imaging for Coronary Revascularization, Medical Therapy, and Noncardiac Surgery. Cardiology in Review 11:2, 60-72
CrossRef746
Donald B. Hunninghake, Mark E. McGovern, Michael Koren, Ronald Brazg, David Murdock, Stuart Weiss, Thomas Pearson. (2003) A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clinical Cardiology 26:3, 112-118
CrossRef747
Annabelle Rodriguez, Rajiv R Doshi. (2003) Potential therapeutic agents that raise high-density lipoprotein cholesterol levels. Expert Opinion on Therapeutic Patents 13:2, 167-175
CrossRef748
M. D. Trip. (2003) Achtergronden van de behandelingsadviezen bij hypercholesterolemiedyslipidemie. Bijblijven 19:2, 83-89
CrossRef749
Gerd Assmann, Jerzy-Roch Nofer. (2003) Atheroprotective Effects of High-Density Lipoproteins. Annual Review of Medicine 54:1, 321-341
CrossRef750
James W. Anderson. (2003) Whole grains protect against atherosclerotic cardiovascular disease. Proceedings of the Nutrition Society 62:01, 135-142
CrossRef751
Gæde, Peter, Vedel, Pernille, Larsen, Nicolai, Jensen, Gunnar V.H., Parving, Hans-Henrik, Pedersen, Oluf, . (2003) Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. New England Journal of Medicine 348:5, 383-393
Full Text752
ES Tai, JM Ordovas, D Corella, M Deurenberg-Yap, E Chan, X Adiconis, SK Chew, LM Loh, CE Tan. (2003) The TaqIB and −629C>A polymorphisms at the cholesteryl ester transfer protein locus: associations with lipid levels in a multiethnic population. The 1998 Singapore National Health Survey. Clinical Genetics 63:1, 19-30
CrossRef753
A. S. Wierzbicki, D. P. Mikhailidis, R. Wray, M. Schachter, R. Cramb, W. G. Simpson, C. B. Byrne. (2003) Statin-fibrate combination therapy for hyperlipidaemia: a review. Current Medical Research and Opinion 19:3, 155-168
CrossRef754
Elena Izkhakov, Eyal Meltzer, Ardon Rubinstein. (2003) Pathogenesis and Management of Diabetic Dyslipidemia. Treatments in Endocrinology 2:4, 231-245
CrossRef755
Odd E Johansen, K??re I Birkeland. (2003) Preventing Macrovascular Disease in Patients with Type 2 Diabetes Mellitus. American Journal of Cardiovascular Drugs 3:4, 283-297
CrossRef756
Emilio Ros, Josefina Oliv??n, Jos?? M. Mostaza, Miquel Vilardell, Xavier Pint??, Fernando Civeira, A. Hern??ndez, Pedro Marqu??s da Silva, A. Rodriguez-Botaro, Daniel Zamb??n, Joan Lima, Jos?? A. G??mez-Gerique, Cristina D??az, Rosa Ar??stegui, Jos?? M. Sol, Gonzalo Hern??ndez. (2003) Atorvastatin versus Bezafibrate in Mixed Hyperlipidaemia. Clinical Drug Investigation 23:3, 153-165
CrossRef757
Jean Ducobu, Luc VanHaelst, Herve Salomon. (2003) Comparison of Micronized Fenofibrate and Pravastatin in Patients With Primary Hyperlipidemia. Journal of Cardiovascular Pharmacology 41:1, 60-67
CrossRef758
ELAHE??? MOSTAGHEL, DAVID WATERS. (2003) Women Do Benefit from Lipid Lowering: Latest Clinical Trial Data. Cardiology in Review 11:1, 4-12
CrossRef759
Daniel J. Rader. (2003) Therapy to reduce risk of coronary heart disease. Clinical Cardiology 26:1, 2-8
CrossRef760
Martin Hersberger, Arnold von Eckardstein. (2003) Low High-Density Lipoprotein Cholesterol. Drugs 63:18, 1907-1945
CrossRef761
Moti L. Kashyap, S. Tavintharan, Vaijinath S. Kamanna. (2003) Optimal Therapy of Low Levels of High Density Lipoprotein-Cholesterol. American Journal of Cardiovascular Drugs 3:1, 53-65
CrossRef762
Timo E Strandberg, Kaisu H Pitkala, Reijo S Tilvis. (2003) Benefits of Optimising Drug Treatment in Home-Dwelling Elderly Patients with Coronary Artery Disease. Drugs & Aging 20:8, 585-595
CrossRef763
Andre J Scheen. (2003) Current Management Strategies for Coexisting Diabetes Mellitus and Obesity. Drugs 63:12, 1165-1184
CrossRef764
Mark W. Stolar, Robert J. Chilton. (2003) Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clinical Therapeutics 25, B4-B31
CrossRef765
Michel Farnier. (2003) Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative. American Journal of Cardiovascular Drugs 3:3, 169-178
CrossRef766
Anoop Misra, Sumit Kumar, Naval Kishore Vikram, Atul Kumar. (2003) The Role of Lipids in the Development of Diabetic Microvascular Complications. American Journal of Cardiovascular Drugs 3:5, 325-338
CrossRef767
Eliot A. Brinton. (2003) Lipid abnormalities in the metabolic syndrome. Current Diabetes Reports 3:1, 65-72
CrossRef768
Enzo Ragucci, Joel Zonszein, William H. Frishman. (2003) Pharmacotherapy of Diabetes Mellitus: Implications for the Prevention and Treatment of Cardiovascular Disease. Heart Disease 5:1, 18-33
CrossRef769
Leann Olansky, Albert Marchetti, Helen Lau. (2003) Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels. Clinical Therapeutics 25, B64-B80
CrossRef770
Udho Thadani. (2003) The Pursuit of Optimum Outcomes in Stable Angina. American Journal of Cardiovascular Drugs 3:Supplement 1, 11-20
CrossRef771
Yong SK Moon, Moti L Kashyap. (2002) Niacin extended-release/ lovastatin: combination therapy for lipid disorders. Expert Opinion on Pharmacotherapy 3:12, 1763-1771
CrossRef772
Graeme J. Hankey. (2002) Role of lipid-modifying therapy in the prevention of initial and recurrent stroke. Current Opinion in Lipidology 13:6, 645-651
CrossRef773
David R. P. Guay. (2002) Update on Fenofibrate. Cardiovascular Drug Reviews 20:4, 281-302
CrossRef774
Kathleen A. Packard, James M. Backes, Thomas L. Lenz, Richard L. Wurdeman, Christopher J. Destache, Daniel E. Hilleman. (2002) Comparison of Gemfibrozil and Fenofibrate in Patients with Dyslipidemic Coronary Heart Disease. Pharmacotherapy 22:12, 1527-1532
CrossRef775
Stephen Colagiuri, James Best. (2002) Lipid-lowering therapy in people with type 2 diabetes. Current Opinion in Lipidology 13:6, 617-623
CrossRef776
W. Duvall, Michael Blazing, Shilpa Saxena, John Guyton. (2002) Journal of Cardiovascular Risk 9:6, 339-347
CrossRef777
F. Martin-Nizard, C. Furman, P. Delerive, A. Kandoussi, J. C. Fruchart, B. Staels, P. Duriez. (2002) Peroxisome Proliferator–activated Receptor Activators Inhibit Oxidized Low-density Lipoprotein–induced Endothelin-1 Secretion in Endothelial Cells. Journal of Cardiovascular Pharmacology 40:6, 822-831
CrossRef778
Pankaj Goyal, Geeta Sharma Da, Baljinderpal S. Bal, Jatinder Singh, Jagjit Singh, Gurpreet Kaur Randhawa, Shaloo Pandhi, Rohit Sharma. (2002) Prospective, noninterventional, uncontrolled, open-chart, pharmacoepidemiologic study of prescribing patterns for lipid-lowering drugs at a tertiary care teaching hospital in North India. Clinical Therapeutics 24:12, 2064-2076
CrossRef779
Jean-Charles Fruchart, Patrick Duriez. (2002) HDL and triglyceride as therapeutic targets. Current Opinion in Lipidology 13:6, 605-616
CrossRef780
Tall, Alan R., . (2002) Exercise to Reduce Cardiovascular Risk — How Much Is Enough?. New England Journal of Medicine 347:19, 1522-1524
Full Text781
James Shepherd. (2002) Diabetes in tomorrow's world: dark clouds do have silver linings. Diabetes, Obesity and Metabolism 4:6, 351-355
CrossRef782
Michael Miller, Barbara Cosgrove, Stephen Havas. (2002) Update on the role of triglycerides as a risk factor for coronary heart disease. Current Atherosclerosis Reports 4:6, 414-418
CrossRef783
Peter W. F. Wilson. (2002) Clinical trials report. Current Cardiology Reports 4:6, 485-487
CrossRef784
Theresa M. Bianco. 2002. Hyperlipidemia Pharmacy Practice. , 461-468.
CrossRef785
Brett L. Cucchiara, Scott E. Kasner. (2002) Atherosclerotic risk factors in patients with ischemic cerebrovascular disease. Current Treatment Options in Neurology 4:6, 445-453
CrossRef786
Annaswamy Raji, Jorge Plutzky. (2002) Insulin resistance, diabetes, and atherosclerosis: Thiazolidinediones as therapeutic interventions. Current Cardiology Reports 4:6, 514-521
CrossRef787
Roberto Corti, Juan Jose Badimon. (2002) Biologic aspects of vulnerable plaque. Current Opinion in Cardiology 17:6, 616-625
CrossRef788
Eric K. Gupta, Matthew K. Ito. (2002) Ezetimibe: The First in a Novel Class of Selective Cholesterol-Absorption Inhibitors. Heart Disease 4:6, 399-409
CrossRef789
William S. Weintraub. (2002) Is atherosclerotic vascular disease related to a high-fat diet?. Journal of Clinical Epidemiology 55:11, 1064-1072
CrossRef790
Ling Li, Marie-Claude Beauchamp, Geneviève Renier. (2002) Peroxisome proliferator-activated receptor α and γ agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis 165:1, 101-110
CrossRef791
Nathan, David M., . (2002) Initial Management of Glycemia in Type 2 Diabetes Mellitus. New England Journal of Medicine 347:17, 1342-1349
Full Text792
Jun Sasaki, Kyosuke Yamamoto, Masato Ageta. (2002) Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: A randomized, double-blind, placebo-controlled, multicenter, crossover study. Clinical Therapeutics 24:10, 1614-1626
CrossRef793
Antonio M. Gotto. (2002) Statins and C-Reactive Protein: Considering a Novel Marker of Cardiovascular Risk. Preventive Cardiology 5:4, 200-203
CrossRef794
Jim Koeller, Robert L. Talbert. (2002) Modification of High-Density Lipoprotein Cholesterol in the Management of Cardiovascular Risk. Pharmacotherapy 22:10, 1266-1277
CrossRef795
Hans-Christoph Diener, Peter Ringleb. (2002) Antithrombotic secondary prevention after stroke. Current Treatment Options in Cardiovascular Medicine 4:5, 429-440
CrossRef796
Asim K. Duttaroy. (2002) Therapy and clinical trials. Current Opinion in Lipidology 13:5, 585-587
CrossRef797
Honey East Holman, G. Swink Hicks, Annette K. Low, Marshall J. Bouldin, Lori D. Russell, Christopher A. Friedrich, C. Andrew Brown. (2002) An Internist???s Update on Cholesterol Management. The American Journal of the Medical Sciences 324:4, 189-195
CrossRef798
Gary M Coppola, Robert E Damon, J.Bruce Eskesen, Dennis S France, James R Paterniti. (2002) Thiourea-based gemfibrozil analogues as HDL-elevating agents. Bioorganic & Medicinal Chemistry Letters 12:17, 2439-2442
CrossRef799
Alicia L. Wolfert, Steven Kolpak. (2002) Hyperlipidemia. Primary Care Case Reviews 5:3, 115-124
CrossRef800
&NA;. (2002) Combined hyperlipidaemia requires aggressive management to reduce cardiovascular risk. Drugs & Therapy Perspectives 18:9, 7-10
CrossRef801
W.Grady Smith, Jiang Wang, An Q Dang, Charles Reeves, David Bibbs, Fred H Faas. (2002) Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia. Clinica Chimica Acta 322:1-2, 77-84
CrossRef802
Sander J. Robins. (2002) Fibrates and coronary heart disease reduction in diabetes. Current Opinion in Endocrinology & Diabetes 9:4, 312-322
CrossRef803
Elliot Sternthal, Neil Ruderman. (2002) Insulin: Promise and problems at 80 years. Current Opinion in Endocrinology & Diabetes 9:4, 283-284
CrossRef804
Judy WM Cheng. (2002) Pharmacotherapeutic options for the management of myocardial infarction. Expert Opinion on Pharmacotherapy 3:8, 1153-1168
CrossRef805
Sunder Mudaliar, Robert R. Henry. (2002) PPAR agonists in health and disease: a pathophysiologic and clinical overview. Current Opinion in Endocrinology & Diabetes 9:4, 285-302
CrossRef806
R Dellavalle, K McNealy, M Graber, J Morelli, L Schilling. 2002. Lipid-lowering agents for preventing melanoma. .
CrossRef807
Y Bossé, M-C Vohl, M Dumont, M Brochu, J Bergeron, J-P Després, D Prud'homme. (2002) Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. Clinical Genetics 62:1, 45-52
CrossRef808
Brian R. Ramjattan, Denis J.G. Callaghan, Uwe Theiss. (2002) Efficacy and tolerability of a “suprabioavailable” formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials. Clinical Therapeutics 24:7, 1105-1116
CrossRef809
Lori Mosca, Angelo Biviano. (2002) Lipid-lowering therapies in the management of acute coronary syndromes. Current Cardiology Reports 4:4, 320-326
CrossRef810
Golyar Keyhan, Jennifer Rosset, Jian Wang, David Miller, Ruth McManus, Robert A Hegele. (2002) Gene-drug interaction: additive influence of mutant APOA1 and testosterone on plasma HDL-cholesterol. Clinical Biochemistry 35:5, 341-346
CrossRef811
Carel W. le Roux, Elaine Murphy, Mary Seed. (2002) A retrospective assessment of the effectiveness of fenofibrate 267 mg on high-density lipoprotein cholesterol levels in patients attending a lipid clinic. Clinical Therapeutics 24:7, 1154-1160
CrossRef812
James M. McKenney. (2002) New Cholesterol Guidelines, New Treatment Challenges. Pharmacotherapy 22:7, 853-863
CrossRef813
Wilbert S. Aronow. (2002) Pharmacologic Therapy of Lipid Disorders in the Elderly. The American Journal of Geriatric Cardiology 11:4, 247-256
CrossRef814
P. Burns, E. Lima, A.W. Bradbury. (2002) What Constitutes Best Medical Therapy for Peripheral Arterial Disease?. European Journal of Vascular and Endovascular Surgery 24:1, 6-12
CrossRef815
G. H. Tomkin. (2002) Hyperglycaemia: the relation to dyslipidaemia and atherosclerosis. Irish Journal of Medical Science 171:3, 161-164
CrossRef816
Victoria Gratl, Raphael C. Cheung, Biao Chen, Changiz Taghibiglou, Stephen C. Van Iderstine, Khosrow Adeli. (2002) Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis 163:1, 59-68
CrossRef817
Joao A. Gomes, Sander J. Robins, Viken L. Babikian. (2002) Treatment of lipid disorders after stroke. Current Atherosclerosis Reports 4:4, A304-A310
CrossRef818
Yohan Boss??, Agn??s Pascot, Martine Dumont, Martin Brochu, Denis Prud???homme, Jean Bergeron, Jean-Pierre Despr??s, Marie-Claude Vohl. (2002) Influences of the PPAR??-L162V polymorphism on plasma HDL2-cholesterol response of abdominally obese men treated with gemfibrozil. Genetics in Medicine 4:4, 311-315
CrossRef819
W. S. Aronow. (2002) Guest Editorial: Should Hypercholesterolemia in Older Persons Be Treated to Reduce Cardiovascular Events?. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:7, M411-M413
CrossRef820
Lori J. Mosca. (2002) Contemporary Management of Hyperlipidemia in Women. Journal of Women's Health & Gender-Based Medicine 11:5, 423-432
CrossRef821
D. C. Chan, G. F. Watts, T. A. Mori, P. H. R. Barrett, L. J. Beilin, T. G. Redgrave. (2002) Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. European Journal of Clinical Investigation 32:6, 429-436
CrossRef822
Eric Van Exel, Anton J. M. de Craen, Jacobijn Gussekloo, Peter Houx, Annetje Bootsma-van der Wiel, Peter W. Macfarlane, Gerard J. Blauw, Rudi G. J. Westendorp. (2002) Association between high-density lipoprotein and cognitive impairment in the oldest old. Annals of Neurology 51:6, 716-721
CrossRef823
Anthony S Wierzbicki. (2002) Stroke in systemic lupus erythematosus. Expert Review of Neurotherapeutics 2:3, 385-390
CrossRef824
D. C. Whitelaw, J. M. Smith, M. Nattrass. (2002) Effects of gemfibrozil on insulin resistance to fat metabolism in subjects with type 2 diabetes and hypertriglyceridaemia. Diabetes, Obesity and Metabolism 4:3, 187-194
CrossRef825
Bryan A. Laffitte, Peter Tontonoz. (2002) Orphan nuclear receptors find a home in the arterial wall. Current Atherosclerosis Reports 4:3, 213-221
CrossRef826
Morris Schweitzer, Daniel Tessier, William D Vlahos, Lawrence Leiter, Jean Paul Collet, Matthew J McQueen, Laurent Harvey, Petar Alaupovic. (2002) A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 162:1, 201-210
CrossRef827
Julie Nigro, Rodney J. Dilley, Peter J. Little. (2002) Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 162:1, 119-129
CrossRef828
Alan Cheng, Joel B. Braunstein, Cheryl Dennison, Caitlin Nass, Roger S. Blumenthal. (2002) Reducing global risk for cardiovascular disease: Using lifestyle changes and pharmacotherapy. Clinical Cardiology 25:5, 205-212
CrossRef829
Aaron Vinik, Mark Flemmer. (2002) Diabetes and macrovascular disease. Journal of Diabetes and its Complications 16:3, 235-245
CrossRef830
Marcelo C. Batiste, Ernst J. Schaefer. (2002) Diagnosis and Management of Lipoprotein Abnormalities. Nutrition in Clinical Care 5:3, 115-123
CrossRef831
Allen B. King, Dana U. Armstrong. (2002) Lipid Response to Pioglitazone in Diabetic Patients: Clinical Observations from a Retrospective Chart Review. Diabetes Technology & Therapeutics 4:2, 145-151
CrossRef832
Thierry Claudel, Ekkehard Sturm, Hélène Duez, Inés Pineda Torra, Audrey Sirvent, Vladimir Kosykh, Jean-Charles Fruchart, Jean Dallongeville, Dean W. Hum, Folkert Kuipers, Bart Staels. (2002) Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. Journal of Clinical Investigation 109:7, 961-971
CrossRef833
(2002) Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. The Lancet 359:9314, 1269-1275
CrossRef834
Susan L. Ravnan, Christy Locke, William P. Yee, Kelli Haase. (2002) Cerivastatin-Induced Rhabdomyolysis: 11 Case Reports. Pharmacotherapy 22:4, 533-537
CrossRef835
David Hawkins, J. Chris Bradberry, Mark J. Cziraky, Robert L. Talbert, David W. Bartels, Joli D. Cerveny. (2002) National Pharmacy Cardiovascular Council Treatment Guidelines for the Management of Type 2 Diabetes Mellitus: Toward Better Patient Outcomes and New Roles for Pharmacists. Pharmacotherapy 22:4, 436-444
CrossRef836
Henretha van Jaarsveld, Gertruida F. Pool. (2002) Beneficial effects of blood donation on high density lipoprotein concentration and the oxidative potential of low density lipoprotein. Atherosclerosis 161:2, 395-402
CrossRef837
Dmitri Sviridov, Paul Nestel. (2002) Dynamics of reverse cholesterol transport: protection against atherosclerosis. Atherosclerosis 161:2, 245-254
CrossRef838
Francisco J. G
mez-Perez, Guillermo Fangh
CrossRef839
Eric K. Gupta, Matthew K. Ito. (2002) Lovastatin and Extended-Release Niacin Combination Product: The First Drug Combination for the Management of Hyperlipidemia. Heart Disease124-137
CrossRef840
&NA;. (2002) Reducing the risk of coronary heart disease in patients with diabetes mellitus requires a multifactorial approach. Drugs & Therapy Perspectives 18:3, 6-9
CrossRef841
Anne Peters Harmel. (2002) Considerations for treating dyslipidemia in special diabetic populations. Diabetes/Metabolism Research and Reviews 18:2, 88-95
CrossRef842
A Gibson, S Asthana, P Brigham, G Moon, J Dicker. (2002) Geographies of need and the new NHS: methodological issues in the definition and measurement of the health needs of local populations. Health & Place 8:1, 47-60
CrossRef843
H. M. Colhoun, M. J. Thomason, M. I. Mackness, S. M. Maton, D. J. Betteridge, P. N. Durrington, G. A. Hitman, H. A. W. Neil, J. H. Fuller, . (2002) Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes. Diabetic Medicine 19:3, 201-211
CrossRef844
Luther T. Clark. (2002) Vascular inflammation as a therapeutic target for prevention of cardiovascular disease. Current Atherosclerosis Reports 4:2, 77-81
CrossRef845
Patrick J. Boyle, Allen Bennett King, Leann Olansky, Albert Marchetti, Helen Lau, Raf Magar, John Martin. (2002) Effects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical records. Clinical Therapeutics 24:3, 378-396
CrossRef846
Michel Accad, Andrew D. Michaels. (2002) Management after myocardial infarction. Current Treatment Options in Cardiovascular Medicine 4:1, 41-54
CrossRef847
Dimitri P. Mikhailidis, Anthony S. Wierzbicki. (2002) The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Current Medical Research and Opinion 18:4, 215-219
CrossRef848
Kathy Ann LaCivita, Gustavo Villarreal. (2002) Differences in Lipid Profiles of Patients Given Rosiglitazone Followed by Pioglitazone. Current Medical Research and Opinion 18:6, 363-370
CrossRef849
Pang H Chong, Robert Kezele, Cory Franklin. (2002) High-Density Lipoprotein Cholesterol and the Role of Statins. Circulation Journal 66:11, 1037-1044
CrossRef850
JACQUES GENEST. (2002) Genetics and Prevention: A New Look at High-Density Lipoprotein Cholesterol. Cardiology in Review 10:1, 61-71
CrossRef851
Miriam Sharpe, Douglas Ormrod, Blair Jarvis. (2002) Micronized Fenofibrate in Dyslipidemia. American Journal of Cardiovascular Drugs 2:2, 125-132
CrossRef852
Anthony S. Wierzbicki, Dimitri P. Mikhailidis. (2002) Beyond LDL-C – The Importance of Raising HDL-C. Current Medical Research and Opinion 18:1, 36-44
CrossRef853
David Williams, John Feely. (2002) Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors. Clinical Pharmacokinetics 41:5, 343-370
CrossRef854
David R Sullivan. (2002) Screening for cardiovascular disease with cholesterol. Clinica Chimica Acta 315:1-2, 49-60
CrossRef855
Mary Y. Sheu, Ashley J. Fowler, Jack Kao, Matthias Schmuth, Kristina Schoonjans, Johan Auwerx, Joachim W. Fluhr, Mao-Qiang Man, Peter M. Elias, Kenneth R. Feingold. (2002) Topical Peroxisome Proliferator Activated Receptor-alpha Activators Reduce Inflammation in Irritant and Allergic Contact Dermatitis Models1. Journal of Investigative Dermatology 118:1, 94-101
CrossRef856
Cyrus Desouza, Mary Keebler, Dennis B. McNamara, Vivian Fonseca. (2002) Drugs Affecting Homocysteine Metabolism. Drugs 62:4, 605-616
CrossRef857
Genovefa D. Kolovou, Dennis V. Cokkinos. (2002) Low Serum Levels of High-density Lipoprotein Cholesterol and Hypolipidaemic Treatment. Current Medical Research and Opinion 18:5, 265-268
CrossRef858
Alan J. Garber. (2002) Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice. Diabetes, Obesity and Metabolism 4:s1, 5-12
CrossRef859
Marc Evans, Alan Rees. (2002) Effects of HMG-CoA Reductase Inhibitors on Skeletal Muscle. Drug Safety 25:9, 649-663
CrossRef860
Jean-Pierre Despr??s. (2002) Micronized Fenofibrate. American Journal of Cardiovascular Drugs 2:2, 133-134
CrossRef861
Jeannette M. Goguen, Lawrence A. Leiter. (2002) Lipids and Diabetes Mellitus: A Review of Therapeutic Options. Current Medical Research and Opinion 18:s1, s58-s74
CrossRef862
M. Elisaf. (2002) Effects of Fibrates on Serum Metabolic Parameters. Current Medical Research and Opinion 18:5, 269-276
CrossRef863
Dimitrios N. Kiortsis. (2002) Micronized Fenofibrate. American Journal of Cardiovascular Drugs 2:2, 133-134
CrossRef864
George Steiner. (2001) The use of fibrates and of statins in preventing atherosclerosis in diabetes. Current Opinion in Lipidology 12:6, 611-617
CrossRef865
D. John Betteridge. (2001) Lipid-lowering trials in diabetes. Current Opinion in Lipidology 12:6, 619-623
CrossRef866
. (2001) Hebben fibraten een gunstig effect op de mortaliteit?. Medisch-Farmaceutische Mededelingen 39:12, 262-263
CrossRef867
James Shepherd. (2001) Issues surrounding age: vascular disease in the elderly. Current Opinion in Lipidology 12:6, 601-609
CrossRef868
Patrick Duriez. (2001) Current practice in the treatment of hyperlipidaemias. Expert Opinion on Pharmacotherapy 2:11, 1777-1794
CrossRef869
Alicia J Jenkins, James D Best. (2001) Novel agents for managing dyslipidaemia. Expert Opinion on Investigational Drugs 10:11, 1901-1911
CrossRef870
Kenneth Cusi. (2001) Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. The Endocrinologist 11:6, 474-490
CrossRef871
Ian S. Young, Jayne V. Woodside. (2001) Fibrates and homocysteine. Nutrition 17:11-12, 973-974
CrossRef872
RANDY LINDE, BONNIE LINDE. (2001) Lipids and Risk Assessment. Cardiology in Review 9:6, 348-358
CrossRef873
R.A Anderson, C.J.H Jones, J Goodfellow. (2001) Is the fatty meal a trigger for acute coronary syndromes. Atherosclerosis 159:1, 9-15
CrossRef874
Marek H. Dominiczak. (2001) Risk Factors for Coronary Disease: the Time for a Paradigm Shift?. Clinical Chemistry and Laboratory Medicine 39:10, 907-919
CrossRef875
Jorge Plutzky. (2001) Peroxisome proliferator-activated receptors in endothelial cell biology. Current Opinion in Lipidology 12:5, 511-518
CrossRef876
Barry A. Franklin, J. NORMAN PATTON, GERALD FLETCHER. (2001) Aggressive Secondary Prevention: A Perspective from the Coronary Interventional Setting. Journal of Interventional Cardiology 14:5, 559-562
CrossRef877
Eva Lonn. (2001) The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases. Pharmacoepidemiology and Drug Safety 10:6, 497-508
CrossRef878
Ades, Philip A., . (2001) Cardiac Rehabilitation and Secondary Prevention of Coronary Heart Disease. New England Journal of Medicine 345:12, 892-902
Full Text879
Hans-Christoph Diener, Peter Ringleb. (2001) Antithrombotic secondary prevention after stroke. Current Treatment Options in Neurology 3:5, 451-462
CrossRef880
Gregory Cohn, Gerardo Valdes, David M. Capuzzi. (2001) Pathophysiology and treatment of the dyslipidemia of insulin resistance. Current Cardiology Reports 3:5, 416-423
CrossRef881
Dennis L. Sprecher. (2001) Targeting triglycerides as prognostic indicators and determining lowest values for patient benefit. Current Cardiology Reports 3:5, 424-432
CrossRef882
Harvey S. Hecht. (2001) New developments in atherosclerosis imaging: Electron beam tomography. Current Atherosclerosis Reports 3:5, 417-424
CrossRef883
Alan Marcus. (2001) Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy. The Endocrinologist 11:5, 368-383
CrossRef884
Philip A. Ades, Gary J. Balady, Kathy Berra. (2001) Transforming Exercise-based Cardiac Rehabilitation Programs Into Secondary Prevention Centers: A National Imperative. Journal of Cardiopulmonary Rehabilitation 21:5, 263-272
CrossRef885
Janet L. Ritter, Sheree Nabulsi. (2001) Fenofibrate-Induced Elevation in Serum Creatinine. Pharmacotherapy 21:9, 1145-1149
CrossRef886
Margaret E. Brousseau, Ernst J. Schaefer. (2001) New developments in the prevention of atherosclerosis in patients with low high-density lipoprotein cholesterol. Current Atherosclerosis Reports 3:5, 365-372
CrossRef887
Helene Duez, Jean-Charles Fruchart, Bart Staels. (2001) Journal of Cardiovascular Risk 8:4, 187-194
CrossRef888
Felicity Kaplan, Khulood Al-Majali, D. Betteridge. (2001) Journal of Cardiovascular Risk 8:4, 211-217
CrossRef889
José Félix Meco, Ramón Vila, Ramon Pujol, Rafael Bros, Pere Domènech, Concepción Fiol, Xavier Pintó. (2001) Improvement in Endothelial Dysfunction in Patients with Hypoalphalipoproteinemia and Coronary Artery Disease Treated with Bezafibrate. Journal of Cardiovascular Pharmacology 38:2, 250-258
CrossRef890
Sidney Rosenblatt, Barry Miskin, N. Bradly Glazer, Melvin J. Prince, Kenneth E. Robertson. (2001) The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coronary Artery Disease 12:5, 413-423
CrossRef891
Sander Robins. (2001) Journal of Cardiovascular Risk 8:4, 195-201
CrossRef892
Nikolaus Marx, Peter Libby, Jorge Plutzky. (2001) Journal of Cardiovascular Risk 8:4, 203-210
CrossRef893
Christie M. Ballantyne. (2001) Treating mixed dyslipidemias: Why and how. Clinical Cardiology 24:S2, 6-9
CrossRef894
G. A. Rongen, C. J. Tack. (2001) Triglycerides and endothelial function in type 2 diabetes. European Journal of Clinical Investigation 31:7, 560-562
CrossRef895
Ian G. Lawrence, Paul G. McNally. (2001) Heart disease in Asian people with diabetes. Practical Diabetes International 18:6, 192-196
CrossRef896
Sheila A Doggrell. (2001) Gemfibrozil prevents major coronary events by increasing HDL-cholesterol and more. Expert Opinion on Pharmacotherapy 2:7, 1187-1189
CrossRef897
YouFei Guan, Matthew D Breyer. (2001) Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney International 60:1, 14-30
CrossRef898
James S. Forrester. (2001) Triglycerides: risk factor or fellow traveler?. Current Opinion in Cardiology 16:4, 261-264
CrossRef899
H GINSBERG. (2001) Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. The American Journal of Cardiology 88:6, 9-15
CrossRef900
John A Papadakis, Haralampos J Milionis, Martin Press, Dimitri P Mikhailidis. (2001) Treating dyslipidaemia in non-insulin-dependent diabetes mellitus — a special reference to statins. Journal of Diabetes and its Complications 15:4, 211-226
CrossRef901
D. John Betteridge. (2001) Dyslipidaemia and diabetes. Practical Diabetes International 18:6, 201-207
CrossRef902
Adam M. Cohen, Daniel J. Rader. (2001) Dyslipidemia. Current Treatment Options in Cardiovascular Medicine 3:4, 347-357
CrossRef903
David S. H. Bell. (2001) Drugs for cardiovascular risk reduction in the diabetic patient. Current Diabetes Reports 1:2, 133-139
CrossRef904
Adriana Branchi, Anna M. Fiorenza, Adriana Torri, Fulvio Muzio, Cristina Berra, Emanuela Colombo, Elena Dalla Valle, Angelo Rovellini, Domenico Sommariva. (2001) Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia. Clinical Therapeutics 23:6, 851-857
CrossRef905
Brett Cucchiara, Scott Eric Kasner. (2001) Use of statins in CNS disorders. Journal of the Neurological Sciences 187:1-2, 81-89
CrossRef906
WILLIAM L. HASKELL. (2001) Chair summary and comments. Medicine and Science in Sports and Exercise 33:Supplement, S528-S529
CrossRef907
Inés Pineda Torra, Giulia Chinetti, Caroline Duval, Jean-Charles Fruchart, Bart Staels. (2001) Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Current Opinion in Lipidology 12:3, 245-254
CrossRef908
Diane M. Becker, Jerilyn K. Allen. (2001) Improving Compliance in Your Dyslipidemic Patient: An Evidence-based Approach. Journal of the American Academy of Nurse Practitioners 13:5, 200-207
CrossRef909
Harvey S Hecht, H.Robert Superko. (2001) Electron beam tomography and national cholesterol education program guidelines in asymptomatic women. Journal of the American College of Cardiology 37:6, 1506-1511
CrossRef910
(2001) The national service framework for diabetes and deficiencies in specialist care - putting the cart before the horse?. Practical Diabetes International 18:4, 113-114
CrossRef911
Scot H. Simpson, Jeffrey A. Johnson, Ross T. Tsuyuki. (2001) Economic Impact of Community Pharmacist Intervention in Cholesterol Risk Management: An Evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists. Pharmacotherapy 21:5, 627-635
CrossRef912
Karen Tordjman, Carlos Bernal-Mizrachi, Laura Zemany, Sherry Weng, Chu Feng, Fengjuan Zhang, Teresa C. Leone, Trey Coleman, Daniel P. Kelly, Clay F. Semenkovich. (2001) PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. Journal of Clinical Investigation 107:8, 1025-1034
CrossRef913
Herbert D Aronow, Eric J Topol, Matthew T Roe, Penny L Houghtaling, Katherine E Wolski, A Michael Lincoff, Robert A Harrington, Robert M Califf, E Magnus Ohman, Neal S Kleiman, Matyas Keltai, Robert G Wilcox, Alec Vahanian, Paul W Armstrong, Michael S Lauer. (2001) Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. The Lancet 357:9262, 1063-1068
CrossRef914
Ezra A. Amsterdam. (2001) Wine and Coronary Heart Disease: Paradise Lost?. Preventive Cardiology 4:2, 55-55
CrossRef915
Ronald B. Goldberg, Hermes Florez. (2001) Cardiovascular disease in diabetes: prevention and intervention. Current Opinion in Endocrinology & Diabetes 8:2, 101-110
CrossRef916
Grażyna Nowicka, Agnieszka Jarosz. (2001) LpAI in HDL subfractions: serum levels in men and women with coronary heart disease and changes under hypolipemic therapy. Clinica Chimica Acta 306:1-2, 43-49
CrossRef917
Christie M. Ballantyne, Gopikishan R. Rangaraj. (2001) The Evolving Role of High-Density Lipoprotein in Reducing Cardiovascular Risk. Preventive Cardiology 4:2, 65-72
CrossRef918
M. Laakso. (2001) Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. Journal of Internal Medicine 249:3, 225-235
CrossRef919
William S. Harris, William L. Isley. (2001) Clinical trial evidence for the cardioprotective effects of omega-3 fatty acids. Current Atherosclerosis Reports 3:2, 174-179
CrossRef920
JOEL B. BRAUNSTEIN, ALAN CHENG, CAROLE FAKHRY, CAITLIN M. NASS, CAMILLE VIGILANCE, ROGER S. BLUMENTHAL. (2001) ABCs of Cardiovascular Disease Risk Management. Cardiology in Review 9:2, 96-105
CrossRef921
(2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. The Lancet 357:9260, 905-910
CrossRef922
Luther T. Clark, Keith C. Ferdinand, John M. Flack, James R. Gavin, W. Dallas Hall, Shiriki K. Kumanyika, James W. Reed, Elijah Saunders, Hannah A. Valantine, Karol Watson, Nanette K. Wenger, Jackson T. Wright. (2001) Coronary Heart Disease in African Americans. Heart Disease97-108
CrossRef923
Margaret E. Brousseau, Marek Bodzioch, Ernst J. Schaefer, Allison L. Goldkamp, Danuta Kielar, Mario Probst, Jose M. Ordovas, Charalampos Aslanidis, Karl J. Lackner, Hanna Bloomfield Rubins, Dorothea Collins, Sander J. Robins, Peter W.F. Wilson, Gerd Schmitz. (2001) Common variants in the gene encoding ATP-binding cassette transporter 1 in men with low HDL cholesterol levels and coronary heart disease. Atherosclerosis 154:3, 607-611
CrossRef924
Samia Mora, Dawn Warner Kershner, Camille Peart Vigilance, Roger S. Blumenthal. (2001) Coronary artery disease in postmenopausal women. Current Treatment Options in Cardiovascular Medicine 3:1, 67-79
CrossRef925
C.E. Tan, L.S. Chew, E.S. Tai, L.F. Chio, H.S. Lim, L.M. Loh, J. Shepherd. (2001) Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. Atherosclerosis 154:2, 469-474
CrossRef926
Paul Logan, Sean Clarke. (2001) Nutritional and Medical Therapy for Dyslipidemia in Patients With Cardiovascular Disease. AACN Clinical Issues: Advanced Practice in Acute & Critical Care 12:1, 40-52
CrossRef927
Christie M. Ballantyne, Franco Pazzucconi, Xavier Pintó, John P. Reckless, Evan Stein, James McKenney, Michele Bortolini, Yann Tong Chiang. (2001) Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clinical Therapeutics 23:2, 177-192
CrossRef928
G. J. Strewler. (2001) Calcium: Good for Your Bones, Good for Your Heart?. International Bone and Mineral Society Knowledge Environment 1:1, 2002061-0
CrossRef929
Hans-Willi M. Breuer. (2001) Hypertriglyceridemia: A Review of Clinical Relevance and Treatment Options: Focus on Cerivastatin. Current Medical Research and Opinion 17:1, 60-73
CrossRef930
Yoichi Uechi, Osahiko Sunagawa, Naoki Ishikawa, Taku Inoue, Masahiro Tamashiro, Tomomasa Kamiyama, Tsutomu Suzuki, Takashi Touma, Koshiro Fukiyama. (2001) Risk Factors for Stiffness of the Wall of the Thoracic Aorta in Patients With Mild Atherosis. Japanese Circulation Journal 65:5, 409-409
CrossRef931
Michael H. Davidson. (2001) Safety Profiles for the HMG-CoA Reductase Inhibitors. Drugs 61:2, 197-206
CrossRef932
Grace Zlaket-Matta, B. Sylvia Vela, Eliot A. Brinton. (2001) The Clinical Relevance and Management of High-Density Lipoprotein Deficiency. The Endocrinologist 11:1, 16-25
CrossRef933
Iris J.A.M. Jonkers, August H.M. Smelt, Arnoud van der Laarse. (2001) Hypertriglyceridemia. American Journal of Cardiovascular Drugs 1:6, 455-466
CrossRef934
Brian Tomlinson, Paul Chan, Wei Lan. (2001) How Well Tolerated Are Lipid-Lowering Drugs?. Drugs & Aging 18:9, 665-683
CrossRef935
Moses Elisaf. (2001) The Treatment of Coronary Heart Disease: An Update. Current Medical Research and Opinion 17:1, 18-26
CrossRef936
Michel Farnier, Sylvie Picard. (2001) Diabetes: Statins, fibrates, or both?. Current Atherosclerosis Reports 3:1, 19-28
CrossRef937
Robert E. Ratner. (2001) Glycemic control in the prevention of diabetic complications. Clinical Cornerstone 4:2, 24-37
CrossRef938
Anthony S. Wierzbicki, Dimitri P. Mikhailidis, Richard Wray. (2001) Drug Treatment of Combined Hyperlipidemia. American Journal of Cardiovascular Drugs 1:5, 327-336
CrossRef939
D. Roger Illingworth, Yale B. Mitchel. (2001) A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial *. Current Medical Research and Opinion 17:1, 43-50
CrossRef940
Marjel van Dam, Anton F.H. Stalenhoef, Janneke Wittekoek, Mieke D. Trip, Martin H. Prins, John J.P. Kastelein. (2001) Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia. Clinical Drug Investigation 21:3, 175-181
CrossRef941
S. Tavintharan, Moti L. Kashyap. (2001) The benefits of niacin in atherosclerosis. Current Atherosclerosis Reports 3:1, 74-82
CrossRef942
D. John Betteridge, Helen Colhoun, Jane Armitage. (2000) Status report of lipid-lowering trials in diabetes. Current Opinion in Lipidology 11:6, 621-626
CrossRef943
David M. Capuzzi, John M. Morgan, Osvaldo A. Brusco, Charles M. Intenzo. (2000) Niacin dosing: Relationship to benefits and adverse effects. Current Atherosclerosis Reports 2:1, 64-71
CrossRef944
Jean-Pierre Després, Isabelle Lemieux, Gilles-R Dagenais, Bernard Cantin, Benoı̂t Lamarche. (2000) HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis 153:2, 263-272
CrossRef945
Evan A. Stein. (2000) Lipid modulation and atherosclerotic events: Extending the clinical spectrum with fibrates and statins. Current Atherosclerosis Reports 2:1, 11-13
CrossRef946
W Philip T James, Arne Astrup, Nick Finer, Jannik Hilsted, Peter Kopelman, Stephan Rössner, Wim H.M. Saris, Luc F Van Gaal. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. The Lancet 356:9248, 2119-2125
CrossRef947
Janet Wittes. (2000) EDITORIAL. Evidence-based Cardiovascular Medicine 4:4, 79-81
CrossRef948
A. David Marais. (2000) Therapeutic modulation of low-density lipoprotein size. Current Opinion in Lipidology 11:6, 597-602
CrossRef949
Ole Faergeman. (2000) Hypertriglyceridemia and the fibrate trials. Current Opinion in Lipidology 11:6, 609-614
CrossRef950
Gilbert R. Thompson, Philip J. Barter. (2000) Therapeutic approaches to reducing the LDL- and HDL-associated risks of coronary heart disease. Current Opinion in Lipidology 11:6, 567-570
CrossRef951
Arthur Ogunko, Kofi Oboubie. (2000) Therapy and clinical trials. Current Opinion in Lipidology 11:6, 671-673
CrossRef952
MacRae F. Linton, Sergio Fazio. (2000) Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. Current Atherosclerosis Reports 2:1, 29-35
CrossRef953
Patrick H. Bowen, John R. Guyton. (2000) Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol. Current Atherosclerosis Reports 2:1, 58-63
CrossRef954
Arnold von Eckardstein, Gerd Assmann. (2000) Prevention of coronary heart disease by raising high-density lipoprotein cholesterol?. Current Opinion in Lipidology 11:6, 627-637
CrossRef955
K. H. Mayer, M. P. Dube, D. Sprecher, W. K. Henry, J. A. Aberg, F. J. Torriani, H. N. Hodis, J. Schouten, J. Levin, G. Myers, R. Zackin, T. Nevin, J. S. Currier, . (2000) Preliminary Guidelines for the Evaluation and Management of Dyslipidemia in Adults Infected with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clinical Infectious Diseases 31:5, 1216-1224
CrossRef956
Michael Tuck. (2000) Microvascular complications of diabetes: the role of angiotensin converting enzyme inhibitors Proceedings of a Round Table Meeting, June 1999, San Diego, USA. Practical Diabetes International 17:8, S1-S12
CrossRef957
Jorge Plutzky. (2000) Emerging concepts in metabolic abnormalities associated with coronary artery disease. Current Opinion in Cardiology 15:6, 416-421
CrossRef958
Marian B Olson, Sheryl F Kelsey, Vera Bittner, Steven E Reis, Nathaniel Reichek, Eileen M Handberg, C.Noel Bairey Merz. (2000) Weight cycling and high-density lipoprotein cholesterol in women: evidence of an adverse effect. Journal of the American College of Cardiology 36:5, 1565-1571
CrossRef959
Gilbert R Thompson, Rossi P Naoumova. (2000) Novel lipid-regulating drugs. Expert Opinion on Investigational Drugs 9:11, 2619-2628
CrossRef960
G. Russell Warnick, Ishwarlal Jialal, MD, PhD, Martin H. Kroll, MD, Nader Rifai, PhD, Thomas G. Cole, PhD, Gerald Cooper, MD, PhD. (2000) Standardization of Lipoprotein Reporting. American Journal of Clinical Pathology 114:5, 696-702
CrossRef961
James W. Anderson. (2000) Dietary fiber prevents carbohydrate-induced hypertriglyceridemia. Current Atherosclerosis Reports 2:6, 536-541
CrossRef962
Alan J. Garber. (2000) Diabetes and vascular disease. Diabetes, Obesity and Metabolism 2:s2, 1-5
CrossRef963
Lucien Campeau. (2000) Lipid lowering and coronary bypass graft surgery. Current Opinion in Cardiology 15:6, 395-399
CrossRef964
James Gavin, Steven Kagan. (2000) Vascular disease prevention in patients with diabetes. Diabetes, Obesity and Metabolism 2:s2, 25-36
CrossRef965
T. Royo, J. Alfon, M. Berrozpe, L. Badimon. (2000) Effect of gemfibrozil on peripheral atherosclerosis and platelet activation in a pig model of hyperlipidemia. European Journal of Clinical Investigation 30:10, 843-852
CrossRef966
Alan J. Garber. (2000) Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?. Diabetes, Obesity and Metabolism 2:5, 263-270
CrossRef967
S. G. Worthley, G. Helft, A. G. Zaman, V. Fuster, J. J. Badimon. (2000) Atherosclerosis and the vulnerable plaque - pathogenesis: Part I. Australian and New Zealand Journal of Medicine 30:5, 600-607
CrossRef968
Ian F. Godsland, Ulrich Winkler, Ojvind Lidegaard, David Crook. (2000) Occlusive Vascular Diseases in Oral Contraceptive Users. Drugs 60:4, 721-869
CrossRef969
Caitlin M. Nass, Stephen D. Wiviott, Jerilyn K. Allen, Wendy S. Post, Roger S. Blumenthal. (2000) Global risk assessment for lipid therapy to prevent coronary heart disease. Current Cardiology Reports 2:5, 424-432
CrossRef970
Eugene Braunwald, Elliott M Antman, John W Beasley, Robert M Califf, Melvin D Cheitlin, Judith S Hochman, Robert H Jones, Dean Kereiakes, Joel Kupersmith, Thomas N Levin, Carl J Pepine, John W Schaeffer, Earl E Smith, David E Steward, Pierre Theroux, Raymond J Gibbons, Joseph S Alpert, Kim A Eagle, David P Faxon, Valentin Fuster, Timothy J Gardner, Gabriel Gregoratos, Richard O Russell, Sidney C Smith. (2000) ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction. Journal of the American College of Cardiology 36:3, 970-1062
CrossRef971
P. Durrington. (2000) A case for lipid-lowering?. Diabetic Medicine 17:s2, 4-5
CrossRef972
Cesare R. Sirtori, Laura Calabresi, Roberto Marchioli, Hanna B. Rubins. (2000) Cardiovascular risk changes after lipid lowering medications: are they predictable?. Atherosclerosis 152:1, 1-8
CrossRef973
Arnold von Eckardstein, Jerzy-Roch Nofer, Gerd Assmann. (2000) Acceleration of reverse cholesterol transport. Current Opinion in Cardiology 15:5, 348-354
CrossRef974
Jonathan Krakoff, B. Sylvia Vela, Eliot A. Brinton. (2000) The role of fibric acid derivatives in the secondary prevention of coronary heart disease. Current Cardiology Reports 2:5, 452-458
CrossRef975
Kevin A. Bybee, James H. O'Keefe, William S. Harris, Shamila Garg, Sabu J. George, Timothy M. Bateman. (2000) Lipid Risk Factor Correlates of Ischemic Heart Disease as Diagnosed by Myocardial Perfusion Scintigraphy. Preventive Cardiology 3:4, 33-39
CrossRef976
James S. Forrester. (2000) Prevention. Current Opinion in Cardiology 15:5, 343-347
CrossRef977
Prediman K Shah. (2000) Focus on HDL: a new treatment paradigm for athero-thrombotic vascular disease. Expert Opinion on Investigational Drugs 9:9, 2139-2146
CrossRef978
Masa-aki Kawashiri, Cyrille Maugeais, Daniel J. Rader. (2000) High-density lipoprotein metabolism: Molecular targets for new therapies for atherosclerosis. Current Atherosclerosis Reports 2:5, 363-372
CrossRef979
J. P. Begley, D. Kerr. (2000) Letters. Diabetic Medicine 17:8, 623-624
CrossRef980
Satoshi Sunayama, Yoshiro Watanabe, Hiroyuki Daida, Hiroshi Yamaguchi. (2000) Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. Current Opinion in Lipidology 11:4, 397-402
CrossRef981
John P.D. Reckless. (2000) Cost-effectiveness of statins. Current Opinion in Lipidology 11:4, 351-356
CrossRef982
Paul N. Durrington, D. Roger Illingworth. (2000) Lipid-lowering drug therapy: more knowledge leads to more problems for composers of guidelines. Current Opinion in Lipidology 11:4, 345-349
CrossRef983
J. R. Greenfield, D. J. Chisholm. (2000) Clinical trials and clinical practice - bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes. Australian and New Zealand Journal of Medicine 30:4, 483-491
CrossRef984
Neil J. Stone. (2000) Hyperlipidaemia and cardiovascular disease. Current Opinion in Lipidology 11:4, 437-439
CrossRef985
Pang H. Chong, Bonnie S. Bachenheimer. (2000) Current, New and Future Treatments in Dyslipidaemia and Atherosclerosis. Drugs 60:1, 55-93
CrossRef986
Christie M. Ballantyne. (2000) Development and assessment of antiatherosclerotic therapies beyond low-density lipoprotein cholesterol and blood pressure. Current Atherosclerosis Reports 2:4, 281-283
CrossRef987
Jorge Plutzky. (2000) Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms. Current Atherosclerosis Reports 2:4, 327-335
CrossRef988
A. Golay. (2000) Are postprandial triglyceride and insulin abnormalities neglected cardiovascular risk factors in type 2 diabetes?. European Journal of Clinical Investigation 30:s2, 12-18
CrossRef989
H. M. Omar Farouque, R. C. O'Brien, I. T. Meredith. (2000) Diabetes mellitus and coronary heart disease - from prevention to intervention: Part I. Australian and New Zealand Journal of Medicine 30:3, 351-359
CrossRef990
Martijn B. Katan. (2000) Trans Fatty Acids and Plasma Lipoproteins. Nutrition Reviews 58:6, 188-191
CrossRef991
Weerapan Khovidhunkit,, Riaz A. Memon, Kenneth R. Feingold, Carl Grunfeld. (2000) Infection and Inflammation‐Induced Proatherogenic Changes of Lipoproteins. The Journal of Infectious Diseases 181:s3, S462-S472
CrossRef992
Ranjan Mukherjee, Jo Anne Saye, Peter R Young. (2000) Nuclear receptors in metabolic diseases. Expert Opinion on Therapeutic Targets 4:3, 377-396
CrossRef993
H. Robert Superko. (2000) Small, dense, low-density lipoprotein and atherosclerosis. Current Atherosclerosis Reports 2:3, 226-231
CrossRef994
Peter H. Jones. (2000) Lipid-Lowering Treatment in Coronary Artery Disease. Drugs 59:5, 1127-1135
CrossRef995
Nicola Abate. (2000) Obesity and cardiovascular disease. Journal of Diabetes and its Complications 14:3, 154-174
CrossRef996
James D. Best, David N. O??Neal. (2000) Diabetic Dyslipidaemia. Drugs 59:5, 1101-1111
CrossRef997
Robert Cramb. (2000) Therapy and clinical trials. Current Opinion in Lipidology 11:2, 223-225
CrossRef998
Francesco Violi, Lorenzo Loffredo. (2000) Systemic cause of unstable atherosclerotic plaques. The Lancet 355:9212, 1362
CrossRef999
James B. Meigs, Randall S. Stafford. (2000) Cardiovascular Disease Prevention Practices by U.S. Physicians for Patients with Diabetes. Journal of General Internal Medicine 15:4, 220-228
CrossRef1000
Ezra A. Amsterdam. (2000) HDL Cholesterol and Triglycerides: Emerging, Emerging?Emerged!. Preventive Cardiology 3:2, 56-57
CrossRef1001
Christoph Wanner, Thomas Quaschning, Karl Weingärnter. (2000) Impact of dyslipidaemia in renal transplant recipients. Current Opinion in Urology 10:2, 77-80
CrossRef1002
Robert S. Rosenson. (2000) Basic mechanisms of stroke prevention with lipid-lowering therapy. Current Atherosclerosis Reports 2:2, 120-125
CrossRef1003
Michael J Zema. (2000) Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. Journal of the American College of Cardiology 35:3, 640-646
CrossRef1004
D. John Betteridge. (2000) Diabetic dyslipidaemia. Diabetes, Obesity and Metabolism 2:s1, S31-S36
CrossRef1005
Gerald F. Watts. (2000) Coronary disease, dyslipidaemia and clinical trials in type 2 diabetes mellitus. Practical Diabetes International 17:2, 54-59
CrossRef1006
Adrian R. Scott, Richard Donnelly. (2000) Case presentations - challenging problems in the management of type 2 diabetes. Diabetes, Obesity and Metabolism 2:s1, S49-S55
CrossRef1007
Karen M. Hvizdos, Karen L. Goa. (2000) Management of Dyslipidaemias. Disease Management and Health Outcomes 7:2, 83-109
CrossRef1008
Jacqueline J. McCormick, Mark A. Deeg. (2000) Pharmacologic Treatment of Dyslipidemia. American Journal of Nursing 100:2, 55-60
CrossRef1009
Jeffrey S. Schwartz. (2000) Ischemic heart disease. Current Treatment Options in Cardiovascular Medicine 2:1, 27-35
CrossRef1010
Jacob Joseph, Jorge Saucedo, J. DavidTalley. (2000) Progress in Interventional Cardiology. Journal of Interventional Cardiology 13:1, 73-76
CrossRef1011
Rajendra H. Mehta, Eduardo Bossone, Kim A. Eagle. (2000) Current concepts in secondary prevention after acute myocardial infarction. Herz 25:1, 47-60
CrossRef1012
Philippe Gervois, Inés Pineda Torra, Jean-Charles Fruchart, Bart Staels. (2000) Regulation of Lipid and Lipoprotein Metabolism by PPAR Activators. Clinical Chemistry and Laboratory Medicine 38:1, 3-11
CrossRef1013
John Wright. (2000) Total parenteral nutrition and enteral nutrition in diabetes. Current Opinion in Clinical Nutrition and Metabolic Care 3:1, 5-10
CrossRef1014
J. Genest, N-H. Nguyen, P. Theroux, J. Davignon, J. S. Cohn. (2000) Effect of Micronized Fenofibrate on Plasma Lipoprotein Levels and Hemostatic Parameters of Hypertriglyceridemic Patients with Low Levels of High-Density Lipoprotein Cholesterol in the Fed and Fasted State. Journal of Cardiovascular Pharmacology 35:1, 164-172
CrossRef1015
Bart De Geest, Sophie Van Linthout, Marleen Lox, Desire Collen, Paul Holvoet. (2000) Sustained Expression of Human Apolipoprotein A-I after Adenoviral Gene Transfer in C57BL/6 Mice: Role of Apolipoprotein A-I Promoter, Apolipoprotein A-I Introns, and Human Apolipoprotein E Enhancer. Human Gene Therapy 11:1, 101-112
CrossRef1016
Michael Schachter. (2000) Erectile Dysfunction and Lipid Disorders. Current Medical Research and Opinion 16:s1, s9-s12
CrossRef1017
Dimitri P. Mikhailidis, Anthony S. Wierzbicki. (2000) HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin. Current Medical Research and Opinion 16:2, 139-146
CrossRef1018
Hanna Bloomfield Rubins. (2000) High Density Lipoprotein and Coronary Heart Disease: Lessons From Recent Intervention Trials. Preventive Cardiology 3:1, 33-39
CrossRef1019
(1999) Drug Treatment of Lipid Disorders. New England Journal of Medicine 341:26, 2020-2021
Full Text1020
Gerald F. Watts, Simon B. Dimmitt. (1999) Fibrates, dyslipoproteinaemia and cardiovascular disease. Current Opinion in Lipidology 10:6, 561-574
CrossRef1021
Gilbert R. Thompson, Philip J. Barter. (1999) Clinical lipidology at the end of the millennium. Current Opinion in Lipidology 10:6, 521-526
CrossRef1022
John R. Crouse. (1999) Effects of statins on carotid disease and stroke. Current Opinion in Lipidology 10:6, 535-542
CrossRef1023
Olivier Montagne, Isabelle Vedel, Isabelle Durand-Zaleski. (1999) Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations. Clinical Therapeutics 21:11, 2027-2035
CrossRef
